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Abstract            
There are currently no effective pharmacologic treatments for the core symptoms of Autism 
Spectrum Disorder (ASD); and candidate treatments are often assumed to act in a similar way 
in people with and without ASD. This may not be the case, as there is recent evidence that 
the excitatory (E) glutamate and inhibitory (I) GABA systems, which are crucial to brain 
development and function, are altered in ASD. Abnormalities of E-I balance at rest in ASD 
are described in the literature, however findings often contradict and mostly stem from cross-
sectional studies. To date, no prior studies of ASD have examined the ‘responsivity’ of the E-
I system to pharmacologic challenge. 
 
No single technique can fully capture E-I dynamics in the living brain, however E-I balance 
can be measured at a number of ‘levels’, using different species-specific modalities. Hence, 
in the present thesis, I aimed to explore the effect of pharmacologically modulating E-I 
balance at the i) intracellular, ii) functional, and iii) extracellular level, in both humans, and 
an animal model of ASD (the Neurexin1 knock out rat), after a pharmacological challenge 
with the E-I acting drug, riluzole. 
 
To first capture E-I dynamics at the intracellular level, I investigated riluzole-evoked changes 
in bulk tissue levels of E-I neurotransmitters in the medial prefrontal cortex (mPFC) and 
basal ganglia (BG)- regions known to be important in ASD- using Magnetic Resonance 
Spectroscopy and ex vivo tissue analyses in humans and rats, respectively. In humans, I 
compared the change in ‘Inhibitory Index’ - the GABA fraction within the pool of glutamate 
plus GABA metabolites - post riluzole challenge in adult men with (n = 17) and without (n = 
20) ASD. Despite comparable baseline measures of GABA and Glx (glutamate + glutamine) 
in the mPFC, I found the response of the Inhibitory Index to riluzole to be diametrically 
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opposite in men with and without ASD. In contrast, in the BG, I reported a significant group 
difference in baseline Glx, in which the ASD cohort had lower Glx levels compared to 
controls, yet both groups responded in the same direction to riluzole challenge, with an 
increase in the Inhibitory Index. These findings were partially replicated in the Neurexin1 
knock out rat- with lower subcortical glutamate also reported in an equivalent basal ganglia 
region (the caudate putamen), compared to wild type controls. However, no differences in E-I 
responsivity were observed in the rodent in either strain or brain region. 
 
Given the reported group differences in E-I responsivity profile of the human mPFC, and that 
E-I imbalances are likely to affect the whole brain, I next explored the responsivity of 
functional connectivity of the mPFC with the rest of the brain, using resting-state functional 
Magnetic Resonance Imaging (rs-fMRI). In the ASD group, functional connectivity was 
abnormal at baseline, but restored to control levels after riluzole administration. Conversely, 
riluzole had no effect on the functional connectivity in the control group, thus highlighting 
again a group difference in responsivity. 
 
Finally, to examine whether extracellular changes in E-I dynamics were driving differences 
in functional connectivity, I explored neurotransmitter efflux into the extracellular space in 
the living rat brain, using in vivo microdialysis. However, riluzole had no measurable effect 
on glutamate nor GABA efflux in either wild type, or Neurexin1 knock out rats. 
 
Overall, I have, for the first time, identified that E-I balance at both the intracellular and 
functional level may be shifted in adult men with ASD, and that the brain in ASD is 
pharmacologically different to that of controls. This has implications for future drug 
discovery in ASD and the results of this thesis could be translated forwards to enhance future 
13 
clinical trial design. Further to this, I found the Neurexin1 knock out rat to have a 
comparable baseline biology to the human condition, which may support its use in future 
studies of back-translate these findings. Such work will be necessary to further understand E-
I pharmacology in ASD, and further validate E-I balance as a tractable therapeutic treatment 
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1.1 Introduction to Autism Spectrum Disorder 
Autism Spectrum Disorder (ASD) is an increasingly common neurodevelopmental condition. 
The frequency of ASD diagnoses in both adults (Brugha et al., 2011) and children (Russell et 
al., 2014) has increased globally over the last 50 years and is currently reported at around 1% 
in the UK, with an estimated 4 times more males affected than females (Ehlers & Gillberg, 
1993). Previously split into the subcategories of Autism, Asperger’s, Childhood 
Disintegrative Disorder and Pervasive Developmental Disorder Not Otherwise Specified 
(PDD-NOS) in the Diagnostic and Statistical Manual of Mental Disorders (DSM) version 4 
(American Psychiatric Association, 2000), ASD is now treated as one umbrella term by the 
DSM-5 (American Psychiatric Association, 2013). For a diagnosis of ASD under the new 
DSM-5 criteria, the following four benchmarks must be met; 1) persistent difficulties with 
social interaction and communication, 2) restricted, repetitive behaviour patterns, 3) 
symptoms must be present from early childhood, and 4) symptoms must limit everyday 
functioning (Table 1.1). Core symptoms can range from mildly to severely debilitating and 
are often complicated by secondary features such as hyperactivity, inattention and intellectual 
impairment (O’Brien & Pearson, 2004; Reiersen & Todd, 2008).   
30 
 
Table 1.1: DSM-5 criteria for ASD diagnosis  
All conditions of A, C and D must be met, with an additional 2 of 4 from B. Adapted from 
DSM-5 (American Psychiatric Association, 2013) 
  
Detail Example 
A. Persistent deficits in social communication and social interaction across contexts 
(not accounted for by general development delays) 
A1. Deficit in socio-emotional reciprocity Abnormal social approach 
Lack of normal back and forth conversation 
Lack of initiation of social interaction 
A2. Deficit in nonverbal communicative 
behaviours 
Abnormal eye contact and body language 
Lack of facial expression and gestures 
A.3 Deficits in developing and maintaining 
relationships appropriate to developmental 
level 
Difficulty playing with and making friends 
Difficulty adjusting behavior to suit social 
context 
Absence of interest in others 
B. Restricted, repetitive patterns of behavior, interests or activities 
B.1 Stereotyped or repetitive speech, 
movement or interest in objects 
Unusual language 
Unusual hand and body movements 
Nonfunctional play with objects 
B.2 Excessive adherence to routines, ritualized 
patterns of verbal or nonverbal behavior 
Insistence on rigidity 
Rituals 
Excessive resistance to change 
B.3 Highly fixated interests that have abnormal 
intensity or focus 
Preoccupations 
Unusual interests or fears 
B.4 Abnormal reactivity to sensory aspects of 
the environment 
Adverse response to specific sounds or 
textures 
C. Symptoms must present in early childhood (but may not fully manifest until 
social demands exceed ability) 
 
D. Symptoms together limit and impair everyday functioning 
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There is increasing evidence that clinicians are able to reliably identify children with ASD as 
young as 2 years of age (Charman & Baird, 2002), and traits of ASD and related disorders 
may be recognised even earlier (Charman et al., 2000). However, despite better general 
awareness of ASD and improved early diagnostic tools (Luyster et al., 2009), most 
individuals do not receive a diagnosis until they reach school age (Yeargin-Allsopp et al., 
2003); and a considerable number are not diagnosed until adulthood (Aggarwal & Angus, 
2015; Geurts & Jansen, 2011). Early indicators include; lack of joint attention or shared 
enjoyment, limited social play, delayed onset of language and unusual ‘insistence on 
sameness’. An ASD diagnosis is based upon behavioural observations combined with 
evidence from a detailed developmental history. The diagnosis can be confirmed using the 
gold standard diagnostic tools; the Autism Diagnostic Observation Schedule (ADOS) (Lord 
et al., 2000), that a trained individual conducts with the patient; and the Autism Diagnostic 
Interview-Revised (ADI-R) (Lord, Rutter, & Couteur, 1994), which is an interview 
conducted with the parent/carer; alongside a comprehensive multidisciplinary review.  
 
If a diagnosis is not given in childhood, identifying ASD later in life becomes increasingly 
difficult. Though the ADOS has a specific module designed for use in verbal adults (module 
4), the materials and activities are designed for children, i.e. ‘Telling a story from a book’ or 
‘Imaginative play’, which may not be age-appropriate. Additionally, the ADOS module is 
selected on the basis of verbal ability, which may not always parallel cognitive ability 
(Gotham et al., 2007). Furthermore, as symptoms must be present from an early age to 
support an ASD diagnosis, in older individuals a detailed developmental history may not be 
available from a parent, or may be flawed due to incorrect recall and recall-bias (Schutte et 
al., 2015). Self- report can be used in lieu of parental interview; the Autism-Spectrum 
Quotient (AQ) is a self-reported questionnaire which can be useful in adults to assess the 
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degree of autistic traits, but as patients often lack insight into their own condition, it cannot 
be used as a stand-alone diagnostic tool (Baron-Cohen et al., 2001; Sizoo et al., 2015). 
Furthermore, the AQ has recently been shown to have poor predictive validity in ‘real world’ 
clinical settings. In development, the AQ was found to be highly effective at identifying ASD 
traits in those with a clinical diagnosis of ASD, compared to healthy controls, however in a 
clinical setting the AQ’s predictive power is poor, and may therefore lead to ‘false negative’ 
results (Ashwood et al., 2016). 
 
Recognition of autistic symptoms in general is clearer in children, with defined 
developmental markers in childhood against which progress can be compared. In contrast, 
such references do not exist in adulthood and can be confused by cultural differences. In 
addition, under long term social pressure to ‘fit in’, adults may have developed coping or 
masking techniques, either consciously or unintentionally. For example, training oneself to 
make eye contact during conversation, using learned jokes, or making contextually 
appropriate gestures or remarks (imitating facial expressions, or making sympathetic sounds 
in response to bad news). This ‘masking’ of symptoms is especially common in women with 
ASD (Lai et al., 2011).  
 
Considering the difficulties of diagnosing ASD in adulthood, it is conceivable that the 
prevalence of ASD in this age group is higher than is currently estimated, with many adults 
remaining undiagnosed and untreated, or misdiagnosed with other psychiatric disorders. This 
may also link to the scarcity of autism research in adults, as shown by a recent assessment 
which found only 15% of ASD research in the UK exclusively focused on adults with the 
condition, with the majority of studies focusing on children, or adolescents (Pellicano et al., 
2014). Hence, though it is prudent and necessary to initiate studies of neurodevelopmental 
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disorders as early in development as possible, this may have come at the expense of research 
into those already living with the condition as an adult.  
 
The pervasive idea that ASD is a neurodevelopmental, and therefore primarily a childhood, 
disorder may also contribute to the limited research in this age group. In reality, ASD is a 
lifelong condition, which persists as the brain matures and changes through life. It is 
important to note that findings from research in children cannot necessarily be extrapolated to 
adults- because the adult brain may respond differently. For example, differences in 
responsivity to drugs across ASD age groups have been reported by Hollander et al (2012), 
who observed significant decreases in repetitive behaviours in adults with ASD taking 
fluoxetine, yet only a modest effect in children with the disorder (Hollander, Phillips, et al., 
2005). A similar pattern of efficacy differences has been observed using fluvoxamine 
(McDougle et al., 1996, 2000). Thus, it should not be assumed that the adult brain is just a 
larger child’s brain- and this must be taken into consideration when attempting to identify 
treatments to alleviate the difficulties of living with ASD as an adult. 
 
1.1.1 Living with ASD as an adult 
The importance of providing mental health support for adults with autism is becoming 
increasingly recognised, for example by the UK government’s 2009 Autism Act and 
subsequent extension, ‘Think Autism’ in 2014. However, in reality, clinical services for 
adults remain markedly limited (UK Government, 2009, 2014). In particular, the transition 
from childhood to adulthood is a difficult time, involving the loss of school structure and 
support, and (in the UK) the transition from Child and Adolescent Mental Health Services 
(CAMHS) to Adult Services. For those adults with ASD, but an IQ>70 and no co-morbid 
psychiatric conditions, gaining support from adult services is near impossible, as they do not 
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fit into either learning disability or mental health streams (Pilling et al., 2012).  
 
The core symptoms of autism; difficulties in social interaction, communication and restricted 
interests, do not typically lend themselves to successful adult relationships in the workplace 
and in social settings. Only 15% of people with an ASD in the UK are in employment (NAS, 
2016), many of whom experience difficulty maintaining employment, not due to 
performance, but due to the requirement to interact and engage with colleagues (Vogeley et 
al., 2013). For high functioning individuals able to work, employment not only offers a 
financial income, but a chance to contribute and be valued in the community (Capo, 2001; 
Scott et al., 2015). In addition to poor employment opportunities, studies (admittedly 
conducted prior to the availability of early intervention strategies) predict that over half of 
patients have poor outcomes in terms of independent living, and forming peer relationships 
(Billstedt et al., 2005; Howlin et al., 2004, 2013).   
 
Though many people with ASD are able to live fully functional lives, a large proportion are 
severely debilitated and require full time care. Compounding the difficulties autistic patients 
face are co-occurring health, psychiatric and developmental disorders thought to affect up to 
70% of individuals (Lugnegård et al., 2011). The presence of these additional challenges are 
strongly associated with reduced quality of life, increased need for professional help and 
poorer prognosis (Carlsson et al., 2013; Levy et al., 2010; Mattila et al., 2010). Subsequently, 
the emotional, social and financial cost to these individuals and their families can be huge, 
particularly in areas where access to services and support is inadequate. It is estimated that 
autism costs the UK £32 billion per year; more than cancer (£12bn), heart disease (£8bn) and 
stroke (£4bn) combined (Buescher et al., 2014). The absence of pharmacological treatment 
options for the core symptoms of ASD and sometimes sub-optimal response of comorbidities 
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to conventional medications (Reiersen & Todd, 2008) contributes to the cost of ASD; yet the 
increased rate of diagnosis has not led to a proportional increase in available treatments. 
1.1.2 Current treatment options 
There are currently no pharmacological treatments for the core symptoms of restricted, 
repetitive behaviours, and social and communication difficulties in ASD. Repurposed 
medications have proven useful in managing associated behaviours; for example; the 
antipsychotics risperidone and aripiprazole are FDA-approved for the treatment of irritable 
behaviour in ASD (Dinnissen et al., 2014; Ghanizadeh et al., 2015; Sharma & Shaw, 2012), 
though they also have many detrimental side effects. Despite their efficacy in reducing 
challenging and repetitive behaviours, they also induce weight gain, sedation and 
extrapyramidal symptoms (Jannsen Pharmaceuticals Ltd, 2009; Otsuka America 
Pharmaceutical, Inc, 2002). Additionally, methylphenidate is often prescribed for ADHD 
(though this also comes with potential side effects) and people with ASD may be especially 
sensitive to these (Reiersen & Todd, 2008; Research Units on Pediatric Psychopharmacology 
Autism Network, 2005). Buspirone may also be prescribed with some efficacy, to reduce 
anxiety (Hsia et al., 2014). However, no pharmaceutical intervention has yielded results in 
terms of improving social communication as a primary outcome.  
 
Due to the current lack of pharmacological treatments, non-pharmacological treatment 
strategies have become the cornerstone of ASD management. Educational intervention 
(communication skills, play, addressing behavioural problems), psychotherapy (applied 
behaviour analysis) and cognitive behavioural therapy (CBT- restructuring maladaptive 
thoughts and behaviours) have all been successful in improving patient quality of life (Myers 
& Johnson, 2007), though more evidence is needed to fully assess their effectiveness 
(AHRQ, 2011). 
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Despite the relative success of these measures, there is a pressing need for effective 
pharmacological treatments for core deficits. The high level of phenotypic variability in 
ASD, by which one patient may present as high functioning yet another with the same 
disorder may be non-verbal, likely reflects the marked aetiological heterogeneity of the 
disorder, and has made the identification of a common underlying pathology challenging. If 
the biology was better understood this could point drug development in the direction of 
viable pathways to target. To advance drug discovery in this field, it is therefore of the utmost 
importance that we continue attempts to expose the underlying patho-aetiology of the 
disorder. 
1.1.3 Aetiology 
Autism was originally viewed as a result of inadequate mother-child bonding, specifically a 
cold attitude on the mother’s part, in what became known as the ‘refrigerator mother theory’ 
(Bettelheim, 1967). Today, the notion of parental fault is generally disregarded, and it is 
widely accepted that there is a neurobiological underpinning to ASD.  
 
It is well established that genetics play an important role in the development of ASD. Early 
twins studies suggested familial hereditability estimates of 56-95% (Colvert et al., 2015), but 
the role of genes in ASD is best demonstrated by the presence of syndromic forms, such as 
Fragile X syndrome and Retts syndrome, which have a clear genetic cause (a single gene 
mutation of the Fragile X Mental Retardation protein (FXMRp) or methyl CpG binding 
protein 2 (MECP2) genes, respectively (Amir et al., 1999; Verkerk et al., 1991). In addition, 
up to 1000 susceptibility genes have been identified, each accounting for a very small 
fraction of ASD cases (Berg & Geschwind, 2012). It has been suggested that the genes 
contributing to ASD fall within 3 main groups: those affecting the glutamate/GABA synapse; 
those involved in chromatin remodelling; and those causing alterations to gene transcription 
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and splicing (De Rubeis et al., 2014). 
 
Genetics are not solely responsible however; multiple environmental risk factors have also 
been identified, such as advanced parental age (Lampi et al., 2013), early prenatal maternal 
viral infection (Atladóttir et al., 2010) and environmental chemical exposure (Al-Hamdan et 
al., 2018; Kalkbrenner et al., 2014). However, aside from syndromic forms of ASD, no single 
genetic alteration or environmental factor has been identified as sufficient or necessary to 
develop an ASD. Instead, it is likely that most cases originate from an interplay of genetic 
predisposition and environmental exposures, which converge onto common molecular 
pathways involved in key neurodevelopmental processes (Baudouin, 2014; Persico & 
Bourgeron, 2006). For example, based on evidence that exposure to toxins such as valproic 
acid and maternal immune activation in prenatal life directly alters glutamate metabolism 
(Wei et al., 2016) and the GABA transcriptome (Dickerson et al., 2014; Richetto et al., 2014) 
respectively in the foetal brain; a candidate pathway susceptible to both genetic (above) and 
environmental risk factors for ASD is the glutamate-GABA system. 
Although a range of both genetic and environmental risk factors for ASD are now 
appreciated to act on glutamate-GABA pathways (Banerjee et al., 2013; Baudouin, 2014; The 
Autism Genome Project Consortium, 2007), the first forays implicating this molecular 
pathway in ASD pathology stemmed from the association of ASD with increased rates of 
epilepsy- a condition known to arise from altered excitatory (E) and inhibitory (I) signalling 
in the brain (Tuchman & Cuccaro, 2011; Tuchman & Rapin, 2002). Whilst the high 
frequency of comorbidity of epilepsy with ASD could indicate shared symptomatology or 
even simply similar diagnostic criteria, it is thought likely to be due to a common underlying 
pathology; a disruption of the E-I system (Lai et al., 2014). Furthermore, other conditions 
which are well accepted to be at least partly due to disruption of E-I balance are also often 
38 
linked to ASD; for example Obsessive Compulsive Disorder (OCD), Attention Deficit 
Hyperactivity Disorder (ADHD), anxiety and depression (Avoli & de Curtis, 2011; Kariuki-
Nyuthe et al., 2014; Lydiard, 2003; Mann et al., 2014; Purkayastha et al., 2015). Early 
developmental problems, such as intellectual disability and ADHD are most commonly 
observed to accompany ASD in childhood (Leyfer et al., 2006; Matson & Shoemaker, 2009; 
Simonoff et al., 2008), whilst in ASD in adulthood, in addition to ADHD and anxiety 
disorders, mood disorders are common (Croen et al., 2015; Ghaziuddin et al., 2002; 
Hofvander et al., 2009; Sterling et al., 2008). A comprehensive list of the conditions highly 
associated with ASD and their proposed pathophysiology are found in Table 1.2. 
 
Though for brevity the present thesis focuses on GABA and glutamate pathways as the 
principle controllers of E-I balance, they should not be viewed in isolation as they interact 
with, and can be modulated by, a number of other neurochemical pathways. Serotonin in 
particular is a particularly influential modulator of E-I balance. For example, in the frontal 
cortex, hippocampus and cerebellum, serotonin induces a decrease of glutamate transmission 
and a parallel increase in GABA (Ciranna, 2006). Likewise, dopamine affects glutamate 
function with different effects depending on the receptor, cell type and brain region, 
involved. In the striatum for instance, D1 receptors potentiate responses mediated by NMDA 
receptors, whereas D2 receptors depress AMPA responses (Tseng & O’Donnell, 2004). 
Given the importance of serotonin and dopamine in modulating E-I balance, it is unsurprising 
that disruptions to these systems have also been implicated in the pathology of ASD (Muller 
et al., 2016; Pavǎl, 2017). The importance of these neurotransmitters is highlighted in Table 
1.2, where disruptions of serotonin and dopamine, amongst others, have been linked to 
disorders often co-morbid with ASD (Clarke et al., 2014; Gleason et al., 2010; Helton & 
Lohoff, 2015; Spencer et al., 2005; Vaswani et al., 2003). Hence, although I focus on GABA 
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and glutamate in the present thesis, it is important to highlight that these are two of many 
neurochemicals altered in the pathogenesis of ASD. 
  
Taken together, these associations strongly implicate differences in the E –I system as a 
potential underlying cause of ASD, and hence a potential therapeutic target. Maintaining a 
balance of excitatory to inhibitory neural control is essential from conception throughout the 
entire lifespan. Any alteration to this system could therefore have profound and far reaching 
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Common in adults, 
less so in children 
(Ghaziuddin et al., 
2002; Hofvander 
et al., 2009) 
E-I imbalance (Mann et 
al., 2014; Pehrson & 
Sanchez, 2015; Veeraiah 
et al., 2014) 
Serotonergic dysfunction 




(Hofvander et al., 
2009; Lugnegård 
et al., 2011; 
Simonoff et al., 
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Table 1.2: Comorbid conditions common to Autism Spectrum Disorders 






et al., 2006; 
Simonoff et al., 
2008) 
May now be 
diagnosed in 
addition to ASD 
under DSM-V, 
where DSM-IV 









(Spencer et al., 2005, 
2007) 
E-I imbalance 
(Purkayastha et al., 2015) 
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1.2 The Excitation - Inhibition System 
Glutamate and -aminobutyric acid (GABA) are respectively the major excitatory and 
inhibitory neurotransmitters in the brain. The processes by which each of these 
neurotransmitters is synthesized, released, removed from the synaptic and extra-synaptic cleft 
and metabolized are all tightly regulated and have, for many years, been targets for drug 
discovery. They are found in all brain regions and have multiple neurobiological functions, 
mediated by different types of receptors. A balanced interaction between glutamate and 
GABA is essential for effective neurotransmission from conception and throughout the whole 
lifespan. The regulation of E-I balance is particularly important during neurodevelopment, 
where GABA and glutamate act in synchrony to regulate the proliferation, migration and 
differentiation of neuronal cells. Balanced neurotransmission is also essential for synaptic 
maturation, refinement of neuronal circuitry and eventually the regulation of cognition, 
emotion and behaviour (Luján et al., 2005).  
 
1.2.1 Pharmacology 
1.2.1.1 Synthesis  
The amino acid glutamine is synthesised by astrocytes and converted to glutamate via the 
enzyme glutaminase in both glutamatergic and GABAergic neurons. In excitatory neurons, 
glutamate is transported into vesicles via vesicular glutamate transporters (vGluT) and 
released into the synaptic cleft upon depolarisation of the neuron. In inhibitory neurons, 
glutamate is converted to GABA, by the glutamic acid decarboxylase (GAD) enzyme. GAD 
exists in two isoforms, GAD65 and GAD67, which have different molecular weights (65 and 
67 kDa respectively), properties, and subcellular localization (Erlander et al., 1991). GABA 
is then transported to vesicles for release via vesicular GABA transporters (vGAT). Upon 
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release, neurotransmitters are taken up by high affinity membrane transporters back into 
neurons and surrounding glia, where they are recycled for continued use. Glutamate may be 
converted to glutamine for storage in astrocytes via glutamine synthase, or converted to 
GABA via GAD in GABA-synthesising inter-neurons (Rowley et al., 2012). In this way, 
GABA and glutamate are in constant flux, each continuously contributing to the synthesis of 





Figure 2.1: Synthesis, release and metabolism of glutamate and GABA 
Glutamine is converted to glutamate via the enzyme glutaminase, which then goes on to 
either be released by excitatory neurons, or converted to GABA via the enzyme glutamic acid 
decarboxylase in inhibitory neurons. Neurotransmitters are taken up into astrocytes and 
neurons to be recycled to glutamate and glutamine, thus the cycle re-starts. Adapted from 
Rowley et al., 2012. 
Abbreviations: 2-OG, 2-oxoglutarate; AAT, aspartate aminotransferase; Aralar, aspartate-
glutamate carrier; Asp, aspartate; EAAT, excitatory amino acid transporter; GABA-T, GABA 
transaminase; GAD, glutamic acid decarboxylase; GAT, GABA transporter; GDH, 
glutamate dehydrogenase; SSA, succinic semi aldehyde; TCA, tricarboxylic acid cycle; 
vGAT, vesicular GABA transporter; vGlut, vesicular glutamate transporter. 
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1.2.1.2 Receptors and signalling pathways 
Neuronal action potentials initiate neurotransmitter release into the synaptic cleft, where they 
act on multiple pre- and postsynaptic receptors (Figure 1.2), triggering a signalling cascade 
within the cell that modulates neuronal activity. Excitatory synaptic transmission is initiated 
by glutamate binding to either ionotropic (AMPA, NMDA or Kainate) ion channel receptors, 
or metabotropic G protein-coupled receptors (mGluR1-5). Activation of ionotropic receptors 
opens the ion channel and allows influx and efflux of sodium (Na+), potassium (K+) and 
calcium (Ca2+) ions, to produce an Excitatory Post Synaptic Potential (EPSP) and fast 
neuronal activity. In comparison, metabotropic receptors are G protein-coupled, and therefore 
have a relatively slower action, as ligand activation first evokes secondary messenger 
signalling cascades prior to ion channel modulation.  
 
GABA receptors are also grouped according to their activation mechanism; GABAB receptors 
are G protein coupled, and are found pre- and postsynaptically, whereas GABAA receptors 
are ionotropic, postsynaptic chloride (Cl-) ion channels. Upon binding to the GABAA 
receptor, GABA evokes a conformational change, which allows the receptor to facilitate the 
passive influx or efflux of Cl- ions, dependent upon the neuronal equilibrium potential for 
chloride (ECl
-). During postnatal life, this presents as an influx, which results in inhibitory 





Figure 1.3: Schematic representation of glutamate and GABA receptors at the synapse 
Glutamate (yellow circles) and GABA (red circles) are released from presynaptic terminals, 
diffuse across the synaptic cleft, and activate receptors located on postsynaptic neurons. 
Additionally, glutamate and GABA can act at receptors on nearby astrocytes and as 
retrograde transmitters on presynaptic nerve terminals. Figure taken from Niswender & 
Conn, 2010. 
Abbreviations: mGluR, metabotropic glutamate receptor; GABAA/B, GABA A and B receptors; 
NMDA, N-Methyl-D-aspartic acid receptor; AMPA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor; Ca2+, calcium; Na, sodium; Cl, chloride; cAMP, cyclic 
adenosine monophosphate  
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Prenatally however, GABA acts very differently. Over the time course of synaptic 
development in utero, GABA synapses develop first, prior to their glutamatergic 
counterparts. Hence GABA initially plays an excitatory role, before ‘switching’ to its 
eventual inhibitory purpose after birth.  
 
Initially, immature neurons have a high level of intracellular Cl- ions compared to the 
extracellular space; therefore when activated by GABA, the relative difference of ECl
-  
(positive) to the resting membrane potential (Vm), causes a net Cl
- efflux via a sodium-
potassium-chloride co-transporter (NKCC1) and membrane depolarisation (Ben-Ari et al., 
2012). The ‘switch’ to inhibition is thought to occur at birth, as preclinical studies indicate a 
dramatic reduction of intracellular Cl- immediately prior to, and post-delivery, in response to 
maternal oxytocin released during labour (Tyzio et al., 2006). Additionally, around the same 
time, there is a distinct change in neuronal chloride co-transporter expression; NKCC1 
expression decreases, and is superseded by expression of potassium-chloride co-transporter, 
KCC2 (Clayton et al., 1998). The decrease in intracellular Cl- means that the relative 
difference between ECl
-  and Vm is now negative, therefore, in mature postnatal neurons, 
lower intracellular Cl- results in a net Cl- influx via KCC2 and membrane hyperpolarisation 







Figure 1.3: The developmental GABA switch from excitation to inhibition 
The shift in GABA function is partly determined by the sequential development of two 
chloride transporters; NKCC1 develops first and imports Cl- upon GABAA receptor 
activation, and KCC2 develops later, and exports Cl- upon receptor activation. This causes 
depolarization and hyperpolarization of the neuron respectively.  




1.2.2 Glutamate and GABA in neurodevelopment 
Glutamate and GABA act together to initiate and control events such as neural proliferation, 
migration, differentiation and synaptogenesis during prenatal brain development and 
throughout postnatal life (Luján et al., 2005).  
 
Prenatally, the proliferation of neuronal progenitor cells is fundamental for generating 
neurons in the correct sequence and location in the brain. Glutamate and GABA receptor 
emergence and activation are believed to regulate this system, and have been identified as 
instrumental in controlling DNA synthesis in dividing neurons (Ben-Yaakov & Golan, 2003; 
Haydar et al., 2000; LoTurco et al., 1995). Post creation, most neurons migrate from their site 
of origin to their intended destination in the cortex, thus creating the complex patterning and 
organization of the brain regions. This too is dependent upon the emergence of GABA and 
glutamate control at the correct time. For example, in the prefrontal cortex, glutamate acts as 
a chemoattractant signal to guide incoming neurons (Behar et al., 1999). For these neurons to 
effectively signal, they need to be positioned and anchored together. This is achieved by a 
complex structure of cell adhesion proteins, most notably neurexins and neuroligins, which 
work together to maintain synaptic stability. These structures are essential for effective 
glutamatergic and GABAergic transmission, and any abnormalities can cause profound 
implications for E-I signalling. Their role in ASD is discussed in further detail in section 1.3. 
 
In addition to correctly positioning cortical neurons, glutamate also alters cortical neuron 
cytoarchitecture prenatally, and during the first postnatal days. Pyramidal neurons are the 
primary excitation unit in the prefrontal cortex, but are also found in abundance throughout 
the cerebral cortex, and in the hippocampus and amygdala; areas known to be associated with 
advanced cognitive function (Spruston, 2008). During pyramidal neuron development, 
51 
glutamate regulates selective inhibition of dendritic growth and dendritic pruning (at non-
toxic levels). Some studies also show a role for glutamate in encouraging dendritic growth 
and branching of cerebellar granule cells (Pearce et al., 1987) and hippocampal cells 
(Mattson et al., 1988). This complex guidance system, mediated by progressive GABA and 
glutamate activity, allows neurons to grow towards their postsynaptic targets, ready to form 
synapses, which enable neurons to fire and wire together. Hence, what begins as a diffuse and 
overlapping networks of neuronal contacts, is in time refined (through repeated E-I activity) 
into better defined local circuits, which may interact to form extensive neural networks.  
 
With such complex shifts in excitatory - inhibitory function in the perinatal period, it is easy 
to imagine that slight alterations in E –I balance could significantly alter the effectiveness of 
neural signalling and could potentially give rise to subtle, but wide-ranging differences in the 
neural networks which coordinate complex behaviours in ASD. 
 
1.3 Excitation – Inhibition Imbalance in ASD 
The development and firing of neural networks are co-ordinated by excitatory glutamate, and 
inhibitory GABA transmission, hence alterations to this system have been proposed to be key 
to the pathology of ASD (Coghlan et al., 2012; Gao & Penzes, 2015; Uzunova et al., 2016). 
Indeed, many known aetiological and genetic risk factors for ASD appear to affect the 
balance of this system (for more details please see below).  
Initially, this may lead to disruption of neurogenesis, neuronal proliferation and migration 
and synaptogenesis (Packer, 2016). However on a grander scale, such disruptions to brain 
cytoarchitecture would inevitably result in affected brain regions being unable to generate 
connections that give rise to fully effective functional networks (Courchesne et al., 2007; 
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Ecker & Murphy, 2014; Stanfield et al., 2008) and thus behaviour would be affected.  
 
1.3.1 Genetic and preclinical evidence 
There is an accumulation of evidence from genetic and preclinical studies to support a role 
for differences in E-I in ASD. 
 
Genetically determined abnormalities in GABA and glutamate signalling pathways have 
consistently been associated with ASD. The GABAA receptor may be of particular 
significance, as studies of ASD susceptibility genes have identified chromosome 15q11-q13 
as a region of interest, and this contains three GABAA receptor subtype genes (β3, γ3 and α5)  
(Pizzarelli & Cherubini, 2011). Mutations in this region, and in particular those in the β3 
subunit (Chaste et al., 2014; Isles et al., 2016; Shao et al., 2003), convey a high risk for ASD. 
Additionally, evidence for the link between GABAA-β3 and autism has been shown in a 
mouse knock-out model, in which an absence of the β3 subunit caused behavioural 
difficulties relevant to autism; such as repetitive and stereotyped behaviours (stereotypical 
cage circumnavigation and ‘tail chasing’) in addition to poor motor co-ordination and 
learning deficits (DeLorey et al., 1998). Likewise, GABAA-5 alterations have been reported 
in adults with ASD, namely in a preliminary PET study reporting significantly reduced 
binding to the 5 subunit across multiple brain regions (Mendez et al., 2013), although this 
finding was not replicated in a larger cohort (Andersson et al., 2017). Post-mortem studies in 
ASD have also pointed to GABA abnormalities including reduced mRNA levels for multiple 
GABAA and GABAB receptor subtypes (Fatemi et al., 2014; Fatemi & Folsom, 2015; Oblak 
et al., 2009, 2010) and GABAA and GABAB receptor protein levels have been are reported to 
be lower the cingulate cortex of adults (Fatemi et al., 2010; Oblak et al., 2010) and prefrontal 
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cortex of children with ASD (Mori et al., 2012). Furthermore, single cell transcriptomic data 
suggest that inhibitory neurons may be a major neuron subtype affected by the disruption of 
ASD gene networks (Wang, Zhao, Lachman, & Zheng, 2018). 
Studies have also uncovered associations between ASD and polymorphisms in genes 
involved in glutamatergic signalling pathways. Fragile X Syndrome, the most common 
genetic form of ASD-like behaviours, is caused by a single gene mutation affecting fragile X 
mental retardation protein (FXMRp) (Verkerk et al., 1991). In healthy individuals, FXMRp 
acts to negatively regulate postsynaptic glutamate receptor (mGluR5) activity, and its absence 
leads to excessive excitatory activity, which presents as an autism-like phenotype (Lozano et 
al., 2014; Yu & Berry-Kravis, 2014). Furthermore, genetic (Dölen et al., 2007) and 
pharmacological (Mehta et al., 2011) reduction of mGluR activity in rodent models, have 
been shown to significantly improve ASD-like behaviours. However, pharmacological 
attempts to reduce mGluR activity in humans with ASD have since failed in clinical trials 
(Berry-Kravis et al., 2016; Scharf et al., 2015), suggesting the E-I imbalance in ASD is not 
straightforward. For example, the numbers of glutamate receptors have also been reported to 
be altered in ASD; mGluR5 has been shown to be significantly higher in ASD (Fatemi et al., 
2011), whereas reduced NMDA receptor expression gives rise to ASD-like behaviours in 
mice (Gandal et al., 2012). Such alterations in receptor density and activity will no doubt 
affect synaptic efficacy, but coupled with this, there is emerging evidence that the structural 
integrity of the synapse itself is also affected in ASD.  
 
Cell adhesion molecules neurexin and neuroligin, and scaffolding proteins Post Synaptic 
Density – 95 (PSD-95) and SHANK act together to establish the structural architecture of E-I 
synapses (see Figure 1.4). Anchoring of the pre- and post-synaptic neuron terminals via this 
matrix is essential to synapse formation, alignment and stability (Lee & Sheng, 2000). 
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Impairment of any one component therefore, could result in irregular molecular assembly of 
the synapse, and hence faulty E-I neurotransmission (Futai et al., 2007; Südhof, 2008; Zhao 




Figure 1.4: Neuroligin-Neurexin complexes stabilize the synapse 
Neurexin, a presynaptic neuronal adhesion molecule, interacts with neuroligins (its post-
synaptic equivalent), which in turn bind intracellularly to Post Synaptic Density protein 95 
(PSD-95). SHANK proteins form a matrix to anchor this complex. Figure taken from State, 
2010. 
Abbreviations: mGluR, metabotropic glutamate receptor; NMDAR, N-methyl-D-aspartate 
receptor; FMRP, Fragile X Mental Retardation Protein; PSD-95, Post Synaptic Density 
protein 95; GKAP, guanylate kinase-associated protein. 
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Of this group of synaptic proteins, the neurexin-neuroligin complex is one of the most studied 
trans-synaptic pairs in ASD. Distinct pairings of these families play discrete roles during 
synaptogenesis; for example, neuroligin-1 regulates excitatory synapse formation (Song et 
al., 1999), whereas neuroligins -2 and -3 regulate inhibitory synapse formation and 
maturation (Levinson et al., 2005; Varoqueaux et al., 2004). In connecting the pre- and post-
synaptic neurons, neurexin-neuroligin interactions mediate signalling across the synapse, 
which in turn modulates synaptic activity and determines the properties of neuronal networks. 
It is therefore unsurprising that genetic alterations to this process have been linked to 
cognitive deficits, such as those seen in autism. Several copy number variants (CNVs) across 
the two families have been associated with ASD, with the highest prevalence for mutations in 
Neurexin-1 (Ching et al., 2010; Feng et al., 2006; Kim et al., 2008; Yan et al., 2008) and 
Neuroligin-3 (Jamain et al., 2003; Yanagi et al., 2012; Yu et al., 2011). Considering the 
essential role of neurexins and neuroligins in structuring the synapse, and the clear link to 
ASD in humans, genetically modified animal models have been created to explore the 
disrupted synaptic mechanisms in ASD.  
 
Neurexin1 homozygous knock out (Nrxn1-/-) mice have been reported to have weak 
excitatory synaptic strength and reduced excitatory post synaptic current (EPSC) frequency 
compared to wild type controls (Etherton, Blaiss, Powell, & Südhof, 2009). Additionally, 
knock out mice have fewer spontaneous and evoked excitatory and inhibitory 
neurotransmitter release events (Kattenstroth et al., 2004; Missler et al., 2003; Zhang et al., 
2005). Behavioural abnormalities have also been observed in the knock-outs; including 
increased grooming behaviours, decreased startle response and impaired nest building and 
social investigation (Dachtler et al., 2015; Etherton, 2009; Grayton et al., 2013; Laarakker et 
al., 2012). More recently, a rat model of Neurexin1 deletion became available. This animal 
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has persistent non-social cognitive deficits, such as hyperactivity, reduced learning ability 
and inattention (Esclassan et al., 2015). Though the human condition can never be fully 
replicated in an animal model, the features observed in Neurexin1 rodents may proxy the 
repetitive behaviours, cognitive deficits and inflexibility/stereotypy which are core to the 
human condition and therefore provide a useful model to study mechanisms underpinning 
ASD in the laboratory (Etherton et al., 2009; Grayton et al., 2013). 
 
Thus, the combined evidence from the aforementioned genetic and pre-clinical studies 
strongly suggest that E-I imbalance is relevant to the pathophysiology of ASD. However, 
directly measuring this imbalance in vivo in the living human brain has proved to be 
challenging. There is hope however, as recent advances in magnetic resonance imaging has 
enabled safe, in vivo quantification of brain metabolites in both healthy individuals, and those 
with ASD. 
 
1.3.2 E-I in the living human brain – metabolite levels 
The first approach to assessing levels of both glutamate and GABA in autistic patients was to 
study plasma metabolite concentrations, which were taken as an indication of what may be 
happening in the brain. Findings were inconsistent using this method, for example, glutamate 
serum levels were found to be significantly higher in children (Hassan et al., 2013) and adults 
(Shinohe et al., 2006) with ASD, yet high serum levels of GABA have also been reported in 
ASD populations (Dhossche et al. 2002). Such inconsistencies may have arisen because the 
blood-brain barrier does not permit free movement of metabolites between intracranial and 
plasma compartments. This is especially true for GABA, which is known to be unable to 
cross this barrier (Van Gelder & Elliott, 1958). Measuring E-I by proxy may therefore not be 
the best approach. Rather, direct measures of neurotransmitters in the living brain are needed 
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to understand E-I balance in situ. Direct measures of glutamate, and more recently, GABA, 
using Magnetic Resonance Spectroscopy (MRS) are now possible. Using this technique, E-I 
levels can be quantified in a predefined brain region of interest, in an awake, living human 
brain.  
 
MRS studies in ASD have largely focused on the basal ganglia and prefrontal cortex. ASD is 
believed to be a disorder of network connectivity (Mohammad-Rezazadeh et al., 2016; Nomi 
& Uddin, 2015), and considering the extent of executive function, socio-emotional and 
repetitive behaviours observed in this condition, the subcortical and prefrontal networks sub 
serving these activities have been linked to both socio-communication deficits and repetitive 
behaviours in ASD (Calderoni et al., 2014; Estes et al., 2011; Holmboe et al., 2010; Horder et 
al., 2013; Kalbe et al., 2010; Kratsman et al., 2016; Martínez-Sanchis, 2015; Prat et al., 2016; 
Qiu et al., 2010). Consistent with this, both structural and signalling abnormalities of these 
regions have been associated with the core symptoms of ASD (Haznedar et al., 2006; 
Hollander et al., 2005; Prat, 2016; Schmitz et al., 2007, 2008). However, the results from 
studies comparing baseline metabolite levels in these regions (and other brain areas) between 
groups are still at variance (see Table 1.3; and for a complete review see Ajram et al., 2018, 
Appendix 1).  
 
Multiple MRS studies have reported an excess of glutamate across the brain in ASD, for 
example in the frontal cortex (Hassan et al., 2013; Joshi et al., 2013), amygdala and 
hippocampal regions (Page et al., 2006) and auditory cortex (Brown et al., 2013). Yet others, 
including research from my own department, have found that there is lower resting glutamate 
levels in ASD participants in the subcortex (Horder et al., 2013), cingulate (Tebartz van Elst 
et al., 2014) and anterior cingulate cortex (Bernardi et al., 2011). Still others have found no 
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differences in glutamate levels across the brain (Ajram et al., 2017; Carvalho Pereira et al., 
2017; Cochran et al., 2015; DeVito et al., 2007; Hardan et al., 2008; Libero et al., 2015; 
Tebartz van Elst et al., 2014). 
 
Though fewer in number, MRS studies of GABA are more consistent and generally find 
lower GABA in the ASD brain; for example GABA has been shown to be lower in the frontal 
cortex (Harada et al., 2011; Kubas et al., 2012), motor and auditory regions (Gaetz et al., 
2014) of children with the disorder. Again, others have also observed no differences in brain 
GABA in ASD (Ajram et al., 2017; Brix et al., 2015; Carvalho Pereira et al., 2017; Gaetz et 
al., 2014; Harada et al., 2011).  
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Brain Region Metabolite measured 
 Glx or Glutamate GABA 
Anterior cingulate 
cortex 
 Hassan et al. 2013 * 
 Joshi et al. 2013  
 Bejjani et al. 2012 * 
 Tebartz van Elst et al. 2014  
 Bernardi et al. 2011  
 Libero et al. 2015   
 Cochran et al. 2015  
 Cochran et al. 2015  
= Brix et al. 2015 * 
Medial prefrontal 
cortex 
= Carvalho Pereira et al. 2017 * 
= Ajram et al. 2017  
= Carvalho Pereira et al. 2017 * 
= Ajram et al. 2017  
Amygdala  Page et al. 2006   
Hippocampus  Page et al. 2006   
Basal Ganglia 
Striatum 
 Horder et al. 2013  
 Hassan et al. 2013 * 
 Harada et al. 2011* 
Thalamus  Hardan et al. 2008 *  
Frontal lobe  Hassan et al. 2013 * 
 
 Harada et al. 2011* 
 Kubas et al. 2012 * 
Lenticular nuclei   Harada et al. 2011* 
Motor cortex   Gaetz et al. 2014 * 
Visual cortex   Gaetz et al. 2014 * 
Auditory cortex  Brown et al. 2013b   Gaetz et al. 2014 * 
Cerebellum  Tebartz van Elst et al. 2014  
 DeVito et al. 2007 * 
 Hassan et al. 2013 * 
 
 
Table 1.3: [1H]MRS quantified glutamate and GABA differences for patients with ASD 
1.5 Tesla; 3 Tesla; 4 Tesla; * Children;  Adolescent;  Adult. A comprehensive review of 
MRS studies in ASD can be found in Ajram et al., 2018 (Appendix 1).  
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Discrepancies between studies may be due to a number of factors, most notably the inevitable 
differences in patient demographics that arise when investigating such a heterogeneous 
population. In particular, variations in current medication and the presence of comorbid 
mental or physical health symptoms, such as anxiety or epilepsy, may alter results, as some 
patients may consequently have pharmacologically altered E-I balance or alterations 
attributable to a co-occurring condition (Pizzarelli & Cherubini, 2011). Likewise, 
inconsistencies between studies of different ages are not surprising given reports that 
glutamate also varies across age groups and brain regions in typically developed participants 
(Kaiser et al., 2005; Sailasuta et al., 2008) and metabolite levels may ‘normalise’ with age in 
people with ASD (Aoki et al., 2012; Ipser et al., 2012). Ultimately however, participant 
variability may stem from the fact that even ‘pure’ ASD is a highly heterogeneous disorder 
(Ecker et al., 2013), and not all individuals necessarily share the same E-I profile. 
 
Practically, between-study differences in experimental protocol may also contribute to 
divergent MRS findings. Different scanner field strengths and protocols will provide different 
measures of metabolites, as (due to their structural similarity) glutamate, glutamine and 
GABA are difficult to isolate and quantify at lower field strengths such as 1.5T (Puts & 
Edden, 2012) and are often combined into one measure of ‘Glx’ in these studies (e.g. 
Bernardi et al. 2011; DeVito et al. 2007 and Horder et al. 2013). At field strengths of 3T or 
above, with specific scanner parameters, such as J-edited MEGAPRESS (MEshcher-
GArwood Point RESolved Spectroscopy) (Edden & Barker, 2007; Mescher et al., 1998) and 
specialised software tools (Edden et al., 2014; Naressi et al., 2001), GABA and 
glutamate/glutamine can be isolated and separately quantified, allowing us to observe them as 
independent components of the E-I system (although in the majority of studies the GABA 
measure is a combined signal with lipid macromolecules). Considering the difference in 
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metabolite composition, it may therefore not be appropriate to compare results at different 
field strengths.  
 
1.3.3 Measuring E-I responsivity in the human brain  
The fact that E-I balance is not static (and so may contribute to this failure to replicate study 
results) has been largely overlooked in the literature. As is evident from Table 1.3, the 
majority of research concerning E-I metabolite levels in ASD has focused on either glutamate 
alone, or only GABA levels. However, glutamate and GABA do not exist in isolation in vivo 
- the system is in constant flux (Hyder et al., 2013; Rothman et al., 2011, 2012; Sibson et al., 
1998). Control of this flux may well be abnormal in ASD, as glutamic acid decarboxylase 
(GAD) levels, which converts glutamate to GABA, have been found to be lower in ASD 
(Fatemi et al., 2002; Yip et al., 2007, 2009), and altered in ASD animal models (Wei et al., 
2016; Zhang et al., 2014). Differences in E-I flux, and subsequent responsivity of the E-I 
system, may therefore need to be taken into consideration in studies of E-I in ASD, yet this 
has not been directly examined in vivo. 
 
1.3.3.1 Choice of drug 
To examine system dynamics, one approach is to provide a challenge to the system and 
capture its response. This may be achieved pharmacologically, and in the experiments 
reported in this thesis I elected to use the drug riluzole, because it has broad actions on E-I 
and should therefore modulate E-I transmission in a range of participants. 
 
Riluzole is an FDA-approved medication for the treatment of amyotrophic lateral sclerosis 
(ALS) and has actions at both GABA and glutamate targets. For example, in both in vitro and 
63 
in vivo studies, riluzole has been shown to inhibit pre-synaptic release of glutamate (Cheramy 
et al., 1992; Doble, 1996; Jehle et al., 2000), potentiate postsynaptic GABAA receptor 
function (He et al., 2002) and block GABA reuptake into the striatum (Mantz et al., 1994). In 
addition to its direct actions on glutamate and GABA pathways, riluzole may also modulate 
E-I via its additional effects on ion channel activity. For example, in vitro studies have shown 
riluzole to decrease sodium (Wang et al., 2008) and potassium (Zona et al., 1998) channel 
activity, as well as inhibiting ionotropic glutamate receptor currents (namely NMDA and 
Kainate; Debono et al. 1993). 
 
In this instance, the polypharmacology of riluzole may be advantageous; as a modulator of 
the E-I system through both glutamatergic and GABAergic mechanisms, riluzole should have 
the potential to modulate E-I flux in the majority of individuals. Importantly, riluzole has a 
well-established pharmacokinetic and safety profile; and a single dose can reach peak plasma 
concentration within a relatively short time frame (1 hour) with relatively low risk of adverse 
effects (Le Liboux et al., 1997). 
 
1.3.3.2 Choice of brain region 
It is clear from Table 1.3 that E-I imbalances are found in a variety of brain regions in ASD. 
For the present study, the dorsomedial prefrontal cortex (containing the anterior cingulate 
cortex) and a sub-cortical region targeting the left basal ganglia were selected as targets as 
both are associated with the social, communication, affective and cognitive functions which 
are disrupted in autism (see page 60 for further detail). The larger area of the dorsomedial 
prefrontal cortex was selected as the region of interest, rather than the anterior cingulate 
alone, in order to compare results with other ongoing studies in the department which used 
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the same methodology. This was also a technical decision, as a large region is needed to 
capture a good signal, thus the voxel extends beyond the size of the ACC. 
 
1.3.3.3 Choice of modality 
Responsivity of the E-I system can be investigated at multiple levels in the human brain, each 
of which tell us something different. As explored in section 1.3.2, MRS enables sampling of 
bulk intracellular measures of metabolites and will allow for comparisons of E-I responsivity 
at a tissue level. In the present thesis, I therefore opted to utilise this technique to investigate 
whether the intracellular dynamics of the E-I system differs in ASD. However, MRS is not 
sensitive to differences in synaptic events, therefore it is not possible to know what 
proportion of the metabolites measured are a result of active neurotransmission. An 
additional approach may therefore help to assess E-I responsivity in terms of its influence on 
brain function.  
 
1.3.4 E-I in the living human brain – functional impact 
Functional connectivity as measured using fMRI refers to the extent that activity across 
interconnected brain regions is synchronized (Friston, Worsley, Frackowiak, Mazziotta, & 
Evans, 1994); i.e. what fires together wires together (Hebbian theory -Hebb 1949). As ‘firing’ 
is primarily determined by the balance between glutamate-driven excitation, and inhibitory 
GABA feedback signalling within local microcircuits (Buzsáki et al., 2007; Kapogiannis et 
al., 2013; Magistretti & Pellerin, 1999), functional connectivity measures can be used to as a 
proxy measure of inter-regional glutamatergic and GABAergic drive. For example, in typical 
individuals, prefrontal glutamate concentration correlates with the strength of prefrontal 
functional connectivity (Duncan et al., 2013); and posteromedial cortex glutamate and GABA 
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predict intrinsic functional connectivity of the default mode network (Kapogiannis et al., 
2013). Likewise, local GABA concentration predicts the extent of inhibition within the motor 
network (Stagg et al., 2014) and striatal GABA levels relate to functional connectivity of the 
basal ganglia (Haag et al., 2015). Any changes to E-I balance may therefore have widespread 
influence on the regulation of the functional connectivity of resting state networks. However, 
functional connectivity can also be modulated through multiple neurotransmitter systems, and 
this should be remembered when interpreting the results from fMRI studies. 
 
It is well established in the literature that functional connectivity, potentially stemming from 
E-I differences, is altered in ASD (Hahamy, Behrmann, & Malach, 2015; Jann et al., 2015; 
Just, Keller, Malave, Kana, & Varma, 2012; Schipul, Keller, & Just, 2011). Under-
connectivity across long-distance networks in ASD has been fairly consistently reported in 
ASD (Cherkassky, Kana, Keller, & Just, 2006; Just, Cherkassky, Keller, & Minshew, 2004; 
Just et al., 2012; Washington et al., 2014), particularly in networks incorporating the 
prefrontal cortex, for example the default mode network (DMN) where reduced connectivity 
in ASD has been linked to severity of social symptoms (Assaf et al., 2010; Weng et al., 
2010).  By contrast, others have found over-connectivity in shorter distance networks in ASD 
(Uddin et al., 2013). For example, social impairments and repetitive behaviours have been 
linked to increased connectivity within cortico-striatal circuitry (Delmonte et al., 2013). 
Taken together, there appears to be a loss of long range neural coherence, coupled with, 
perhaps compensatory, increases in short-range cortico-subcortical connectivity in ASD at 
rest (reviewed by Rane et al. 2015).  However, to date, no one has examined the dynamics of 




Hence, the present thesis also incorporated a resting state fMRI study to examine whether 
there are group differences in the response of functional connectivity of networks associated 
with ASD after E-I challenge with riluzole. 
  
As noted above, the MRS and functional connectivity measures used in the human studies in 
this thesis have limitations. For instance, MRS is a direct measure of glutamate and GABA 
but only at a ‘bulk’ tissue (and mainly intracellular) level; and fMRI is an indirect measure of 
network activity that does not directly measure extracellular levels of neurotransmitters in the 
living brain. Examination of neurotransmitter efflux into the extracellular space is however 
possible in animal models using in vivo microdialysis. 
 
1.3.5 E-I in the rodent brain – sampling the extracellular space 
Microdialysis is an established sampling technique for the in vivo measurement of 
neurotransmitter efflux into the extracellular space of discrete brain regions (see methods 
section 2.2.4.2 for further detail). For example, microdialysis has proven effective at 
capturing increases in prefrontal and caudate efflux of glutamate following amphetamine 
(Del Arco, Martínez, & Mora, 1998) and haloperidol treatment respectively (Yamamoto & 
Cooperman, 1994). Pertinently, this technique has also captured decreases in glutamate efflux 
from the ventral posterolateral nucleus of the thalamus following riluzole administration in 
prior rodent studies (Abarca et al., 2000). GABA can also be reliably captured using this 
method (Wydra et al., 2013), and most importantly both glutamate and GABA may be 
sampled from the same brain region at the same time; and measures can be taken at multiple 
time points over a few hours, in freely moving, live rodents (Zapata et al., 2009).  
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To investigate extracellular E-I responsivity using this technique, it was first necessary to 
select an appropriate animal model of ASD. It is essentially impossible to capture the 
complex and heterogeneous phenotype of the human condition with one genetic or 
environmental alteration, and consequently a broad array of animals modelling different 
aspects of ASD have been generated (Burrows et al., 2015; Esclassan et al., 2015; Liu et al., 
2016; Mabunga et al., 2015; Shinoda et al., 2013; Stewart et al., 2014). For my study, I 
selected the Neurexin1 homozygous knock out rat (Nrxn1-/-), as previously described in 
section 1.3.1, because it models disruption at glutamate and GABA synapses, and hence 
potentially the E-I imbalance, which is associated with ASD. To mirror the human arm of the 
experiment, Nrxn1-/- rats or wild type controls were given either a single oral dose of 
riluzole, or equivalent vehicle (placebo), and GABA and glutamate efflux were measured. To 
my knowledge, this is the first time that E-I response to pharmacological challenge has been 




1.4 The present thesis: aims and hypotheses 
The evidence presented thus far suggests that E-I imbalances contribute to the pathology of 
ASD, yet to date, nobody has ever investigated what is likely to be a crucial element - E-I 
responsivity. This is important as differences in E-I pathways in ASD may not necessarily be 
best understood by capturing data in the ‘resting state’ or at a single time point. Instead, what 
is important in ASD may be the responsivity, or flux, of the E-I system.  
 
To assess E-I responsivity, we can examine how the system is – or is not – shifted by a 
challenge. To this end, riluzole was selected as a pharmacological probe to activate both 
glutamate and GABA pathways.  
 
There is no single modality which can fully assess whether there are E-I responsivity 
differences in the living brain, therefore I employed a range of modalities to probe E-I at 
different resolutions – i) bulk tissue, ii) functional network and iii) extracellular levels. I 
could address i) and ii) in humans but needed to address iii) in an animal model; the Nrxn1-/- 
knock-out rat (see Figure 1.5).  
 
1.4.1 Clinical Studies 
1.4.1.1 E-I responsivity of adult men with ASD: 1[H]MRS  
1[H]MRS was used to investigate whether the responsivity of bulk E-I metabolites differed 
between adult men with and without ASD at the intracellular level, when challenged with the 
pharmacological probe, riluzole. The targets selected for MRS study were the dorsomedial 
prefrontal cortex (Chapter 3) and the basal ganglia (Chapter 4). 
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1.4.1.2 E-I responsivity of adult men with ASD: Resting state fMRI  
The selected brain regions do not act in isolation, rather they function as part of wider brain 
networks. Therefore, where a group difference in MRS measured E-I responsivity was found 
(in the dorsomedial prefrontal cortex, see Chapter 3), resting state fMRI was used to 
investigate the functional connectivity of that brain region with the rest of the brain. I 
hypothesized that there would be an ASD-control difference in resting state functional 
connectivity response to riluzole challenge. Specifically, I anticipated the ASD group would 
demonstrate reduced functional connectivity of the prefrontal cortex at baseline, compared to 
controls, and that functional connectivity of this region would increase upon administration 
of riluzole. Comparatively, I hypothesised that riluzole would not affect the functional 
connectivity of the control group, as they would re-balance E-I after a rilzuole challenge. 
This study is reported in Chapter 3. 
 
1.4.2 Pre-clinical studies 
1.4.2.1 Validating the Neurexin1-/- rat as a model of E-I imbalance 
observed in the human studies: Ex vivo 
Prior to investigating responsivity differences in the Nrxn1-/- rat, I first investigated whether 
baseline E-I differences between the knock out rat and wild type controls were comparable to 
the clinical cohort in terms of their baseline neurochemistry. Equivalent brain regions to the 
human study were dissected (prefrontal cortex and caudate putamen) and the bulk 




1.4.2.2 E-I responsivity of Neurexin1-/- rats: Ex vivo 
I next examined bulk intracellular differences in E-I metabolites ex vivo in the prefrontal 
cortex and caudate putamen of Nrxn1-/- and wild type rats after riluzole administration. 
Specifically, I tested the hypothesis that there would be group differences in E-I responsivity, 
in terms of bulk measures of E-I metabolites, which would match the results of the human 
MRS study. This approach is reported in Chapter 5. 
 
1.4.2.3 E-I responsivity of Neurexin1-/- rats: In vivo microdialysis 
Finally, I used in vivo microdialysis to investigate changes in extracellular flux of E-I 
metabolites, after riluzole administration. Specifically, glutamate and GABA efflux in the 
medial prefrontal cortex and caudate putamen were compared following administration of 
riluzole or 1% HEC (vehicle) in wild type and Nrxn1-/- rats. I hypothesised that there would 
be group differences in responsivity to riluzole in terms of local extracellular 
neurotransmitter efflux. This study is reported in Chapter 6. 
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1.4.3 Summary of thesis plan 
To summarise, the following thesis will examine E-I responsivity at the intracellular, 










Figure 1.5: Schematic representation of study design and the level at which E-I 
responsivity will be examined 
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Chapter 2  
General Methods 
2.1 Measuring E-I in humans 
2.1.1 Study design 
A case-control, crossover repeated measures study was designed to compare in vivo 
metabolite levels ‘at rest’ (placebo) and when ‘activated’, by a standard 50 mg oral dose of 
riluzole. A placebo condition was deemed essential to control for non-specific effects such as 
anxiety which may independently alter E-I dynamics in both the patient and control 
population (Lydiard, 2003). 
 
Participants were scanned on two occasions, one week apart to ensure full drug ‘wash-out’ 
between scans (riluzole half-life is estimated at 12 hours (Le Liboux et al., 1997)). The order 
of drug administration was pseudo-randomised (crossover) to ensure half of participants 
received placebo on their first visit, and half received riluzole. The participant, clinicians and 
study lead were blind to this randomisation to exclude bias.  
 
At the start of each session, a brief medical assessment was performed by a study clinician to 
check normal heart rate, blood pressure and respiratory function before participants were 
given either a capsule of riluzole or matched placebo to swallow with water. The tablet was 
administered 45 minutes prior to the participant entering the scanner, to ensure data 
collection began at the time of estimated peak drug effect (1-hour post dose). During the wait 
period, participants completed study questionnaires. After the scan, participants were re-
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assessed by a clinician and completed an adverse-effect form before leaving the facilities. See 
Table 2.1 for an overview of the study design: 
 
 Prior to Scan First Scan Second Scan 
Recruitment X   
Patient Information and Informed Consent X   
Medical Assessment  
(via questionnaire and physical examination) 
X X X 
Questionnaires 
 
X X X 
Oral administration of placebo/riluzole  X X 
MRI Scan 
 
 X X 
Adverse Effects Interview 
 
 X X 
 
Table 2.1: Study overview 









On both visits, the total scan duration was approximately 60 minutes. During this time, a 
structural MRI image was obtained, followed by two MRS acquisitions, then resting state 
fMRI. If there was time remaining, Arterial Spin Labelling (ASL) data were also acquired but 
were not used in this thesis. See Figure 2.1 for an overview of the scan timeline: 
 
 
Figure 2.1: Timetable of in-scanner events 
An example time course of events from the time of drug administration. Riluzole or placebo 
was administered at time zero, followed by a 45-minute wait, during which time study 
questionnaires were completed. The participant entered the scanner 45 minutes post-dose and 
the structural scan was performed. MRS data acquisition began 60 minutes after drug 





2.1.2 Study materials and compounds 
The study was performed on a 3 Tesla (3T) GE Excite II Magnetic Resonance Imaging 
scanner (GE Medical Systems, WI, USA) at the Centre for Neuroimaging Sciences, Kings 
College London, UK. 
 
2.1.2.1 Drug and placebo 
Riluzole was obtained from the manufacturer, Sanofi, UK, and dispensed by the Maudsley 
Hospital Pharmacy (South London and the Maudsley NHS Foundation Trust, UK). 
 
Placebo, ascorbic acid (vitamin C), was obtained from the manufacturer, Dalkeith 
Laboratories Ltd, UK, and dispensed by the Maudsley Hospital Pharmacy. Both riluzole and 
placebo were encapsulated by a pharmacist such that both tablets appeared identical, and 
drug administration was double-blind. The drug or placebo assignment information was held 
by the Maudsley Hospital Pharmacy and the Chief Investigator, who performed the 
randomization using a computer algorithm (Haahr, 1998).  
 
2.1.2.2 Study Questionnaires 
In the wait time between drug administration and the scanning protocol, participants were 
invited to complete a series of questionnaires: 
 
Autism Spectrum Quotient (AQ): A screening instrument of 50 statements which measures 
autistic traits in adults. The subject was asked to indicate to what extent they agree with the 
statements, for example: ‘I find social situations easy’. Scores range from 0-50, with the 
diagnostic cut off being >32 (Baron-Cohen et al., 2001). 
76 
State-Trait Anxiety Inventory (STAI): We asked participants to complete the ‘State’ part of 
the STAI as a measure of current anxiety levels before both scans. Scores range between 20-
80, with a higher score indicating higher anxiety (Spielberger et al., 1970). 
 
Obsessive Compulsive Inventory- Revised (OCI-R): This questionnaire comprises of 18 
questions which measure to what extent obsessive and compulsive traits interfere with the 
subject’s life (Abramowitz & Deacon, 2006). A score of >21 indicates obsessive compulsive 
disorder, with the mean score of an OCD patient being 28 (Foa et al., 2002). This was used in 
this study as an additional measure of mental state, and as a proxy measure of current traits of 
rituals and compulsions, which are found in ASD but are not always well documented by the 
ADOS. 
 
Barkley’s Current Scale: The participant was asked to complete the Barkley’s self-
assessment, which measures inattention and hyperactivity (Barkley & Russell, 2011). The 
same questionnaire was then given to the participant to take home for an informant (family 




We recruited a total of 37 adult men aged 18-60, 17 of which had a confirmed ASD 
diagnosis, and 20 age- and IQ-matched controls. Adults with ASD were recruited from a 
database of patients at the Maudsley Behavioural Genetics Clinic who had consented to be 
contacted for research. Control participants were recruited from the local community. All 
potential participants were provided with information sheets (see Appendix 2) and had the 
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study rationale and protocol explained verbally. Written, informed consent was obtained prior 
to study commencement, by a trained member of the research team (see Appendix 3). 
 
2.1.3.2 Inclusion and Exclusion criteria  
Men with ASD had their clinical diagnosis of autism spectrum disorder confirmed using the 
Autism Diagnostic Observation Schedule and where an informant was available, Autism 
Diagnostic Interview – Revised. This was usually carried out in the clinic at the time of their 
initial diagnosis; if this was the case, it was not repeated for the study. 
Participant suitability was assessed using a thorough pre-recruitment screening questionnaire, 
completed over the phone with a researcher. 
 
Inclusion criteria for all participants were; IQ above 70; absence of current psychoactive 
medication, and being medication free for a minimum of 6 weeks to avoid potential 
confounds from drug interactions. For the same reason, only participants who consumed less 
than 28 units of alcohol per week, and smoked less than 4 cigarettes per day were deemed 
eligible for inclusion. Exclusion criteria for all participants were; comorbid psychiatric or 
medical condition which may affect brain development (e.g. epilepsy or psychosis), head 
injury, or genetic or chromosomal disorder associated with ASD (e.g. Fragile X or tuberous 
sclerosis). In the ASD group, known genetic disorders were screened by checking patient 
records for any outstanding diagnoses. Additionally, both groups were asked if they had any 
knowledge of chromosomal or genetic disorders within their family, or if they had ever had 
tests for, or been told they had a chromosomal or genetic disorder themselves. Participants 
were also excluded if they had a recent history of psychoactive substance abuse, drug allergy 
(particularly to E-I acting drugs) or any contraindication to MRI scanning, for example metal 
in the body. Full exclusion criteria and rationale are provided in Appendix 4. 
78 
2.1.4 Magnetic Resonance Spectroscopy 
Proton Magnetic Resonance Spectroscopy ([1H]MRS) is a rapidly developing neuroimaging 
technique that allows non-invasive in vivo analysis and quantification of neurochemicals and 
their metabolites. Using this methodology, it is possible to quantify excitatory and inhibitory 
neurotransmitters (glutamate and GABA) within specific, pre-defined regions of brain tissue; 
and thus, to examine the potential biochemical underpinnings of neurological and psychiatric 
disorders. MRS has the advantage of being non-invasive, without the need for injections, or 
radioactive materials. As such, patients tend to be more comfortable and the level of study 
compliance for repeat visits is high.   
 
2.1.4.1 The Physics of 1[H]MRS 
2.1.4.1.1 Nuclear magnetic resonance 
[1H]MRS works on the principle that hydrogen (1H) nuclei, otherwise known as protons, are 
in constant precession (spinning around their own axes); which contributes to the induction of 
a magnetic moment. As shown in Figure 2.2 A, in the absence of a magnetic field, protons ‘at 
rest’ (without artificial stimulation) are in random alignment. The application of an external 
magnetic field (Bo) generated by an MRI scanner magnetizes a proportion of protons and 
causes them to align themselves along the magnetic field lines (Figure 2.2 B). This produces 
a net magnetisation effect, longitudinal to the applied magnetic field. Under normal 
circumstances, the aligned hydrogen nuclei continue to precess around their axes with the 
frequency of their precession being proportional to the applied magnetic field strength 




𝜔0 =  𝛾 𝛽0 
 
Where 0 represents precessional (Lamor) frequency (MHz),  is the gyromagnetic ratio 
(MHz/T) and 0 is magnetic field strength (T). 
 
2.1.4.1.2 Excitation, relaxation and MR signal acquisition 
The application of a radiofrequency (RF) pulse, Brf, (an additional time-dependent magnetic 
field, equal to the Lamor frequency) causes the nuclei to absorb energy, and transition to a 
higher energy state, thus creating an overall excitation effect. The RF is usually applied 
perpendicular to Bo (Figure 2.2 C), which alters the original direction of proton alignment, 
and causes the protons to spin at a new angle, away from Bo. This new angle of proton 
orientation is termed the flip angle and is directly proportional to the direction and amplitude 
of the applied RF pulse (usually 90 degrees). This changing of the direction of proton 
alignment causes an induced current in the coil of the scanner- this current can be measured 
and is commonly referred to as the MR signal.  
 
When the RF pulse stops, the protons return to their original lower energy state, and line up 
with the direction of the scanner’s magnetic field once more (Figure 2.2 D). This return to 
equilibrium is termed relaxation, specifically ‘T1 longitudinal relaxation’ and is defined as 
the time taken for the protons to realign with Bo after a radiofrequency pulse application. 
During relaxation, protons ‘decay’ and release their absorbed energy. As the protons return to 
their original alignment, the magnetic fields of the individual protons interact with each other 
and exchange energy. This results in an overall loss of signal, and is termed ‘T2 transverse 
relaxation’. Both T1 and T2 times vary, depending on the intrinsic properties of the tissue 
80 
that is being imaged. We can therefore use this information to distinguish between different 
tissue types in the brain, i.e. structural MRI. 
 
Multiple RF pulses are applied during a single scan, at a predetermined rate, termed 
repetition time (TR). Together with the inversion time (TI- time between different pulse 
sequences) and echo delay time (TE- time between the application of the RF pulse and the 
detection of the response signal) they affect the appearance of the signal readout; variations 





Figure 2.2: Schematic representation of proton behaviour in an MRI scanner 
A) Hydrogen atoms, or protons, outside a scanner orientate in random directions;  
B) once under the influence of the strong magnetic field (Bo) created by the scanner, the 
protons align with the direction of the magnetic field;  
C) a radiofrequency pulse (Brf) is applied perpendicular to Bo and the protons tilt and change 
their direction of alignment;  
D) once the applied radiofrequency pulse fades, protons return to their equilibrium position, 
as in (B) and release energy in the form of their own radiofrequency signal- this is termed 
‘decay’ and can be measured and quantified.   
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2.1.4.2 Generating a structural MR image  
The MR signal obtained from an MRI scan does not immediately translate to a structural 
image. First, the signal must be expressed in an intermediate form, in k-space, before being 
reconstructed into an image via a Fourier Transform. The final image is given as a map of 
pixels in grey scale- each one representing a spatial location, and coloured to indicate the 
level of tissue contrast. 
 
Tissues with high proton density will release a larger signal (brighter) than those with lower 
proton density (darker). Additionally, the longer a signal takes to decay, the lower the signal 
intensity will be and the darker the pixel will appear. We can externally manipulate tissue 
contrast by varying parameters such as the TE, TR and flip angle; to achieve a T1-weighted 
image, the TR must be short, in order to reduce the recovery time before the application of 
the next RF pulse, whereas T2-weighted images are dependent upon long TE times, given 
that TE controls the amount of T2 decay that can occur. MR sequences can be designed to 
give different weightings to either T1 or T2, depending on the needs of the researcher. 
T1-weighted imaging shows tissues with high fat content (e.g. white matter) as bright and 
compartments filled with water (e.g. CSF and ventricles) as dark, and is therefore used to 
demonstrate anatomical structures. In comparison, T2-weighted images show the opposite- 
water filled regions are bright and tissues with high fat are dark. This is especially useful for 
demonstrating pathology since most lesions are associated with an increase in water content, 
and are easily identifiable as bright spots.  
 
The present study included an initial structural MRI scan, namely a 3D fast spoiled gradient-
recalled echo (FSPGR) acquisition (number of slices = 124, slice thickness= 1.1mm, 
inversion time (TI) = 450 ms, repetition time (TR) = 7.084 ms, echo time (TE) = 2.84 ms, 
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field of view= 280 mm, flip angle= 20o). This was then used to set the voxel locations for the 
spectroscopy scans. 
 
2.1.4.3 Defining a region of interest 
[1H]MRS data acquisition was performed in two regions of interest; a medial prefrontal 
cortical region, comprising the anterior cingulate cortex (primarily grey matter), and a 
subcortical region; in the left basal ganglia, comprising of the head of the caudate, the 
anterior putamen and the global pallidus internal capsule, plus white matter tracts (see Figure 
2.3) using the following parameters: 
 
Bilateral dorsomedial prefrontal cortex; 25 (left-right) x 30 (superior-inferior) x 40 
(anterior-posterior) mm3; TR = 2000 ms, TE = 68 ms. 
 












Figure 2.3: Examples of placement of [1H]MRS voxels 
A. Example of subcortical voxel placement, including the head of the caudate, putamen 
and internal globus pallidus. 
B. Example of anterior cingulate cortex voxel placement 
 
 
2.1.4.4 Generating a metabolite spectrum 
In MRS, instead of using the MR signal to construct images, the frequency information is 
used to identify chemical compounds. Specific molecules within a scanning region of interest 
can be identified by the way in which their protons behave in the applied magnetic field 
sequences of the scanner. Within a given field strength, protons in different molecules 
experience different levels of ‘chemical shielding’, whereby surrounding electron clouds 
affect the magnetic field experienced by the proton; i.e. if the electrons are close to the 
proton, there is a shielding effect and the proton ‘experiences’ a minimally smaller magnetic 
field. The extent to which the shift caused by shielding occurs, depends on the structure of 
the molecule and the position of the proton within the molecule- for this reason, it is known 






to identify it. Much like with MRI structural data, a Fourier Transform is applied to the MRS 
data output to separate the signal into individual frequencies, which are expressed in the form 
of a magnetic resonance spectrum. The spectrum is a plot of signal intensity on the y-axis 
(roughly proportional to metabolite concentration), versus chemical shift on the x-axis. 
Chemical shift is reported in magnetic field-independent units; parts per million (ppm) of the 
proton frequency, so the output is the same regardless of the magnetic strength of the scanner. 
The position of a peak on the x-axis measures the chemical shift relative to a reference (by 
convention, the chemical shift of tetramethylsilane (TMS) protons is defined as 0 ppm) and 
can be used to identify chemicals (see Figure 2.4 and Table 2.2). 
 
In principle, the area under each peak is proportional to the number of protons contributing to 
the metabolite of interest, however this is not an absolute concentration, but rather an 
indication of the level of metabolite, which can be compared between time points or between 



























Figure 2.4: An example [1H]MRS spectrum 
A spectrum is a frequency analysis (Fourier Transform) of the signal that is detected during 
an MRS study. The height of the peak is equivalent to the strength of the signal and the 
position on the x-axis is determined by the degree of chemical shift, which is specific to each 
chemical and can be used to identify it. N-acetly-aspartate (NAA) can be identified by the 
large peak at 2 ppm, which is due to the combined J-coupling effect of the three protons in its 
CH3 group. If shown, the water peak would be at 4.7 ppm. The water peak is suppressed in 
most MRS spectra as it would be dramatically larger than the metabolic peaks. Figure 
adapted from Blüml and Panigrahy, 2013. 
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Chemical shift (ppm) Metabolite Properties 
0 Tetramethylsilane (TMS) Reference 
2.0 N-Acetyl-Aspartate (NAA) Neuronal marker 
2.2 - 2.4 Glutamine/GABA Neurotransmitters 
3.0 Creatine (Cr) Energy metabolism 
3.2 Choline (Cho) Cell membrane marker 
3.5 Myoinositol (mI) Glial cell marker 
4.7 Water - 
 
Table 2.2: Observable metabolites using [1H]MRS 
Various metabolites and neuronal markers can be identified by their degree of chemical shift, 
measured in parts per million (ppm). Note that some metabolites have multiple peaks, but the 
ones most useful for quantification are listed above. 
 
In addition to chemical shift, the spectrum is also modulated by J-coupling. J-coupling is the 
result of the interaction between neighbouring protons; uncoupled protons yield single peaks, 
whereas coupled protons give peaks split into two or three. The resulting distinct peak pattern 
and size tells us about bond distance and bond angles and helps to identify molecules. For 
example, the three protons of the -CH3 group of NAA combine to create one large peak at 2 
ppm, which is characteristic of NAA (Figure 2.4). J-coupling modulates signal intensity 
depending on the sequence type and acquisition parameters of the scan. The most important 
parameter is the Echo delay Time (TE) (time between the applied RF pulse and signal 
readout). During this time, the signal from each metabolite peak relaxes with its own 
characteristic T2-relaxation time (a measure of signal decay) and the signal amplitude of J-
coupled proton is modulated. Long echo times (TE  135 ms) simplify spectra by reducing 
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the number of detectable peaks, and are therefore mostly used in clinical practise where clear 
peak identification is needed. By contrast, short echo times (TE< 35 ms) allows the detection 
of an increased number of metabolites and give a better signal to noise ratio than long TE. 
One common pulse sequence is Point RESolved Spectroscopy (PRESS), a 90o - 180o - 180o 
sequence of RF pulses, which gives better visualisation of metabolites with longer relaxation 
times. Whilst this sequence captures glutamate clearly, GABA has proven difficult to reliably 
measure, mainly due to the large overlap between GABA peaks (at 3.0 ppm, 2.3 ppm and 1.9 
ppm) and those of other metabolites which are present in much higher concentrations. GABA 
is found in the human brain at around 1mM, significantly lower than most other metabolites, 
and 40,000 times lower than water (Puts & Edden, 2012).  
 
MEshcher-GArwood Point RESolved Spectroscopy (MEGAPRESS) is, at this stage, the 
standard technique for obtaining GABA measurements in MRS, and can be incorporated into 
the basic PRESS sequence. Unlike conventional PRESS, MEGA-PRESS can separate the 
GABA signal from that of other metabolites, by taking advantage of known J-couplings 
within the GABA molecule. Using a ‘difference-edited technique’, MEGA-PRESS collects 
two datasets which differ in the way they affect GABA spin. In one set, an editing pulse is 
applied at 1.9 ppm which selectively refocuses the GABA signal at 3.0 ppm- this is referred 
to as ‘ON’. In the second, control dataset, the editing pulse is either not applied, or applied at 
a different frequency that does not affect GABA signals or any other metabolite of interest- 
this is referred to as ‘OFF’. During processing of the data, the ON signal is subtracted from 
the general OFF signal, to leave only the data affected by the GABA-specific editing pulse, 
i.e. GABA (Edden & Barker, 2007; Mescher et al., 1998). This process is referred to as J-
difference editing.  
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2.1.4.5 Spectral data processing 
In this study, MRS spectra were pre-processed using SAGE (Spectroscopy Analysis, GE 
Healthcare Technologies, WI, USA) spectral analysis software (SAGE 2007, GE Healthcare 
Technologies, WI, USA) to perform the edit ON – edit OFF subtraction, to extract the 
subtraction (difference) spectrum, the unedited spectrum (equivalent to a conventional 
PRESS spectrum) and the unsuppressed water spectrum. These spectra were further 
processed and quantified using JMRUI (Java based Magnetic Resonance User Interface) 
version 4 software (Naressi et al., 2001) and each participant’s raw data was checked for 
quality to ensure adequate signal to noise ratio and absence of artefacts. If required and 
appropriate, artefacts were removed using JMRUI peak fitting and removal algorithm to 
restore data integrity. Metabolite concentrations were estimated using the AMARES 
algorithm (Advanced Method for Accurate, Robust and Efficient Spectral fitting of noisy 
MRI data). In the subtraction spectrum; GABA (+ macromolecule) at 3.0 ppm, Glx 
(Glutamate + Glutamine; as the measure of glutamate) as two peaks at 3.8 and 3.75 ppm and 
N-acetylaspartate (NAA) at 2.01 ppm were estimated. In the unedited spectrum; Choline at 
3.19 ppm, Creatine at 2.99 ppm and, NAA at 2.01 ppm were estimated. To correct for inter-
subject variations in water levels, each metabolite was multiplied by an individual Water 
Scaling Constant (WSC); 
 





𝑀𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒𝑊𝑎𝑡𝑒𝑟 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑  = 𝑀𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒𝑅𝑎𝑤 𝑣𝑎𝑙𝑢𝑒 ×  𝑊𝑆𝐶 
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Additionally, partial volume effects (group variation in proportions of grey matter (GM), 
white matter (WM) and cerebrospinal fluid (CSF) in the [1H]MRS voxels) are a potential 
confound in spectroscopy. This is of particular relevance to the present study, as previous 
literature has indicated volumetric differences between ASD and control participants 
(Haznedar et al., 2006). To assess voxel composition, the initial structural MRI scan was 
segmented into GM, WM and CSF using SPM2 (UCL). The position of the voxel was then 
registered to the corresponding segmented structural scan and the GM, WM and CSF content 
of this region was calculated using in-house software. Assuming CSF contains negligible 
amounts of the metabolites of interest, all data was corrected for varying levels of CSF in the 
voxel as follows: 





𝑀𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝐶𝑆𝐹 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 =  𝑀𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑊𝑎𝑡𝑒𝑟 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑  ×  𝐶𝑆𝐹 𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 
 
2.1.4.6 Limitations of [1H]MRS 
Though sequences such as MEGAPRESS have greatly advanced our ability to measure the 
GABA signal, there remain some problems in the reliability of its detection. When 
MEGAPRESS is implemented at 3T using the standard acquisition parameters of a 68 ms 
echo time (TE), as in the present study, there is potential for contamination of the GABA 
peak with co-edited macromolecular (MM) signals (Edden et al., 2012; Henry et al., 2001; 
Rothman et al., 1993). This is because the ON pulse applied at 1.9 ppm, also affects the MM 
signal at 3.0 ppm, the same frequency as the GABA signal. As a result, the final edited 
GABA measure is contaminated with MM and potentially as much as 45% of the total 
GABA signal output is known to be due to MM, rather than GABA alone (Mullins et al., 
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2014). Modifications to the MEGAPRESS sequence have been devised that reduce the MM 
signal (Harris et al., 2015; Henry et al., 2001), though this often results in also diminishing 
the GABA signal, which is small to begin with. The most common approach therefore, is to 
acknowledge the presence of MM within the GABA signal and report it as such - it is often 
referred to as GABA+MM or GABA+. Whilst this allows for comparison across studies, 
there is always the query over whether results are driven by GABA or MM. 
 
Likewise, depending upon the magnetic field strength of the scanner used, it is not always 
possible to differentiate between glutamate and its metabolite glutamine, due to the overlap 
of their resonant peaks. As a result, the combined signal is commonly reported as Glx 
(Ramadan et al., 2013).  
 
The need to supress the large water signal in order to detect metabolites also poses a problem, 
as insufficient and variable methods of suppression may result in variation of metabolite 
levels across subjects and studies. 
 
Another cause for inter-study variation is the way in which we choose to express metabolite 
levels. It is common in MRS literature for metabolite concentrations to be expressed as a 
ratio, relative to a metabolite which is deemed to be more stable- most often this is creatine. 
This is problematic in atypical brains however; creatine levels have been shown to be 
disrupted in ASD, with reductions in the thalamus, insula, corpus callosum (Friedman et al., 
2003) and head of the caudate (Levitt et al., 2003); and increased levels in amygdala-
hippocampal regions (Page et al., 2006) and the medial prefrontal lobe (Murphy et al., 2002). 
This widespread variability in creatine findings has reduced its use as an internal reference 
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point (Rackayova et al., 2017), and therefore the present study used absolute measures of 
metabolites only to avoid such confounds. 
 
Finally, and perhaps most importantly, [1H]MRS, specifically when applying MEGAPRESS 
techniques, is inherently limited by the size of the voxel and the lack of specificity and spatial 
resolution within the voxel. [1H]MRS is essentially a crude tool which restricts us to bulk 
measurements of metabolites- i.e. a specific region of interest’s capacity to hold metabolites- 
we cannot say whether these metabolites are active or metabolic, or specify whether they 
originate in neurons or in extracellular space. This macroscopic approach may provide insight 
into gross regional metabolite changes, but does not allow for circuit level analysis. 
 
2.1.5 Resting State Functional Magnetic Resonance Imaging 
Unlike Magnetic Resonance Imaging, which maps brain structure, or Magnetic Resonance 
Spectroscopy, which measures metabolite concentration, Functional Magnetic Resonance 
Imaging (fMRI) measures and maps brain activity.  
 
2.1.5.1 Concept 
fMRI was initially based on the premise that whilst performing a task, or action, specific 
areas of the brain are engaged; for example, the motor cortex is active during movement. It is 
now known that certain brain networks are also active ‘at rest’, i.e. even when the brain is not 
engaged in a specific task, certain regions which are known to function together are active in 
synchrony (Biswal et al., 1995). These so-called resting state networks can be examined to 
investigate the brain’s functional organisation and to examine whether it is altered in 
psychiatric disorders.  
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As in the construction of MR images (described in detail in the previous section), acquisition 
of fMRI data relies on the magnetisation of hydrogen atoms, which are manipulated with 
various applied radiofrequency pulses, and emit a signal which is measured. When neural 
activity in any particular area of the brain increases, this is matched by a slight increase of 
around 1% in the detected MR signal. Rather than a direct correlation between neural activity 
and MR signal output, the change in signal is an indirect effect caused by the change in 
regional blood flow which follows neural activity.  
 
This is dependent on two factors; firstly, oxygenated and oxygen-depleted blood have slightly 
different magnetic properties due to the bonding of haemoglobin. When oxygenated, 
haemoglobin is diamagnetic (repelled by a magnetic field), but paramagnetic (attracted to a 
magnetic field) when deoxygenated. Deoxygenated blood therefore slightly distorts the 
magnetic field in its immediate vicinity, creating microscopic field inconsistencies, which 
lead to the shortening of the T2 relaxation time within the tissue voxel- this is termed static 
dephasing. Therefore, variations in tissue oxygenation as a result of altered blood supply 
caused by regional changes in brain activity can be mapped by T2*-weighted MRI 
(Holdsworth & Bammer, 2008). 
 
The second effect is the somewhat paradoxical fact that neural activity prompts an increase in 
blood flow in surplus of that needed to satisfy the increase in oxygen metabolism, and thus 
blood actually becomes more oxygenated shortly after neural activity increases. This blood 
oxygenation level dependent (BOLD) effect is the basis for fMRI (Ogawa et al., 1990). At 
rest, the brain remains highly active, and these patterns of activity can reveal particular 
networks of areas which work together, so called resting state networks (RSNs) (Biswal et 
al., 1995). Resting state networks reflect the functional connectivity between different brain 
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regions, irrespective of their anatomical or structural connectivity. The strength of these 
RSNs can be affected by disease and can therefore be used to understand network activity in 
psychiatric disorders (Garrity et al., 2007; Greicius, 2008; van de Ven et al., 2004).  
 
2.1.5.2 Resting state fMRI BOLD data acquisition 
The most common image sequence for fMRI acquisition is echo planar imaging (EPI), in 
which data is captured during a succession of rapid field gradient reversals following RF 
excitation of protons. As in MR imaging, the contrast that is achieved is determined by 
several acquisition parameters, such as the TE, TR and flip angle. The speed at which images 
are acquired means that a whole brain may be imaged in as little as a few seconds, and the 
imaging is less sensitive to motion (i.e. head movement) than conventional MR. Furthermore, 
this speed also allows for the capturing of rapidly changing physiological processes such as 
blood flow and kinetic energy (DeLaPaz, 1994).  
 
In the present study (Chapter 3), resting state fMRI acquisition parameters were as follows: 
an EPI sequence, TR = 2 seconds, TE = 30 ms, 256 volumes. Slice thickness = 3 mm, 
number of slices = 38, slice spacing = 0.3 mm. Each slice comprised of 64 x 64 voxels with a 
field of view of 240 mm, for a final voxel size of 3.75 mm x 3.75 mm x 3.3 mm. Pulse and 
respiration parameters were also acquired during the fMRI scan, for the purposes of 
correcting for physiological artefacts (or noise) in the fMRI dataset, using a 
photoplethysmogram pulse oximeter and a chest band, respectively. 
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2.1.5.3 Resting state fMRI BOLD data processing  
Once data is acquired, the observed changes in the BOLD signal are reconstructed into a 4-
dimensional time series which reflects the changes in neuronal activity. The data undergo 
multiple pre-processing steps, including;  
 
Slice-time correction- as multiple ‘slices’ of the brain are being scanned in quick succession, 
the BOLD signal is sampled at different time points through different layers in the brain. 
Ideally, we want data from the whole brain at the same time point- correcting for slice timing 
allows us to see whole sections as if they were sampled at the same time, to prevent errors 
arising from a region spanning multiple slices. For each voxel, slice timing correction 
examines the time course, and shifts it by a small amount to interpolate between the points 
sampled to provide the time course that would have been observed had every slice within a 
volume been sampled at the same time. 
 
Motion correction- due to the rapid sampling of multiple slices in a short space of time, 
errors can arise from movement, however small, which may cause the brain to be in the 
wrong location for some images, or cause loss of data entirely if the movement is so gross the 
head moves out of the selected scanning volume. Motion correction is particularly important 
in resting state fMRI, when global brain activity is taken into account, and especially when 
comparing control and patient groups, who may significantly differ in their ability to remain 
still whilst in the scanner for extended periods of time. Effects of motion can be removed by 
correcting for motion-related components (as regressors) within the general linear model 
analysis, and further corrected when comparing across subjects by also normalising to a 
standard brain space, or co-registration. Brain normalisation is initiated by segmenting the 
brain into its component GM, WM and CSF tissue types and overlaying the structural and 
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functional images, thereby linking the functional data to the anatomical. Scans are then 
spatially normalised, establishing a one-to-one correspondence between the brains of 
different participants with a common template brain. This allows us to both determine what 
happens generally across individuals, and also identify any differences between groups, 
within a particular study and across other studies. Linear registration using a program such as 
SPM (UCL) accounts for major differences in head shape and positioning (though 
positioning should be somewhat accounted for by initial head placement in the scanner by 
radiographers), before nonlinear registration warps the brain images and accounts for smaller 
differences in anatomy (Friston, Ashburner, & Wellcome, 1997). 
 
Spatial smoothing is performed to average individual data points with their neighbours and 
thus lower the signal to noise ratio, increase sensitivity and increase the validity of statistical 
tests by normalising the error distribution of each point. However, this technique does reduce 
spatial accuracy of the data and may result in misrepresentation of where specifically 
activation is taking place (Mikl et al., 2008). 
 
Lastly, high-pass filtering is performed to ‘clean’ the final data signal and separate out any 
remaining noise. If you know the signal frequency you should be obtaining, you can remove 
any frequencies too low to be relevant, i.e. remove low frequencies and pass through high 
frequencies. 
 
The main approach to resting state fMRI data, and the one used in the present study, concerns 
connections between regions (functional connectivity). A commonly used method for 
analysing this is a hypothesis-driven seed-based analysis. This approach uses an extracted 
BOLD time course from an a priori region of interest and examines the temporal correlation 
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between this signal and the time course from all other brain regions. In this way, a functional 
connectivity map of correlation between a chosen region and the rest of the brain can be 
created. This map allocates Z scores for each voxel, showing how well its time series 
correlates with the time series of the seed region. Two regions are said to be functionally 
connected if the time series of their activation are correlated (Biswal et al., 1995; Fox et al., 
2005). 
 
In the present study, fMRI data were processed using FSL 5.0.0. The following pre-
processing steps were applied: motion correction using MCFLIRT; slice-timing correction 
using Fourier-space time-series phase-shifting; non-brain removal using BET; spatial 
smoothing using a Gaussian kernel of FWHM 5 mm; grand-mean intensity normalisation of 
the entire 4D dataset by a single multiplicative factor; and highpass temporal filtering 
(Gaussian-weighted least-squares straight line fitting, with sigma = 50.0 s).  
 
Manual inspection and removal of artefactual connectivity components was then carried out 
using hypothesis-free Probabilistic Independent Component Analysis as implemented in 
MELODIC (Multivariate Exploratory Linear Decomposition into Independent Components) 
Version 3.10, part of FSL (Analysis group, FMRIB, Oxford; Jenkinson, Beckmann, Behrens, 
Woolrich, & Smith, 2012). The decisions as to whether to exclude each component from a 
given fMRI scan were made by a researcher blind to group and to drug status.  
 
2.1.5.4 Limitations of resting state fMRI 
A much-criticised limitation of fMRI is that it does not measure neuronal function directly, 
rather it is a measure of secondary physiological correlates of neural activity- it is therefore 
not truly quantitative and there is always a risk that group or individual differences are 
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physiological rather than neurological. Additionally, caution must be exercised in processing 
fMRI data, hence the need for the extended measures described above. Further care must be 
taken when interpreting the data; in many pathologic conditions, cerebral blood volume and 
cerebral blood flow may be perturbed, and so the BOLD effect in these regions might present 
differently than in healthy regions despite otherwise normal underlying neuronal activity. 
 
Additionally, whilst spatial resolution is highly accurate, temporal resolution of fMRI is 
inherently limited by the slow speed of the BOLD response, and therefore sub-millisecond 





2.2 Measuring E-I in rodents 
The following pre-clinical protocols (Figure 2.5) were designed to complement the human 
study described above (section 2.1.1). Two separate studies were undertaken; firstly, an 
initial investigation into the pharmacokinetic profile of riluzole at the selected experimental 
dose was performed in wild type rats only (detailed in Chapter 5). Next, an in vivo 
microdialysis study determined the effect of riluzole on E-I efflux of extracellular 
neurotransmitters and metabolites in wild type and Neurexin 1 alpha () knock out (Nrxn1 -
/-) rats (detailed in Chapter 6). Brain tissue collected from this study was also analysed to 
evaluate the effect of riluzole on bulk tissue levels of E-I neurotransmitters (Chapter 5). 
 
 
Figure 2.5: Representation of pre-clinical study designs 
A. Pharmacokinetic study of blood and brain tissue concentrations of riluzole after a 
single, oral 4 mg/kg dose of riluzole in wild type (+/+) adult Wistar rats. 
B. In vivo microdialysis and ex vivo tissue analysis of wild type (+/+) and Nrxn1 -/- (-/-) 
rats after either 4 mg/kg oral dose of riluzole or equivalent vehicle. 
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2.2.1 Animals 
Adult male Nrxn1 -/- rats and littermate controls were sourced from SAGE labs (now 
Horizon Discovery, USA) and housed at Eli Lilly in standard conditions; 07:00 to 19:00 light 
phase, constant temperature (21°C) and humidity, ad libitum food and water, and 
environmental enrichment. 
Nrxn1 -/- rats contain a biallelic deletion, specifically, a 16 base pair 
(ACCACTCTCTACATCG) frameshift deletion in exon 1 of the Nrxn1 gene (see Figure 2.6), 















Figure 2.6: Location of the 16 base pair deletion in the Nrxn1 gene 
Nrxn1 -/- rats contain a deletion (red) in the Nrxn1 gene in exon 1 (white) 
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2.2.2 Drug and vehicle  
Riluzole was obtained from SIGMA (Sigma, UK) and formulated in 1% HEC (hydroxyethyl 
cellulose; containing 0.25% Tween 80 and 0.05% antifoam) at 4 mg/kg (2 ml/kg).  
Vehicle was 1% HEC. 
 
2.2.2.1 Dose calculation 
50 mg oral dose of riluzole was administered in the human imaging study. To achieve an 
equivalent dose in the pre-clinical studies, a dose translation from human to rodent was 
calculated using body surface area as a guide (Reagan-Shaw et al., 2008): 
 





where Km is the body weight to surface area ratio (human Km = 37; rat Km = 6) as defined by 
FDA guidelines (USA Food and Drug Administration, 2002).  
 
50 mg human dose is equivalent to 0.625 mg/kg for a standard 80 kg male or female, 
therefore using the above formula, where the human Km = 37 and rat Km = 6, the equivalent 
rat dose is 3.85 mg/kg. 
 
A 4 mg/kg dose in adult rats is consistent with previous dosing regimens in neuropathic pain 
experiments (Chew et al., 2014) and experiments investigating glutamate transporter activity 
(Sung et al., 2003). 
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2.2.3 Pharmacokinetics of riluzole 
The following study aimed to determine riluzole brain and plasma concentration over a time 
course of 4 hours in adult male Wistar rats. 
 
12 male Wistar rats were dosed orally (p.o.) with 4 mg/kg riluzole. Animals were culled 0.5, 
1, 2 or 4 hours after drug administration by a non-Schedule 1 procedure by exposure to a 
rising concentration of CO2 delivered at 10 L/min for 2.5 min, n=3/group. Blood was 
collected by cardiac puncture into Li-heparin tubes and placed on a rotating table. Following 
removal of blood, the brains were removed and the forebrain cut at the level of the optic 
chiasm (using a 2 mm brain dissection block), weighed and then frozen on dry ice. Plasma 
was separated by centrifugation at 3,000 rpm for 7 min (Centaur 2; MSE) and frozen on dry 
ice. Brain and plasma samples were stored at -80°C pending analysis by Liquid 
Chromatography and Mass Spectroscopy (LC-MS/MS; see section 2.2.6 for further details). 
 
2.2.4 Effect of riluzole on E-I responsivity; in vivo microdialysis 
The following study aimed to determine the effect of riluzole on GABA and glutamate efflux 
in the medial prefrontal cortex (mPFC) and caudate putamen (CPu) of 16 wild type rats and 
15 Nrxn1 -/- rats. 
 
2.2.4.1 Surgical implantation of microdialysis probes   
Rats were anaesthetised with Isoflurane® (2.5% in O2 at 1 L/min) and administered the 
analgesic Buprenorphine® (0.075 ml subcutaneously (s.c.)), before being positioned on the 
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stereotaxic frame. Surgical anaesthesia was then maintained at 2-2.5% Isoflurane® in O2 at 0.5 
L/min, and body temperature was maintained at 36-37◦C using a heated pad.  
MAB 4.7.4 and MAB 4.7.3 microdialysis probes (cuprophan membrane; 6 kDa cut-off; 
MicroBiotech AG, Sweden) were implanted stereotaxically into the medial prefrontal cortex 
and caudate putamen, respectively, of each rat whilst being perfused with artificial 
cerebrospinal fluid at a flow rate of 1.5 µl/min (aCSF; containing NaCl 141 mM, KCl 5 mM, 
MgCl2 0.8 mM and CaCl2 1.5 mM) using the following coordinates: 
 
From bregma and dura surface, with nose bar set to -3.3 mm:  
Medial prefrontal cortex, 4 mm probe (MAB 4.7.4);  
Anterior +3.0 mm 
Lateral ±1.5 mm 
Vertical (from dura) -5.0 mm 
Angle = 12 degrees 
 
Caudate putamen, 3 mm probe (MAB 4.7.3); 
Anterior +0.3 mm  
Lateral -3.0 mm 
Vertical (from dura) -6.0 mm 
 
Probes were fixed in place with two scull screws and dental cement. Animals were allowed to 




2.2.4.2 In vivo microdialysis 
2.2.4.2.1 Concept 
Microdialysis allows for the sampling, and subsequent quantification, of neurotransmitters 
from the interstitial space in discrete brain regions. The principle element which enables this 
sampling is the microdialysis probe, which is used to capture molecules from the 
extracellular space. Once the probe is inserted into the brain tissue, constant perfusion of a 
solution (in this case, aCSF) begins, and substances on the outside surface of the dialysis 
membrane diffuse through the membrane into the probe along their concentration gradient 
(see Figure 2.7). The perfusate is infused slowly and continuously through the length of the 
dialysis probe into the outflow tubing where it can be collected for quantification. It is 
presumed that the amount of neurotransmitter measured in the resulting sample, or dialysate, 
will depend upon the level of synaptic activity and therefore neurotransmitter efflux in that 
brain region (see Chefer et al. 2009 for a full review). Importantly for the present study, both 
GABA and glutamate efflux can be reliably captured using this methodology (Bourdelais & 
Kalivas, 1992; Dietze & Kuschinsky, 1992).  
 
2.2.4.2.2 Protocol 
The day after probe implantation, 4 animals per experimental day were connected to the 
microdialysis rig. This consisted of a liquid swivel suspended on a counterbalanced arm, 
connected to an infusion pump filled with aCSF. Prior to attaching the animals to the rig, a 
single sample was collected over 6 minutes at a flow rate of 5 µl/min to measure aCSF alone 
and ensure the rig was functional. The sample was also analysed along with all other samples 
in order to identify potential contaminants. 
The rats were then attached and flow rate reduced to 1.5 µl/min for a 90 minute pre-sample 
settling period. Dialysate samples were collected at 20 minute intervals thereafter for a total 
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of 15 samples. After six ‘baseline’ samples (120 min) were collected, animals were 
administered with either 4 mg/kg riluzole or vehicle (1% HEC) p.o. All samples were 




















Figure 2.7: Schematic illustration of a microdialysis rig (A, B) and probe (C) 
A. The microdialysis probe is surgically implanted into the rodent brain; the inlet is 
connected to an infusion pump, and the outlet attached to a sample tube to collect the 
dialysate 
B. The probe is implanted into a specific brain region 
C. Artificial CSF (perfusate) is perfused into the microdialysis probe via the inlet, and 
dialysate containing neurotransmitters of interest is collected via the outlet 
Images adapted from Chefer et al. 2009. 
C 
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2.2.4.3 Limitations of in vivo microdialysis 
Microdialysis has a few key disadvantages which must be considered. Firstly, it has limited 
time resolution, particularly in this study, as samples are collected over a period of 20 
minutes- therefore samples do not provide real time information regarding changes in the 
extracellular environment. 
 
Secondly, microdialysis is an invasive technique and some tissue damage is likely to occur 
during probe implantation- at least 220 m, and potentially as much as 1 mm, surrounding 
the probe has shown signs of trauma which affect neurotransmitter release in some studies 
(Borland et al., 2005). However, as all animals will undergo the same surgery, it is expected 
that this particular limitation will not preclude comparisons across groups. 
 
Additionally, the efficiency or ‘recovery’ of the probe itself may be questioned. The recovery 
is defined as the percentage of metabolites measured (recovered) in the immediate vicinity of 
the probe, relative to the (estimated) amount of metabolite present in the wider space in 
which the probe sits. Several factors can affect recovery, including but not limited to; flow 
rate, length of the probe membrane (longer = more recovery), temperature and molecular 
weight/shape of the substance being recovered. An in vitro assay was therefore performed to 
estimate the recovery of the microdialysis probes used in the present study, in order to better 
estimate the local extracellular concentration of riluzole in each region (see Appendix 5).  
 
Finally, the dimensions of the microdialysis probes indicate that samples cannot be taken 
directly from the synaptic cleft, rather they may detect compounds further from the site of 
release. A critical question therefore, is whether dialysate measures are reflective of true 
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synaptic release and/or uptake of the measured analyte, or whether they represent ‘overflow’ 
of neurotransmitters from non-synaptic sources, e.g. astrocytes and glia.  
 
Action potential-controlled release of neurotransmitters requires the opening of Na+ and Ca2+ 
channels, which may be experimentally blocked by tetrodotoxin (TTX) or excluding calcium 
from the perfusate, respectively. This approach has conclusively shown that dopamine, 
norepinephrine, serotonin, and acetylcholine present in brain dialysates is derived from 
action-potential controlled release (reviewed by Westerink 2000 and Westerink et al. 1988). 
However, basal dialysate levels of GABA and glutamate have shown no dependence on Na+ 
and Ca2+ channels using this method and growing evidence suggests that synaptic GABA and 
glutamate are only involved in short distance signalling which may not reach the 
microdialysis probe (Del Arco, Segovia, Fuxe, & Mora, 2003). Hence, the extracellular 
concentrations of glutamate and GABA may therefore not provide a reliable indication of 
their synaptic exocytotic release. Many microdialysis studies show changes in extracellular 
GABA and glutamate following pharmacological modulation, yet the origin of these changes 
is unknown. One proposal is that changes to Glu-GABA levels could reflect changes in the 
activation of neuron-astrocyte networks, rather than absolute levels of neurotransmitters 
released from synaptic terminals (for review- see Del Arco et al. 2003). 
 
2.2.5 Effect of riluzole on E-I responsivity; ex vivo 
Following microdialysis, brain tissue was dissected and analysed to investigate bulk 
intracellular tissue measures of GABA and glutamate in the prefrontal cortex (PFC), caudate 
putamen (CPu) and thalamus (Th) of 16 wild type rats and 15 Nrxn1 -/- rats. 
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2.2.5.1 Protocol 
Animals were culled by a non-Schedule 1 procedure by exposure to a rising concentration of 
CO2 delivered at 10L/min for 2.5 min, prior to decapitation by guillotine. Brains were removed 
and the following regions dissected; PFC, CPu, Th and bilateral cerebellum (Cb). For 
consistency, dissections were performed using a brain dissection block according to the method 
outlined in section 2.2.5.2. Time from dose to dissection was recorded. Samples were weighed 
and then frozen on dry ice prior to storing at -80oC pending analysis. Samples were dansylated 
and derivatized (section 2.2.6.1) before analysis by LC-MS/MS (section 2.2.6.2).  
 
2.2.5.2 Brain dissection  
Brains regions were dissected using a cutting block based on Heffner et al’s method for rapid 
dissection of the rat brain (Heffner et al., 1980). Both the cutting block and single edged razor 
blades were kept on ice during dissection. The rat brain was rapidly removed and placed on its 
dorsal surface in the block (Figure 2.8). 
 
Blade 1 (red line in Figure 2.8) was inserted tangential to the most posterior aspect of the 
olfactory tubercles. Two blades (orange line, Figure 2.8) were then inserted anterior to the 
first at intervals of 2 mm. Two further blades (green line, Figure 2.8) were inserted posterior 
to the first at intervals of 2 mm. All blades were removed from the block with the coronal 
brain slice attached and placed on a glass plate over crushed ice, and brain regions were then 











Figure 2.8: Diagrammatic representation of brain cutting block 
Representation of brain orientation and razor placement (coloured lines) to obtain coronal 




Figure 2.9: Dissection guide for coronal brain slices 
Dissections were performed along the red dashed line to dissect individual brain regions. 
Section numbers refer to those in Figure 2.8. 
  
111 
2.2.6  Sample analysis 
Brain tissue, plasma and microdialysis dialysate sample analysis was performed at Eli Lilly 
using in house protocols. Analyses were performed by SS and GC; a brief description of their 
methodology is outlined below. 
 
2.2.6.1 Dansylation and derivatization 
2.2.6.1.1 Brain tissue preparation 
Brain tissue samples were homogenised prior to analysis. Briefly, samples were defrosted on 
ice and ice-cold acetonitrile (ACN) was added at a 90:10 ratio with H2O. The tissue was then 
sonicated for 30 seconds using a Vibro sonic probe set at 50% amplitude. The resultant 
homogenous suspension was then allowed to stand in the fridge at 4oC for 30 minutes to aid 
protein precipitation. The samples were then briefly vortexed before being spun at 20,000 x g 
for 15 minutes at 8oC. 80 μl of supernatant was then carefully decanted off into a clean 2 ml 
screw top vial tube. Samples were then derivatized using a dansylation method. 
 
2.2.6.1.2 Sample dansylation 
High performance liquid chromatography (HPLC) is the method of choice for separation, 
identification and quantitative determination of different metabolites in a solution (see section 
2.2.6.2). However, many metabolites of interest cannot be detected by HPLC as they do not 
possess the necessary properties. Dansylation is a chemical derivatization method which 
introduces these properties (e.g. increased molecular weight or hydrophobicity) into the 
sample to increase their sensitivity for detection (Tapuhi et al., 1981; Walker, 1994). 
Dansylation was performed in accordance with standard methods, which were adapted for the 
purposes of this experiment (Cai, Zhu, & Li, 2010). Briefly; to each brain, plasma and 
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dialysis sample, buffer (1M Bis-Tris, pH10), deuterated internal standards and dansyl 
chloride (0.1% w/v in acetone) were added and mixed. 
 
Internal standards are necessary for controlling for differences in extraction, chromatography 
and detection between samples and are often an isotopically labelled version of the molecule 
to be quantified. In the present study, stable deuterium (D) labelled isotopes of GABA (D6-
GABA) and glutamic acid (D5-Glutamic acid) were used. 
 
Samples were vortexed and heated at 65oC for 30 min, then evaporated to dryness under a 
stream of purified N2 at 65
oC for 90 min. Samples were re-suspended in 50:50 (v/v) 
ACN:H2O containing 10 mM ammonium formate and 0.06% formic acid. Samples were then 
centrifuged at 13,000 rpm for 10 min at ambient temperature and samples loaded into vials 
for chromatography. A portion of sample (10 µl) was also directly loaded onto the liquid 
chromatography – mass spectrometer (LC-MS/MS) (API 4000, Sciex, Canada) using a 
chilled auto-sampler (PAL HTC-xt, CTC Analytics, Switzerland). 
 
2.2.6.2 Liquid Chromatography – Mass Spectroscopy (LC-MS/MS) 
High Performance Liquid Chromatography (HPLC) is a form of column chromatography, in 
which a sample in liquid form is injected into the LC and the different chemical components 
are separated as they travel at different speeds through the column. The output of the LC 
column is then directed into a mass spectrometer (MS) where it is ionized (using electrospray 
ionization- ESI) and a mass spectrum is generated. Different metabolites can then be 
identified according to their position on the resultant mass spectrum. MS/MS refers to the 
combination of two mass analysers in one mass spectrometer. Hence using LC-MS/MS 
113 
allows for further increased sensitivity and therefore specificity. This is of particular 
importance for detecting metabolites with similar molecular weights. 
 
In the present study, chromatographic separation of dansylated samples (including drug 
standards) was performed under a 13 min gradient (including washout and a re-equilibration 
step) using Shimadzu LC-20AD XR binary pumps (plus a CBM-20 controller) and a 2.6 μm 
Phenomenex Kinetex, XB-C18 HPLC column. Samples were prepared by 1:10 dilution in 
internal standard and calibration curves for each metabolite and for riluzole were run at the 
end of each batch of samples for quantification. Mobile phase A consisted of ACN:H2O 5:95 
(v/v), 2 mM ammonium formate and 0.06% formic acid, and mobile phase B; ACN:H2O 95:5 
(v/v), 2 mM ammonium formate and 0.06% formic acid. 
 
LC-MS/MS was operated with both negative and positive ESI transition ion detection modes 
(negative for glutamate and glutamine; positive for GABA). A 120 ms dwell time was used 
on the majority of analytes (except for GABA at 25 ms) with MS conditions optimized 




Transition ions measured (ESI negative ionization mode):  
Glutamic acid was detected by monitoring the m/z 378.1 → 143.9 transition and its D5 
analog internal standard at 384.2 → 234.0 (collision energy; -22 V, collision cell exit 
potential; -9 V). 
Glutamine was detected by monitoring the m/z 378.1 → 234.0 transition (collision energy; -
33 V, collision cell exit potential; -7 V). 
Transition ions measured (ESI positive ionization mode):  
GABA was detected by monitoring the m/z 343.0 → 170.2 transition and its D6 analog 
internal standard at 343.0 → 170.2 (collision energy; 25 V, collision cell exit potential; 12V). 
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Negative transition ion mode   
Glutamic acid  m/z 379.1 → 143.9 Rt2.75 min 
Dwell 120 ms; DP -85; CE -22; CXP -9   
D5-Glutamic acid m/z 384.2 → 234.0 Rt2.75 min 
Dwell 120 ms; DP -90; CE -29; CXP -6   
Glutamine m/z 378.1 → 234.0  
Dwell 120 ms; DP -95; CE -33; CXP -7   
Positive transition ion mode   
GABA m/z 337.0 → 170.2 Rt3.25 min 
Dwell 25 ms; DP 66; CE 25; CXP 12   
GABA –D6 m/z 343.0 → 170.2 Rt3.25 min 
Dwell 25 ms; DP 66; CE 26; CXP 14   
 
Table 2.3: LC-MS/MS detection conditions 
Conditions for the detection of glutamate, glutamine and GABA using LC-MS/MS 
Mass/charge number of ions (m/z): The units of the horizontal axis of a mass spectrum. In 
mass analysis, electrons are taken from molecules to create charged ions. The number of 
electrons removed is the charge number. 
Dwell time: The time in which the m/z ion signal is collected. 
Collision energy (CE): To obtain structural information, analyte ions are fragmented by 
colliding them with neutral molecules in a process known as Collision Induced Dissociation 
(CID). Voltages are applied to the analyte ions to add energy to the collisions and create 
more fragmentation; the higher the CE, the more fragmentation. 
De-clustering potential (DP): An applied voltage which helps prevent ions from clustering 
together 




2.2.7  Data analysis 
2.2.7.1 Pharmacokinetics of riluzole 
Riluzole in the brain and plasma were expressed as mean ( SEM) ng/g and ng/ml respectively. 
A brain:plasma ratio was calculated as brain concentration of riluzole/plasma concentration. 
Graphs were produced using GraphPad Prism Version 7 (GraphPad Software, USA). 
 
2.2.7.2 Microdialysis and ex vivo samples 
Microdialysis data were expressed as a percentage change from a pre-dosing control period. 
This was obtained by averaging the three samples collected prior to drug delivery (=100%) and 
expressing values as a percentage change from this value. The amount of analyte and drug in 
each microdialysate sample was recorded in ng/mL using their respective calibration curves. 
Statistical analyses were undertaken using 2-way ANOVA with Repeated Measures (SAS) 
using log transformed percentage data and comparing the response profiles post drug or vehicle 
administration. Riluzole levels were expressed as a molar concentration and compared using 
linear regression in GraphPad Prism. 
 
Levels of neurotransmitter in ex vivo brain tissue were recorded in ng/g tissue wet weight. 
Statistical analyses were undertaken using 2 way- ANOVA (SAS) to test for main effect of 
drug, main effect of group and drug by group interactions. The SAS package allowed for 
missing values that were an occasional issue with collection of microdialysis samples. This 
was achieved through ‘multiple imputation’, whereby each missing value was replaced with a 
set of plausible values that represent the uncertainty about the right value to impute. The 
multiply imputed datasets are then analysed using standard methods, as would be used for 
complete datasets (SAS Institute, 2018). A probability value of p<0.05 was considered to be 
statistically significant for all analyses.  
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2.2.8 Tissue histology for verification of probe placement 
In order to verify the placement of the microdialysis probes, a supplementary experiment was 
conducted to visually check the approximate probe location. Two adult male Wistar rats 
(Charles River, UK), of a similar age and kept in the same conditions as the experimental 
cohort, were used as subjects. Rats were anaesthetized with Isoflurane® (2.5% in O2 at 1 
L/minute) and administered the analgesic Buprenorphine® (0.075 ml subcutaneously) before 
being positioned on the stereotaxic frame. Surgical anaesthesia was then maintained at 2-
2.5% Isoflurane® in O2 at 0.5 L/min, and body temperature was maintained at 36-37◦C using 
a heated pad. In place of a microdialysis probe, a needle of similar proportions was implanted 
stereotaxically into the medial prefrontal cortex and caudate putamen, at co-ordinates 
outlined in section 2.2.4.1. A small amount of Toluidine Blue dye (1 μl) was injected into the 
tract using a Hamilton microsyringe.  
 
Animals were culled immediately by a non-Schedule 1 procedure of decapitation by 
guillotine, whilst under anaesthetic sedation. Brains were removed and stored in 4% Formalin 
at room temperature. Formalin-fixed brains were ‘snap’ frozen in a beaker of isopentane 
cooled in a cardice (CO2) bath prior to cryo-sectionning. The cerebellum was cut with a razor 
to give a flat surface, and the brain was mounted onto the (pre-cooled) specimen disc with an 
OCT mounting medium, Shandon Cryochrome embedding resin (Thermo Scientific, 
UK). 
Sections were performed, anterior to posterior, on a Leica CM1900 Cryostat (Leica 
Microsystems, GmbH), with the tissue temperature maintained at -18oC. 30 m thick sections 
were cut and ‘lifted’ onto room temperature ColorFrost Plus microscope slides (Thermo 
Scientific, UK). They were air-dried and scanned unstained on a Aperio AT Scanscope 
(Leica Biosystems). 
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Images were acquired using the Aperio ScanScope AT slide scanner which digitizes 
whole/part sections from 3x1” glass files (proprietory .tif style) and stores files to the Lilly 
supported server; YE02aperioprd01. This is maintained and interfaced through Aperio 
Spectrum Digital Image Library (eSlide Manager Version 12.2.1.5006). The images were 
viewed using the Aperio Software application, ImageScope.  
 
Probe placement: 
The following mPFC co-ordinates were chosen for the microdialysis study to best replicate 
and map to the region of interest selected in the human MRS study: bregma +3.0 mm, lateral 
±1.5 mm, vertical (from dura) -5.0 mm, angle: 12 degrees in bregma plane. Though 
experimental co-ordinates were +3.0 mm from bregma, Figure 12 in Paxinos and Watson’s 
stereotaxic rat brain atlas was used for comparison (+2.76 mm from bregma) to best match 
the anatomy depicted in the atlas (Paxinos & Watson, 2009). 
 
The following CPu co-ordinates were chosen to best replicate and map to the region of 
interest in the human MRS study, the basal ganglia: bregma +0.3 mm, lateral ±3.0 mm, 
vertical (from dura) -6.0 mm. Though experimental co-ordinates are + 0.3 mm from bregma, 
Figure 31 in Paxinos and Watson’s stereotaxic rat brain atlas was used for comparison (+ 
0.24 mm from bregma) to best match the anatomy depicted in the atlas. Using these co-
ordinates, I visualized the ideal probe placement using the Paxinos and Watson brain atlas 
(Paxinos & Watson, 2009), and compared this image with the actual placement observed. See 
Figure 2.10 and 2.11 for prefrontal cortex and caudate putamen placements, respectively. 
 
The staining and visible probe tract in both brain regions confirmed the microdialysis probes 








Figure 2.10: Microdialysis probe placement- medial prefrontal cortex 
A) Imagined probe placement using atlas stereotaxic co-ordinates, 4 mm microdialysis 
probe depicted in green  
B) Representative example of actual probe placement, 4 mm microdialysis probe depicted 
in blue  
C) Close up view of probe tract terminating in the infralimbic layer 2 region. Toluene blue 
stains the area where the microdialysis probe would lie. 
Abbreviations: ac; anterior commisure, AcbC; nucleus accumbens core, AcbSh; nucleus 
accumbens shell, Cg1; cingulate cortex area 1, Cpu; caudate putamen, DP; dorsal 
peduncular cortex, fmi; forceps minor corpus callosum, IL; infralimbic cortex, lo; lateral 










Figure 2.11: Microdialysis probe placement- caudate putamen 
A) Imagined probe placement using atlas stereotaxic co-ordinates, 3 mm microdialysis 
probe depicted in orange  
B) Representative example of actual probe placement, 3 mm microdialysis probe depicted 
in orange  
C) Close up view of probe tract terminating in the centre of the caudate putamen. Toluene 
blue stains the area where the microdialysis probe would lie. 
Abbreviations: ac; anterior commissure, cc; corpus callosum, cg; cingulum, cg2; cingulate 
cortex area 2, CPu; caudate putamen, IPAC; interstitial nucleus of the posterior limb of the 
anterior commissure, lo; lateral olfactory tract, LV; lateral ventricle, M1; primary motor 
cortex, M2; secondary motor cortex, MS; medial septal nucleus, Pir; piriform cortex, rf; 
rhinal fissure, S1; primary somatosensory cortex, S2; secondary somatosensory cortex 
C 
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2.3 Ethical considerations 
2.3.1 Clinical research 
Ethical approval for all aspects of the clinical research outlined in the present thesis was 
provided by Camden and Islington London NHS Research Ethics Committee; study reference 
13/LO/0091. Written, informed consent was obtained by all participants prior to study 
commencement, by a trained member of the research team (see Appendix 3).  
 
2.3.2 Pre-clinical research 
All housing and experimental procedures were performed in compliance with guidelines set 
by the Animal Care and Use Committee of Eli Lilly and Company and the U.K Home Office 
Animals Scientific Procedures Act 1986. Research was carried out under Project Licence; 
PPL30/3226. All efforts were made to minimize animal suffering and to reduce the number 
of animals used in accordance with the 3Rs (Replacement, Refinement and Reduction). 
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2.4 Concluding remarks 
Conducting clinical and pre-clinical research in both an academic group, and in an industry 
research setting allowed me to have access to different expertise and equipment, whilst 
gaining a wide variety of research skills. The array of different techniques available enabled 
me to investigate E-I pharmacology at multiple different levels; namely the E-I dynamics of 
intracellular human (Chapters 3 and 4) and rodent (Chapter 5) brain regions, the functional 
connectivity of those brain networks (Chapter 3), and finally E-I dynamics in the 
extracellular synaptic space in an animal model of ASD (Chapter 6). 
However, back and forward translating the findings of these different approaches between 
animal and human studies proved challenging- the implications of which are discussed 





Shifting brain inhibitory balance and connectivity of the 
prefrontal cortex of adults with autism spectrum disorder 
Previous investigations into Excitation (E) – Inhibition (I) balance in the living ASD brain 
have returned inconsistent findings using both MRS and fMRI techniques. One explanation 
for this may be that differences in E-I pathways in ASD are not static - they are in constant 
flux- and therefore are not best captured at a single time-point (i.e. ‘at rest’). However, no-
one has examined E-I flux or ‘responsivity’ to challenge in ASD. The following paper 
published in Translational Psychiatry (2017) aimed to test the hypothesis that there are group 
differences in the dynamics of E-I balance in the living ASD brain. I investigated this on two 
different levels; intracellular changes in E-I flux, using MRS; and network level changes in 



























RM ANOVA RM ANOVA 
  
Between groups Within groups 
Control ASD 
F p F p   
n = 20 n = 17 
Placebo Riluzole Placebo Riluzole   
Grey 54.5 (0.7) 49.9 (3.9) 53.8 (3.4) 53.9 (3.5) 0.2 0.67 1.3 0.27 
White 22.6 (1.1) 22.3 (0.9) 22.6 (0.7) 22.2 (0.8) 0.3 0.59 1.2 0.28 
CSF 23.2 (4.3) 22.2 (3.6) 20.2 (2.7) 19.5 (2.1) 6.9 0.01 5.9 0.02 
 
 
Supplementary Table 1: Prefrontal cortex voxel composition 
There were no significant main effects of group or drug on the proportion of grey or white 
matter in the prefrontal cortex voxel. There was a significant effect of riluzole (F (1,32) =6.9, 
p=0.01) and group (F (1,32) =5.9, p=0.02) on the proportion of CSF in the voxel, hence 

















Supplementary Table 2: Detail of fMRI result 












COPE-MAX COPE-MEAN Brain Region 
(mm) (mm) (mm) 
      
Comparison of connectivity of DMPFC seed, on placebo, in ASD group vs. control group (Figure 4A), between subjects 
ASD>HV 2 831 0.0034 2.46 4.19 28 -52 16 0.21 0.121 
Right occipital white matter, right 
intracalcarine cortex 
ASD>HV 1 786 0.0049 2.31 4.01 -38 -46 22 0.218 0.084 Left cerebral white matter 
HV>ASD 1 894 0.0021 2.68 3.96 12 -16 -24 0.626 0.247 Brainstem 






5.44 4.01 24 -70 8 0.116 0.061 
Right occipital white matter, right 




462 0.0139 1.86 3.57 -58 -60 -4 0.135 0.0756 Left lateral occipital cortex 
Comparison of effect of placebo vs. riluzole (negative slope of riluzole) in ASD vs. negative slope in controls (Figure 4C) 
ASD>HV 3 904 
9.49E-
05 
4.02 3.81 24 -70 8 0.157 0.094 
Right occipital white matter, right 
intracalcarine cortex, right lateral 
occipital cortex 
ASD>HV 2 525 0.0063 2.2 3.79 20 -64 -22 0.204 0.0937 Right Cerebellum 
ASD>HV 1 439 0.0186 1.73 3.66 -36 -40 -36 0.154 0.0888 Left cerebellum 
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3.1 Additional findings not included in the peer-reviewed 
publication 
Additional analyses which were not incorporated into the publication are detailed below. 
3.1.1 E-I responsivity and clinical symptoms 
3.1.1.1 [1H]MRS 
In the ASD cohort, where MRS data was available at two time points, the relationship 
between riluzole-evoked change in the inhibitory index, and clinical symptom profile was 
investigated. The percentage increase in the inhibitory index was shown to be inversely 
correlated with social ability, as measured using the ADOS (Pearson correlation; n=12, r=- 
0.663, p=0.019). Though there was a low n for the ADI, mainly due to advanced parental age, 
there was also a significant association between the ADI communication score and change in 
the inhibitory index (Pearson correlation; n=7, r =-0.803, p=0.03). Specifically, patients with 
lower social and communication scores (i.e. those who were least impaired according to the 
assessment) responded to riluzole with a larger percentage increase in PFC GABA fraction, 
than those who were deemed to have more difficulties (see Figure 3.1).  
The inhibitory index at baseline (placebo condition) did not correlate with any measure from 
the ADOS or ADI. 
 
3.1.1.2 Functional connectivity  
There were no significant associations between baseline, or change, in functional 





Figure 3.1: Riluzole evoked changes in PFC inhibitory index are related to core 
symptom domains in ASD 
Riluzole-evoked percentage increase in the inhibitory index in ASD is inversely correlated 
with social ability, as measured by the ADOS: Pearson correlation; n=12, r=-0.663, p=0.019. 
Removal of the apparent outlier (x=24.7, y=4) did not affect significance (Pearson correlation 
with outlier removed; n=11, r=-0.71, p=0.014). 
  



















ASD R2 linear = 0.44 
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3.1.2 Metabolites levels and functional connectivity 
As local changes in E-I metabolites are thought to influence wider network activity (Duncan 
et al., 2013; Stagg et al., 2014), the association of metabolite levels and functional 
connectivity were investigated. 
There were no significant correlations of baseline glutamate, GABA or the inhibitory index at 
rest with baseline functional connectivity (data not shown). Likewise, there was no 
association between the riluzole-evoked change in PE and change in any MRS measure 
(Table 3.1). Additionally, baseline metabolite levels were not associated with the degree of 
change in connectivity (Table 3.1).  
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Pearson Correlation Δ PE -0.495 -0.542 0.186 
Sig. (2-tailed) 
 
0.213 0.166 0.66 
N 
 
8 8 8 
Pearson Correlation Δ PE -0.491 0.138 0.719 
Sig. (2-tailed) 
 
0.263 0.768 0.068 
N 
 
7 7 7 
      










Pearson Correlation Δ PE 0.171 0.223 0.157 
Sig. (2-tailed) 
 
0.543 0.424 0.593 
N 
 
15 15 14 
Pearson Correlation Δ PE 0.308 0.101 -0.17 
Sig. (2-tailed) 
 
0.33 0.743 0.598 
N 
 
12 13 12 
 
Table 3.1: Correlation of MRS metabolites with functional connectivity (PE) 
There were no significant associations between baseline or riluzole-evoked change in 




3.2 Additional conclusions not included in the peer-reviewed 
publication 
3.2.1 Clinical correlates- MRS 
In addition to group differences in responsivity, the present study also identified a range of 
responses to riluzole in the ASD group; individuals with more ASD symptoms had the least 
shift in GABA fraction. Specifically, men with more social and communication difficulties 
(as measured by higher scores on the ADOS and ADI, respectively) showed the least 
response to riluzole (Figure 3.1). This is broadly consistent with previous findings that 
riluzole (Ghaleiha et al., 2013; Wink et al., 2011), and GABA acting drugs (such as 
arbaclofen (Frye, 2014)), have shown promise in reducing symptoms in some, but not all, 
ASD individuals. This may not be unexpected in a spectrum condition, but may inform the 
biological underpinnings of these symptoms. As there were no reported correlations between 
baseline GABA or glutamate measures with clinical symptoms scores, it may not be 
differences in baseline E-I metabolites which drives symptom severity- rather it is the lack of 
dynamic flux, and responsivity of the system which contributes to symptomatology. 
 
3.2.2 Clinical correlates- fMRI 
As highlighted in Ajram et al., 2017, the number of ASD participants who had both a full set 
of clinical assessment scores prior to scanning, and imaging data at both time points was 
lower than planned (ADOS n=12, ADI n=7). No clinical correlates were found with 
functional connectivity measures. Future investigations with a larger cohort will be necessary 
to increase power. 
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3.2.3 MRS-fMRI 
It is widely established in the literature that local glutamate and GABA levels at rest 
determine the activity of neural networks (Duncan et al., 2013; Enzi et al., 2012; Horn et al., 
2010; Kapogiannis et al., 2013; Kwon et al., 2014) . However, no one has investigated 
whether changes to metabolite flux correlate with changes in functional connectivity.  
There were no significant correlations between resting inhibitory index, GABA or glutamate 
levels with baseline functional connectivity of the ACC (data not shown). Likewise, there 
was no association between change in any MRS measure and change in ACC functional 
connectivity (Table 3.1). It was postulated that baseline metabolite levels may be predictive 
of the extent of change in functional connectivity elicited by riluzole, however no significant 
associations between any metabolite at rest and riluzole-evoked change in PE were found 
(Table 3.1). 
 
Again, however, results are limited by the small sample size in these analyses, as not all 
participants obtained usable data on both scanning occasions, in both MRS and fMRI. 
 
Finally, the present study focused on the prefrontal cortex as a region of interest, however, 
sub-cortical regions including the basal ganglia are also implicated in ASD. The following 






Shifting brain inhibitory balance of the basal ganglia of adults 
with autism spectrum disorder 
4.1 Introduction 
The previous chapter identified differences in the way that the adult prefrontal cortex of men 
with and without ASD responds to an E-I challenge with riluzole. However, subcortical 
pathology has also been implicated in ASD (Dawson et al., 2005; Dichter et al., 2012; Kohls 
et al., 2012; Langen et al., 2012; Naaijen et al., 2015). These findings are also consistent with 
the known role of fronto-striatal circuits in the processing of higher order cognitive and 
emotive information in neurotypical populations. Moreover, studies of both ASD and 
disorders which share traits with ASD, such as obsessive compulsive disorder (OCD), have 
documented a relationship between repetitive or stereotyped behaviours and abnormalities of 
basal ganglia structure and function (Calderoni et al., 2014; Langen et al., 2009; Rojas et al., 
2006; Whiteside et al., 2004). 
 
Therefore, in an extension to the prior chapter, (Ajram et al. 2017), I also used [1H]MRS to 





The research outlined in the present chapter took place as part of the study outlined in 
Chapter 3. The general methods are largely as described in Ajram et al., 2017 (pages 125- 
133). In brief, participants were scanned on two occasions, one week apart; and were given 
either a 50 mg oral dose of riluzole, or equivalent placebo. The order of drug administration 
was both randomised and double-blinded and order effects were controlled for by ensuring 
roughly half of participants received riluzole first, and half received placebo. MRS data 
acquisition began 1 hour after drug administration (see Figure 2.1 for a detailed timetable of 
in-scanner events). 
 
4.2.1 [1H]MRS data acquisition 
[1H]MRS data were acquired on a 3 Tesla GE Excite II Magnetic Resonance Imaging 
scanner (GE, USA). An initial structural scan was performed, which was then used to set the 
MRS voxel locations; namely a 3D inversion recovery prepared fast spoiled gradient-recalled 
echo (IR-FSPGR) acquisition (number of slices = 124, slice thickness = 1.1 mm, inversion 
time (TI) = 450 ms, repetition time (TR) = 7.084 ms, echo time (TE) = 2.84 ms, field of 
view=280 mm, flip angle=20°).  
Single voxel J-edited MEGAPRESS spectra were then acquired in the left basal ganglia (see 
Figure 4.1 for example voxel placement) according to the following parameters: 
Left basal ganglia, comprising of the head of the caudate, lateral thalamus and caudate 
putamen; 35 x 25 x 30 mm3; TR = 1800 ms, TE = 68 ms. 
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The left basal ganglia was selected to correspond with previous data collection from this 
region in our department, and to enable future cross-study comparisons of different E-I 
interventions in this region (Horder et al. 2013 and unpublished data from Murphy lab, 











Figure 4.1: [1H]MRS basal ganglia voxel position 
Basal ganglia region of interest outlined in white (35 x 25 x 30 mm3) incorporating the head 




Left Right  
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4.2.2 [1H]MRS data analysis 
[1H]MRS data were pre-processed using previously described methods (see Chapter 2, 
section 2.1.4.5). Briefly, the unedited MRS spectrum and unsuppressed water spectrum were 
extracted using GE SAGE software (SAGE 2007, GE Healthcare, USA), prior to 
quantification of metabolites using jMRUI version 4 software (Naressi et al., 2001). Each 
spectrum was manually checked for quality (see Figure 4.2).  
Metabolite concentrations were estimated at 3.0 ppm for GABA and Glx at two peaks; 3.8 
ppm and 3.75 ppm. Absolute measures were calculated by dividing the peak amplitude by 










4.2.3 [1H]MRS voxel composition calculation 
As described in further detail in Chapter 2 (section 2.1.4.5), partial volume effects are a 
potential confound for spectroscopy. Therefore, the relative levels of grey matter (GM), white 
matter (WM) and cerebrospinal fluid (CSF) were measured. No significant group differences 
were found in either grey or white matter (see Table 4.1). Assuming negligible levels of 













Table 4.1: Percentage tissue composition in control (n=20) and ASD (n=17) basal ganglia [1H]-MRS voxels 
There was no significant effect of group or drug on percentage composition of grey or white matter, nor CSF, in the basal ganglia voxel. RM 
ANOVA; degrees of freedom=1 for each analysis.     
  




Region Measure Control, n=20 ASD, n= 17 F p F p 
  Placebo Riluzole Placebo Riluzole  
Basal 
ganglia 
Grey 50.1 (1.1) 44.9 (3.6) 47.1 (3.2) 50.1 (1.3) 1.3 .26 1.4 .24 
 White 42.3 (1.3) 41.0 (2.5) 42.0 (1.5) 42.1 (1.5) 1.3 .26 1.1 .24 
 
 CSF 7.6 (1.7) 6.5 (2.5) 7.9 (1.7) 7.7 (1.5) 2.0 .16 3.6 .07 
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4.2.4 Statistical analysis 
Statistical analyses were performed using IBM SPSS v.22 software (IBM SPSS Statistics for 
Macintosh, Version 22.0, USA). Figures were generated using GraphPad Prism version 7 for 
Windows (GraphPad Software, USA). Participant group comparisons were performed using 
independent samples t-tests. The numbers included in each MR analysis depended upon a 
stringent quality check of data available for each participant per analyses at each time point.  
The [1H]MRS voxel composition in each group was compared using repeated measures two-
way analysis of variance (RM 2-way ANOVA) with ‘group’ as between-subjects factor and 
‘drug’ as within-subjects factor (control n=20, ASD n=17). A complete dataset of two time 
points for Glx levels was obtained for 29 participants and was compared using a RM 2-way 
ANOVA. Likewise, a complete dataset of two time points for the inhibitory index was 
obtained for 26 participants and was compared using a RM 2-way ANOVA. The State score 
measure of anxiety was included as a covariate in analysis of the inhibitory index, as anxiety 
is closely linked to GABA (Lydiard, 2003) and participants with ASD scored significantly 
higher than controls on measures of anxiety. Clinical scores were compared using 
independent samples t-tests. 
Pearson correlation analyses were also used to compare the relationship of baseline, and the 
change in Glx and the inhibitory index with ASD symptom scores. For consistency, the State 




4.3.1 Participant demographic and clinical symptoms 
As reported in Chapter 3, participants did not significantly differ in age or IQ (p=0.44 and 
0.15 respectively). As expected, the ASD group scored significantly higher in self-rated 
neuropsychological tests, including assessments of autism traits (AQ; p<0.001), anxiety 
(STAI; p=0.004) and obsessionality (OCI-R; p<0.001). The average scores across the gold 
standard diagnostic tests for ASD were above the cut off level for a diagnosis of autism. 
 
4.3.2 Lower resting Glx levels in the ASD basal ganglia  
At baseline (placebo), there were no group differences in the inhibitory index, or absolute 
levels of GABA in the basal ganglia region (see Table 4.2). There was however a significant 
group difference in baseline Glx, see Figure 4.3 and Table 4.2 (main effect of group, F (1,29) 
=4.926, p=0.034). Riluzole did not significantly affect Glx levels in either group. 
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Table 4.2: E-I changes in the basal ganglia of men with and without ASD, after riluzole or placebo administration. 
Riluzole increased the inhibitory index in both ASD and control groups in the basal ganglia. Baseline (placebo condition) Glx was significantly 
lower in the ASD group. Inhibitory index and GABA analyses were corrected for State anxiety measures. GABA and Glx mean and SEM are 
expressed as (x103). Significant p values are highlighted in bold. df = degrees of freedom. Repeated measures ANOVA displays between group 
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Figure 4.3: Significantly lower baseline Glx in ASD basal ganglia 
Significantly lower Glx levels were observed in the ASD basal ganglia in the placebo 
condition, i.e. at baseline, compared to controls. ANOVA; main effect of group, F (1,29) 
=4.926, p=0.034. Glx levels are presented as x103.  
 
4.3.3 No group difference in E-I responsivity in the basal ganglia 
To examine changes in E-I balance, as before, the inhibitory index was chosen as the 
dependent variable for further investigations. 
 
Despite a trend towards a higher resting inhibitory index in controls, there were no 
statistically significant baseline group differences in inhibitory index in the basal ganglia (see 
Table 4.2). Riluzole increased the inhibitory index in both groups, to a similar degree, see 




























Figure 4.4: Riluzole increases the inhibitory index in the basal ganglia of both groups 
Riluzole significantly increased the inhibitory index in the basal ganglia of both ASD and 
control participants; ANOVA; main effect of drug, F (1,23) =4.382, p=0.048.   
 
4.3.4 E-I responsivity and clinical symptoms 
In the ASD cohort, where good quality MRS data was available at two time points, the 
relationship between riluzole-evoked change in the inhibitory index, and clinical symptom 
profile was investigated. There was no significant correlation between change in inhibitory 
index, or any domain of the ADOS or ADI. Likewise, there were no significant associations 
between baseline inhibitory index and ADOS or ADI scores. Despite the ASD cohort 
showing significantly lower baseline Glx compared to the control group, there were no 
significant correlations between Glx and ASD symptom scores (see Table 4.3). As there were 
no significant correlations between symptoms and responsivity, and due to the relatively low 































degree of responsivity for the basal ganglia. This was possible to some extent in the 
prefrontal cortex (see previous chapter), where patients with lower social scores on the 
ADOS responded with the least change in the inhibitory index (Figure 3.1). 
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-0.37 0.376 -0.008 
Significance 
(p) 
0.90 0.23 0.98 







0.034 0.009 -0.19 
Significance 
(p) 
0.91 0.98 0.49 






0.614 -0.145 0.35 
Significance 
(p) 
0.19 0.82 0.45 







0.428 0.389 -0.89 
Significance 
(p) 
0.40 0.52 0.85 
N 6 5 5 
 
Table 4.3: Correlation basal ganglia E-I measures with clinical symptom scores 
There were no significant correlations between the inhibitory index at baseline (placebo) or in 
change in the inhibitory index with any clinical measure. The ASD cohort had lower Glx 
level in the basal ganglia at rest, but there were no significant correlations between baseline 





In line with Ajram et al. (2017), this study provides direct evidence that E-I balance can be 
pharmacologically shifted in both the ASD and control brain. In the basal ganglia, this shift 
occurs to the same extent, and in the same direction in both groups, despite baseline 
differences in E-I balance. 
 
4.4.1 Baseline metabolite differences 
Consistent with findings from the prefrontal cortex, there were no baseline differences in the 
level of basal ganglia GABA in men with ASD relative to controls. However, there was a 
significant group difference in baseline Glx (Figure 4.3), with lower Glx in the ASD cohort. 
Lower subcortical glutamate in ASD is consistent with previous research from this 
department (Horder et al., 2013), but contradicts other findings of higher (Hassan et al., 2013) 
or no difference (Harada et al., 2011; Hardan et al., 2008) in glutamate indices relative to 
controls in the same region in ASD. This discrepancy may reflect inter-study differences, 
particularly in age, as both the present study and that of Horder et al., who report similar 
results, examined adults, whereas the others focused solely on children. Furthermore, unlike 
most studies, patients in the present study were psychoactive medication-free and had no co-
morbid mental health conditions (particularly those with a known E-I underpinning cause, 
e.g. epilepsy) and therefore my findings cannot be explained by such potential confounds. 
Additionally, both Hassan et al. and Harada et al. recruited both male and female subjects, 
whereas the present study only recruited males. Brain chemistry has previously been shown 
to differ with age and sex in both healthy controls and ASD patients, hence differences in 
patient demographics may contribute to inconsistencies in the literature (Charles et al., 1994; 
Robinson et al., 2013; van de Lagemaat et al., 2014).  
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4.4.2 E-I response to challenge 
In the basal ganglia, both groups responded in same way to riluzole; by increasing the 
inhibitory index after E-I challenge (Figure 4.4). This was in contrast to the group difference 
in the pattern of response to riluzole in the prefrontal cortex; whereby riluzole increased the 
inhibitory index in ASD, but decreased it in controls (see Appendix 6 for a table of basal 
ganglia and prefrontal cortex results). Collectively these findings indicate that the ASD group 
consistently responded with an increase in GABA tone to riluzole challenge, irrespective of 
the brain region tested, whereas controls had a regionally specific response profile. In the 
prefrontal cortex, the control group E-I balance was ‘shifted’ towards glutamate, whereas in 
the ASD group E-I balance was shifted towards GABA. In the basal ganglia, both groups 




Figure 4.5: Representation of E-I shift in response to riluzole in the prefrontal cortex 
and basal ganglia 
In the prefrontal cortex, riluzole shifted E-I balance towards glutamate in controls, but 
towards GABA in ASD. Conversely, in the basal ganglia; riluzole shifted E-I balance 
towards GABA in both groups 
Key: orange circle represents GABA portion; green circle represents Glx portion; red arrow 
represents shift towards GABA; green arrow represents shift towards Glx. Proportions are 
not to scale and are intended to show direction of change, not size of change. 
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4.4.3 Regional cellular organisation 
Though the degree of response in the two brain regions was not formally compared, it is clear 
that responsivity to E-I challenge is different in the prefrontal cortex and basal ganglia in 
controls, but not in ASD. Using MRS, it is not possible to fully understand the reason for the 
lack of a regionally distinct response profile in the ASD cohort, however both structural and 
neurochemical differences in the cortex and sub-cortex of the ASD brain compared to the 
typically developing brain, may play a role.  
 
The prefrontal cortex consists primarily of excitatory pyramidal neurons, and a multitude of 
glial cells, which act as glutamate stores (Elston, 2003). Comparatively, the basal ganglia, in 
particular the striatum, is comprised primarily of GABAergic medium spiny neurons and has 
many inhibitory projections (Lanciego et al., 2012). Such regional differences in cellular 
organisation will no doubt infer differences in regional glutamate and GABA receptor 
distribution, which may in turn impact their availability for modulation by riluzole. For 
example, the degree of binding of GABA to GABAA receptors has been shown to differ 
throughout the control brain, depending on subunit assembly (Halonen et al., 2009) and in 
controls, glutamate receptors are generally more highly conserved in the PFC, compared to 
basal ganglia regions (Breese & Leonard, 1994). Likewise, the expression of enzymes 
involved in converting glutamate to GABA, which maintain E-I dynamics, such as GAD65 
and GAD67 is known to differ between regions (Collins, 1972; Müller & Langemann, 1962). 
However, as discussed below, the composition and function of both brain regions are known 
to be altered in ASD (Calderoni et al., 2014; Fatemi et al., 2002; Hassan et al., 2013), which 




4.4.4 Glial contribution 
[1H]MRS samples the total tissue metabolite pool within both neurons and glia. The relative 
proportions of these two cell types differ from region to region (Pakkenberg & Gundersen, 
1988; Sherwood et al., 2006), and may therefore contribute to the pattern of findings here. 
For example, there are a multitude of glial cells in the prefrontal cortex, which far outnumber 
neurons. Glial cells (astrocytes and microglia) are responsible for the uptake and storage of 
glutamate as glutamine, and the subsequent release of glutamine to be converted to glutamate 
for neurotransmission. They therefore act as a metabolic store, and are required in high 
quantities in the prefrontal cortex in particular due to the high metabolic demand of 
maintaining highly active prefrontal neurons with long dendritic projections (Sherwood et al., 
2006). In addition to glutamate storage, glia help regulate E-I balance and maintain synaptic 
integrity (Auld & Robitaille, 2003; Domercq et al., 2013; Durieux et al., 2015; Graeber, 
2010; Liang et al., 2006; Wake et al., 2009). In the prefrontal cortex (Chapter 3) the change 
in GABA fraction was correlated with the change in Glx in controls but not ASD. Therefore, 
it is possible that the typical neuronal-glia relationship is preserved in controls and maintains 
E-I balance. 
 
In contrast, abnormalities in glia have been implicated in ASD (Bernstein et al., 2009; 
Durieux et al., 2015; Fatemi et al., 2008; Onore et al., 2012; Shigemori et al., 2015); and 
higher glial numbers have been shown in neurodevelopmental models and patients with ASD 
(Dickens et al., 2014; Suzuki et al., 2013). Moreover, differences in both glial number and 
activation state have been shown to be concentrated in prefrontal (e.g. ACC), and not in basal 
ganglia regions (Suzuki et al., 2013). Thus, I speculate that the proportions of cell 
populations contributing to E-I balance in the basal ganglia in ASD may be more similar to 
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controls and so the responsivity to E-I challenge is also similar. Unfortunately, MRS is not 
yet sensitive enough to tease out any differences in glial and neuronal alterations. 
 
4.4.5 Receptor and enzyme contribution 
As the cellular composition of both brain regions are known to be altered in ASD, so too are 
the regional distribution of receptors and enzymes which determine E-I balance. GABAA 
receptor expression has been shown to be abnormal across the ASD brain, with altered levels 
observed in the hippocampus (Blatt et al., 2001) and nucleus accumbens (Mendez et al., 
2013). Pertinently- both GABAA and GABAB receptor expression is reportedly altered in the 
prefrontal cortex and anterior cingulate cortex of children and adults with ASD compared to 
controls (Fatemi et al., 2010, 2014; Mori et al., 2012; Oblak et al., 2009, 2010). This may go 
some way to explain why the effect of riluzole in the prefrontal cortex is different in ASD 
and controls, as one mechanism of action of riluzole is to potentiate GABA receptor activity.  
 
Likewise, glutamate receptor expression is known to be altered across the brain in ASD- 
particularly in the cerebellum, where lower AMPA and higher NMDA and mGluR5 receptors 
have been reported (Fatemi et al., 2011; Purcell et al., 2001).  A near-significant trend 
towards increased mGluR5 levels in the prefrontal cortex of ASD patients was reported by 
Lohith et al., (2013), yet lower levels in the same region and in animal models have been 
reported by others (Chana et al., 2015). With limited available post-mortem samples, it is 
difficult to fully map receptor levels across the human ASD brain, yet regional 
inconsistencies in receptor expression and perhaps function are apparent, which may interfere 
with riluzole’s efficacy and could contribute to the pattern of results presented in this chapter. 
Similarly, the expression of enzymes which regulate glutamate-GABA flux is compromised 
in ASD. The majority of investigations into GAD65 and GAD67, which convert glutamate to 
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GABA, focus on the cerebellum (Fatemi et al., 2002; Yip et al., 2007, 2009), where the 
concentration of enzymes is reportedly lower than in controls. In animal models, however, 
such as the valproic acid mouse model of ASD, the basal ganglia and prefrontal cortex have 
been examined. In these animals, GAD67 was found to be lower in the prefrontal cortex, but 
increased in the basal ganglia, whereas GAD65 was reduced in both regions (Wei et al., 
2016). GAD65 is associated with synaptic terminals, and is therefore thought to impact 
synapatic transmission, whereas isoform 67 is associated with axonal regions and maintains 
metabolic stores (Esclapez, Tillakaratne, Kaufman, Tobin, & Houser, 1994; Martin & 
Rimvall, 1993). Both synaptic function, and metabolic stores of E-I metabolites awaiting use 
in transmission, may therefore be altered in ASD. Additionally, further metabolic alterations 
have been reported in the prefrontal cortex of patients with ASD by Shimmura et al., (2013), 
who highlighted decreased levels of kidney-type glutaminase in the anterior cingulate cortex, 
inferring altered glutamate-glutamine balance, which again, may impact the responsivity of 
the ASD prefrontal cortex. 
 
Taken in combination; differences in regional cellular composition, receptor availability, and 
transmitter metabolic pathways may converge to create group differences in responsivity of 
the ASD brain, and may go some way to explain the differences observed in the prefrontal 
cortex in the present study.  
 
Furthermore, the finding of altered baseline functional connectivity of the prefrontal cortex in 
the ASD group in Chapter 3, could also be considered as a contributing factor to regional 
responsivity differences. Therefore, whilst it is possible that the MRS response difference in 
GABA might explain the functional connectivity response, it could in fact, be the other way 
around. Thus, one cannot know whether by altering FC of the rest of brain with ACC in 
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ASD, a secondary effect is a shift in metabolite in this ‘reconnected’ region. Long-range 
connections are complex and thus the shift in connectivity may have been accompanied by 
metabolite shifts in multiple inter-connected subcortical and cortical components of this 
pathway including in posterior cortices. Unfortunately, I did not acquire MRS across whole 
brain, which might have helped to understand the relationship between metabolite shifts and 
functional connectivity changes. 
 
The explanations suggested above may well be an over-simplification. Although both the 
control and ASD groups responded in the same direction to riluzole challenge in the basal 
ganglia, it is unclear whether this is a ‘normal’ response in ASD and indeed the baseline E-I 
was abnormal in this region in the ASD group. The MRS voxels used in these experiments 
incorporated, multiple anatomical structures. Both cortical and sub-cortical voxels captured a 
mix of CSF, grey matter and white matter; and although the voxel composition was 
segmented to control for variation in tissue composition, the target was sizeable. The basal 
ganglia voxel itself encroached upon the thalamus, insula, internal capsule and caudate 
putamen and it is well documented that the size, in terms of both volume and surface area, of 
basal ganglia structures is altered in ASD (Estes et al., 2011; Sato et al., 2014; Schuetze et al., 
2016), therefore the ASD voxel in our studies and in work by other teams may capture 
different parts of the basal ganglia than the voxel in control group. That being said, there 
were no significant group differences in the percentage composition of either voxel in either 
grey or white matter (Supplementary Table 1 and Table 4.1), but it is impossible to tell which 
anatomical regions the relevant proportions of tissue belong to. 
 
The relative proportions of white (PFC ~ 40%, basal ganglia ~ 20%), but not grey matter 
(~50% in both PFC and basal ganglia) differed between the two brain regions tested, though 
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since there were no differences in each voxel’s composition between groups and variations in 
voxel composition were accounted for, the tissue composition at the level of grey/white 
matter is unlikely to account for the differences in regional responsivity in the groups. 
4.5 Limitations 
Thus, [1H]MRS is a valuable, yet relatively ‘crude’ measure of E-I balance, and can only 
show bulk measures of total metabolite levels within relatively large regions of brain. As a 
result, MRS is unlikely to be sensitive to synaptic levels of neurotransmitters and should not 
therefore be assumed to measure neural signalling (Dager et al., 2008). Additionally, the 
metabolite measures acquired do not reflect absolute concentrations of GABA and glutamate; 
as they are contaminated with other signals (e.g. the GABA signal also contains 
macromolecule and is reported as GABA+; and the Glx signal is a combination of glutamate 
and its metabolite glutamine). It is possible therefore that the presence of these additional 
molecules may confound results (see General methods, section 2.1.4.6 for further details). 
Steps to minimise the impact of these combined signals are now available, using suppression 
and editing techniques (Edden et al., 2012; Harris et al., 2015; Ramadan et al., 2013; Shungu 
et al., 2016). Whilst this technology was not available for the present study, future work 
should utilise these techniques to aim for a ‘pure’ sample of glutamate and GABA. 
 
I also acknowledge that, although based upon prior power calculations, the sample size for 
this study was still modest. However, according to previously published data from our 
scanner, n=12 is sufficient to detect a 10% alteration in E-I levels at a power of 0.8 (Stone et 
al., 2012). I can be confident therefore that any significant findings (such as the group 
difference in basal Glx levels) are sufficiently powered, and similarly, findings of no 
difference are unlikely to be due to a lack of power. In analyses where no significant results 
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were found, for example where there were no group differences in response to riluzole in the 
basal ganglia, sample analysis calculations indicate that a total n of 262 would be necessary 
to find a statistically significant difference between groups (Clin Calc LLC, 2018). If putative 
differences were obtained with such large numbers, they may be statistically significant, but 
are unlikely to be clinically significant.  
 
Finally, this study was intended as an initial ‘Proof of Concept’ study to test responsivity 
differences in ASD, but was not powered to examine symptom correlates. To accommodate 
correlation analyses, with an estimated moderate-large effect size (r=0.5) between acute 
changes in the inhibitory index and primary symptom measures, at =0.05 and a power of 
0.9, the sample size would need to be n=31. Thus, the absence of a relationship between 
symptoms and E-I responsivity in ASD may represent a false negative finding. Future work 
will be required to confirm the findings from this study (particularly with regards to clinical 
correlates) in a larger cohort and determine if these are generalisable, for example, to females 
with ASD, to other age groups and/or to individuals with intellectual difficulties.  
 
4.6 Conclusions 
For the first time, I have shown that E-I balance can be pharmacologically ‘shifted’ in control 
subjects and in patients with an established E-I imbalance. Furthermore, the nature of 
responsivity to E-I challenge differs between adult men with and without ASD. Specifically, 
the control subjects’ response to riluzole in the prefrontal cortex and basal ganglia is in 
opposite directions, whilst participants with ASD respond in the same direction, irrespective 
of brain region. While this evidence that E-I balance can be modulated in ASD gives reason 
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for hope in the search for pharmacological treatment options, I have also shown that the 
response in the ASD brain is pharmacologically atypical. The latter may have important 
implications for drug development and suggests we cannot assume that drugs work in the 
same way in the neurodevelopmental spectrum as in unaffected individuals.  
 
4.7 Next steps 
It is clear from both the MRS and fMRI data presented thus far that there are alterations in E-
I flux in ASD. However, with the techniques available in humans, it was not possible to tell 
how changes to metabolite levels at a cellular level drive changes in functional connectivity. 
Direct measurement of changes in extracellular E-I (efflux) following riluzole administration 





The Neurexin1 knock out rat as a model of ASD: Initial 
preclinical investigations 
5.1 Introduction 
Genetic alterations which compromise E-I synaptic stability have been consistently linked to 
neurodevelopmental disorders (Jamain et al., 2003; Südhof, 2008; Zhao et al., 2017). In 
particular, copy number variations in the Neurexin1 gene have been repeatedly observed in 
patients with ASD (Bucan et al., 2009; Ching et al., 2010; Dabell et al., 2013; Feng et al., 
2006; Gauthier et al., 2011; Glessner et al., 2009; Kim et al., 2008; The Autism Genome 
Project Consortium, 2007; Yan et al., 2008) and may contribute to 0.5% of total incidences 
(Etherton et al., 2009). Mostly, disruptions to the alpha () isoform of Neurexin1 are 
implicated, and Neurexin1 has therefore become a target for manipulation in animal models. 
 
Studies using Neurexin1 homozygous knock out (Nrxn1 -/-) mice and rats have shown that 
removing this gene causes deficits in social behaviour which may proxy the core symptoms 
of the human condition (Dachtler et al., 2015; Esclassan et al., 2015; et al., 2009; Grayton et 
al., 2013; Laarakker et al., 2012). Additionally, Nrxn1 -/- models show abnormalities in E-I 
transmission, including decreased excitatory synaptic strength, reduced EPSC frequency and 
reduced release of both excitatory and inhibitory neurotransmitters (Etherton et al., 2009; 
Kattenstroth et al., 2004; Missler et al., 2003; Zhang et al., 2005). The Nrxn1 -/- rat was 
therefore selected as a model for continuing investigations into E-I flux in ASD. However, 
whilst the existing literature infers an E-I imbalance in this model, no one has directly 
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investigated E-I flux in a Nrxn1- deficient animal. The following experiments were 
therefore designed to determine the face validity of the Nrxn1 -/- rat as a model of disrupted 
E-I and test whether the neurochemistry of the Nrxn1 -/- rat would match that of the human 
patient population, both at baseline, and after riluzole administration. 
 
For consistency, the following rodent experiments aimed to mirror those undertaken in the 
human MRS study. First, it was necessary to establish an equivalent dose and route of 
administration of riluzole which would be comparable across species, and confirm the 
pharmacokinetics (PK) in this rat model (see Study 1, section 5.2). Next the aim was to 
establish whether the baseline findings of the human MRS study were comparable with the 
neurochemistry of the animal model at baseline. To this end, HPLC was used to capture bulk 
intracellular levels of metabolites in specific volumes (weights) of tissue as this method has 
been shown to produce equivalent results to MRS (Fatouros et al., 2000). Bulk measures of 
neurotransmitters were measured ex vivo in equivalent brain regions in rats, namely the 




5.2 Study 1: Riluzole pharmacokinetics in the rodent 
50 mg is the standard oral dose prescribed to adults with Amyotrophic Lateral Sclerosis 
(ALS) and was therefore deemed a suitable dose to use as an initial challenge for the human 
study (Bryson et al., 1996; Joint Formularly Committee, 2017). Using a dose translation 
equation, 4 mg/kg riluzole oral dose (p.o.) was calculated as the rodent equivalent to the 50 
mg tablet administered to humans (see General Methods section 2.2.2.1 for full details). This 
dose was within the range used in previous rodent studies (Chew et al., 2014; Sung et al., 
2003), with minimal side effects (which appear over 10 mg/kg), and far below the lethal dose 
(LD50) of 85 mg/kg (Sanofi-Aventis, 2010). Riluzole at a similar dose (5 mg/kg) shows rapid 
brain penetration which is dependent upon plasma concentrations (Milane et al., 2009); but 
this data comes from intraperitoneal injections in mice. However, as the literature on riluzole 
PK in the rodent varies greatly in dose concentration, route of administration and animal 
species (Milane et al., 2009; Ravi et al., 2013; Wu et al., 2013), a PK study was conducted in 
wild type adult Wistar rats to establish the presence of riluzole in the rat brain and plasma 
after a 4 mg/kg oral dose. 
 
5.2.1 Methods 
The full protocol can be found in General Methods section 2.2.3. Briefly, 12 male Wistar rats 
(average weight 319.9  4.1 grams) were culled by a rising concentration of CO2 0.5, 1, 2, or 
4 hours (n=3/group) after a 4 mg/kg oral dose of riluzole (in 1% HEC). Blood was collected 
by cardiac puncture and plasma separated by centrifugation. Following removal of blood, 
brains were removed and the forebrain cut at the level of the optic chiasm. Forebrains were 
weighed and all samples were frozen and stored at -80oC pending analysis. Samples were 
analysed using previously described methods (General Methods section 2.2.6). Plasma and 
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brain concentrations of riluzole are presented as ng/ml or ng/g of sample respectively and the 




5.2.2.1 Riluzole is present in the plasma and brain after 4 mg/kg dose 
Riluzole was detected in the brain and plasma at each time point measured, with peak 
exposure times of 3 and 4 hours post-dose, respectively (Table 5.1 and Figure 5.1). Brain 
exposure was approximately 5 times that of plasma exposure, as determined by the 
brain/plasma ratio (see Table 5.1). 
 
 
Table 5.1: Mean riluzole brain and plasma concentrations after 4 mg/kg oral dose 
 
Time (hr) Plasma Concentration (ng/ml) 
Mean (±SEM) 




0.5 647 (81) 3413 (507) 5.24 (0.4) 
1 576 (24) 3470 (19) 6.09 (0.5) 
2 1011 (72) 5683 (418) 5.67 (0.6) 




Figure 5.1: Plasma (A) and brain (B) concentration of riluzole after 4 mg/kg oral dose in 
wild type rats 
(A) Riluzole is present in the plasma up to 4 hours post 4 mg/kg oral dose, with a peak 
concentration at the 4 hour time point. 
(B) Riluzole is present in the brain up to 4 hours post 4 mg/kg oral dose, with a peak 









































































After a single oral dose of 4 mg/kg, riluzole was present in both the rat brain and plasma from 
the initial sampling time of 30 minutes up to 4 hours post-dose. Peak plasma concentrations 
were achieved at 4 hours post-dose, and peak brain concentration at 3 hours post dose. The 
drop in brain riluzole concentration after 3 hours, and subsequent increase in plasma levels 
may indicate riluzole starting to leave the brain and being effluxed through the blood-brain 
barrier (BBB) back to the bloodstream. Furthermore, brain exposure in the rat was found to 
be around five times higher than that of plasma exposure. This is consistent with previous PK 
studies in mice, where brain levels of riluzole were found to be four (Milane et al., 2009) or 
five (Colovic et al., 2004) times higher than plasma levels. 
 
In addition to confirming the presence of riluzole in the rodent brain, this study also has 
implications for the previously conducted human study. Though plasma concentrations of 
riluzole in humans are well documented, the levels of riluzole in the human brain after dosing 
have not been evaluated. Whilst riluzole is able to cross the blood-brain barrier (Sanofi-
Aventis, 2010), levels are impossible to directly sample in the living human brain. Assuming 
the brain:plasma ratio is equivalent in humans and rodents, it could be estimated that the 
concentration of riluzole in the human brain is likely to be around five times that of the 
plasma. Taken together with the known plasma levels of 50 mg oral riluzole in humans at 
Cmax (1 hour post-dose) as between 52-300 ng/ml
1 or 0.2-1.2 M (Abbara et al., 2011; 
Groeneveld et al., 2008; Le Liboux et al., 1997), it was anticipated that, at an estimated five 
                                                 
1 This value varies greatly between and within studies, for example Le Liboux et al., record 
Cmax at 1 hour post-dose as 180 ± 1220 ng/ml.  
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times higher concentration in the brain, riluzole would be at a concentration that should be 
sufficient to cause the changes in E-I dynamics observed in the human studies outlined in 
previous chapters.  
 
5.3 Study 2: E-I responsivity of Neurexin 1 -/- rats (ex vivo) 
Having established that riluzole was present in the rat brain, the next stage was to examine 
whether the drug had an equivalent effect on E-I responsivity of the PFC and CPu as in the 
human sample. Firstly, experiments investigated whether there were any initial E-I 
differences in Nrxn1 -/- rat at baseline, compared to wild type controls. To compare the 
results to the human findings, baseline GABA and glutamate levels were examined. 
However, as the measure of glutamate used in the human MRS studies was in fact Glx 
(glutamate and glutamine combined), levels of glutamine were also measured in the rodent.  
 
5.3.1 Methods 
16 adult male Wistar Nrxn1 -/- rats and 16 littermate controls were sourced from SAGE labs 
and housed in standard conditions (see General Methods chapter 2.2.1 for further detail). One 
Nrxn1 -/- rat had to be sacrificed after microdialysis surgery as the cement used to attach the 
probes did not bond to the skull, and was therefore excluded from all analyses to give an 
experimental sample of n=15 Nrxn1 -/- and n=16 wild types. Rats did not differ in weight 
(WT, 493.8  11.6 grams; Nrxn1-/-, 495.2  15.9 grams; t=0.07 (29), p=0.94) or age (WT, 
23.4  0.4 weeks; Nrxn1-/-, 21.7  1.5 weeks; t=1.14 (29), p=0.26). See Figure 5.2. 
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All rats underwent microdialysis probe implantation surgery followed by in vivo 
microdialysis experiments (see General Methods section 2.2.4 for further details). Rats were 
dosed with either 4 mg/kg riluzole (in 1% HEC), or vehicle only (1% HEC); WT vehicle n=8, 
Nrxn1-/- vehicle n=7, WT riluzole n=8, Nrxn1-/- riluzole n=8. Following in vivo 
microdialysis, animals were culled using a non-Schedule 1 procedure by exposure to a rising 
concentration of CO2 prior to decapitation by guillotine. Brains were removed and the PFC 
and CPu dissected and frozen pending analysis (see General Methods section 2.2.5.1 for 
further detail). Time from vehicle/drug administration to sample freezing (dose to dissection 
time, DTD) and time from euthanasia to sample freezing (post mortem interval, PMI) were 
recorded (Table 5.2). 
 
Brain tissue samples were analysed using previously described methods (General Methods 
section 2.2.6). Independent samples t-tests were used to compare group weight, age, DTD 
and PMI times (within drug treatment sub-groups). One-way ANOVA was used to compare 
DTD and PMI times across all groups. Two-way ANOVA was used to compare regional 
brain weights, with region and group as the variables of interest. Baseline glutamate, 
glutamine and GABA levels and glutamine-glutamate ratios were compared using 
independent t-tests. Values were then converted to the inhibitory index. In the human MRS 
study, the inhibitory index was expressed as GABA/(GABA + Glx), where Glx represented 
the combined measure of glutamate and glutamine. For consistency across studies, the 
inhibitory index in the rodent was also expressed as GABA/(GABA + Glx), where Glx is the 




Figure 5.2: Experimental rats did not differ in weight or age 
There were no significant differences between wild type and Nrxn1 -/- rats in weight (t=0.07 
(df=29), p=0.94) or age (t=1.14 (df=29), p=0.26). 
 

























Post mortem interval (PMI), minutes (mean  SEM) 







Table 5.2: Mean time from dose to dissection and from dissection to sample freezing 
There were no significant differences between groups in time from dose to dissection, or post 






















































5.3.2.1 Regional brain weight  
There were no significant group differences when comparing the weight of each dissected 




Figure 5.3: Regional brain weights 


























5.3.2.2 Baseline metabolite levels in the rat prefrontal cortex 
There were no significant group differences in baseline (vehicle) GABA or glutamate levels 
between wild type and Nrxn1 -/- rats in the PFC (GABA, t=0.11 (13), p=0.91; glutamate, 
t=0.54 (13), p=0.60, WT n=8, Nrxn1 -/- n=7), see Figure 5.4 A and B, respectively. 
There was however, a significant group difference in baseline glutamine in the same region 
(glutamine, t=3.16 (12), p=0.008, n=7/group), see Figure 5.4 C, and the ratio of glutamate to 
glutamine was significantly lower in Nrxn1 -/- rats compared to wild types (t=3.18 (12), 
p=0.008, n=7/group), Figure 5.4 D. When glutamate and glutamine levels were combined, as 
in the human study (Glx), there was no significant group difference between baseline levels; 






Figure 5.4: Baseline GABA (A), glutamate (B), glutamine (C) and Glu/Gln ratio (D) in 
the prefrontal cortex of wild type and Nrxn1 -/- rats 
There were no significant group differences in baseline (vehicle) measures of GABA (A) or 
glutamate (B), but there was a significant group difference in baseline glutamine (C) in the 
PFC (t=3.16 (12), p=0.008, n=7/group). This translated to a significant group difference in 

























































































































































5.3.2.3 Baseline metabolite levels in the rat caudate putamen 
There were no significant group differences in baseline (vehicle) GABA or glutamine levels 
between wild type and Nrxn1 -/- rats in the CPu (GABA, t=0.18 (13), p=0.86; glutamine, 
t=1.1 (13), p=0.31, WT n=8, Nrxn1 -/- n=7). See Figure 5.5 A and C, respectively. 
There was however, a significant group difference in baseline glutamate in the same region 
(glutamate, t=2.14 (11), p=0.05, WT n=6, Nrxn1 -/- n=7, see Figure 5.5 B), and the ratio of 
glutamate to glutamine was significantly lower in Nrxn1 -/- rats compared to wild types 
(t=2.81 (12), p=0.02, WT n=6, Nrxn1 -/- n=7, see Figure 5.5 D). When glutamate and 
glutamine levels were combined, as in the human study (Glx), there were no significant 






Figure 5.5: Baseline GABA (A), glutamate (B), glutamine (C) and Glu/Gln ratio (D) in 
the caudate putamen of wild type and Neurexin1-/- rats 
There were no significant group differences in baseline (vehicle) measures of GABA (A) or 
glutamine (C), but there was a significant group difference in baseline glutamate (B) in the 
caudate putamen (t=2.14 (11), p=0.05, WT n=6, Nrxn1 -/- n=7). This translated to a 
significant group difference in the baseline glutamate/glutamine ratio (t=2.81 (11), p=0.02, 


























































































































































5.3.2.4 No effect of riluzole on rat PFC or CPu inhibitory indices 
There were no main effects of group, nor drug on the inhibitory index in the PFC (Figure 5.6 
A; main effect of group; F (1,25) =0.06, p=0.95, and drug; F (1,25) =0.52, p=0.48), nor CPu 




Figure 5.6: Effect of riluzole on rodent prefrontal cortex (A) and caudate putamen (B) 
inhibitory index 
There were no significant effects of group nor drug on Nrxn1 -/- and wild type rat PFC (A), 
































































































In line with baseline findings from patients with ASD, Nrxn1 -/- rats had significantly lower 
baseline glutamate in the caudate putamen. However, despite a comparable regional E-I 
imbalance, unlike the human condition, no significant effects of riluzole on E-I flux were 
reported in either brain region. This could indicate either a lack of efficacy of riluzole in 
engaging the relevant targets to produce an observable response, or alternatively could be due 
to technical issues relating to study design and translation. 
 
5.3.3.1 Study design 
Groups did not differ in weight, or age, and dissected brain regions were equivalent weights 
across all groups. The time taken to perform the dissections was similar across groups, as was 
the time from vehicle/riluzole dose to dissection. Total time from dose to sample collection 
was around 4 hours for all groups (see Table 5.2).  
 
5.3.3.2 Baseline E-I balance of the rat prefrontal cortex 
There were no group differences in baseline GABA, or glutamate levels in the PFC of wild 
type and Nrxn1 -/- rats. However, the Nrxn1 -/- group had significantly higher levels of 
prefrontal glutamine (Figure 5.4 C). Additionally, glutamate-glutamine ratios were 
significantly lower in the Nrxn1 -/- rats compared to wild type controls (Figure 5.4 D).  
 
The increased glutamine, and accompanying lower glutamine-glutamate ratios found in the 
Nrxn1 -/- PFC are consistent with reports of altered glutamine in the human condition. For 
example, lower glutamate-glutamine ratios have been reported in the anterior cingulate cortex 
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(ACC) of ASD patients compared to controls (Shimmura et al., 2013); and in the only human 
MRS study to measure isolated glutamine, Cochran et al. (2015) reported increased levels in 
the ACC of children with ASD. 
 
The cause of the shift towards glutamine in the Nrxn1 -/- group is unknown, however 
disruptions to the regulation of the glutamine-glutamate cycle are a contributing factor to E-I 
imbalance in ASD, and may play a role here (Fatemi et al., 2002; Shimmura et al., 2013). 
Glutamine synthetase for example (which converts glutamate to glutamine in glial cells), is 
reportedly higher in the ACC of animal models of ASD (Silvestrin et al., 2013) and may 
represent increased astrocytic clearance of glutamate in ASD. Additionally, ACC 
glutaminase, which converts glutamine back to glutamate in neurons, is lower in ASD 
patients (Shimmura et al., 2013). Both may theoretically result in a shift towards glutamine, 
rather than glutamate, as observed here. Additionally, the regulation of this cycle occurs in 
glial cells, which themselves are known to be altered in the ASD PFC. Microglial density is 
reportedly increased in the PFC of mGluR5 knock out autism mouse models, and both 
number, organisation and activation states of microglia have been reported as abnormally 
high in patients and animal models (Morgan et al., 2010, 2012; Suzuki et al., 2013; Vargas et 
al., 2005). 
 
5.3.3.3 Baseline E-I balance of the rat caudate putamen 
There were no group differences in baseline GABA, glutamine, nor combined Glx in the 
CPu. However, there was significantly lower glutamate in the Nrxn1 -/- group, and as a 
result, the glutamine-glutamate ratio was also significantly lower (Figure 5.5).  
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As in the PFC, it is possible that disruptions to the glutamate-glutamine system are 
responsible for the lower glutamate levels observed in the Nrxn1 -/- CPu. Such alterations 
may also be reflective of widespread glutamate dysfunction. This supports the theory of 
altered glutamatergic activity in ASD in both alternative animal models (Wei et al., 2015) 
and human studies (Horder et al., 2013). 
 
5.3.3.4 Comparisons with human findings of the present thesis 
Overall, across both brain regions tested, the baseline neurochemistry of the Nrxn1 -/- model 
was largely consistent with that of the human condition; 
 
In Chapter 3, no differences in baseline GABA or Glx in the human PFC were reported, 
which matches the results observed in the rodent. However, when glutamate and glutamine 
were examined as individual metabolites in the present study, significant group differences in 
rodent PFC glutamine were found, which were not captured by MRS. This highlights the 
potential importance of separating the combined Glx measure in future MRS studies in 
humans, as any group differences in human glutamine levels may have been overlooked, and 
thus the combined Glx findings may present a false negative result.  
 
Likewise, the baseline neurochemistry of the basal ganglia was replicated. In Chapter 4, 
significantly lower baseline Glx was reported in the basal ganglia of the ASD patient 
population. This was comparable to the lower glutamate measured in the CPu of the neurexin 
model of ASD.   
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Having established an equivalence of the model at baseline, differences in responsivity of the 
E-I system were next investigated. 
 
5.3.3.5 Responsivity of the rat brain to riluzole 
Unlike in the human cohort, where distinct regional differences in E-I responsivity were 
found, riluzole had no effect on E-I flux in either brain region tested (Figure 5.6).  
 
At the time the brain regions were analysed (~4 hours post-dose), pharmacokinetic analyses 
from Study 1 indicated that riluzole was present in both the brain and plasma (Figure 5.1). 
Due to the time lag and difference in study protocols, the ex vivo animal findings at 4 hours 
post-dose cannot be directly compared to the findings 1 hour post-dose in the human. For 
both humans and rodents, the maximum effects of riluzole are thought to occur one hour 
post-dose (Sanofi-Aventis, 2010); therefore any changes in E-I flux at this time may have 
been missed in the rat. By the time data was collected at 4 hours post dose in Study 2, the 
system may have ‘normalised’, and E-I balance restored. Considering the significant delay 
from dose to sample measurement, it is also unknown whether riluzole was present at a 
sufficient concentration in the brain to produce an effect on E-I. At 4 hours post-dose in wild 
type rats, the average riluzole plasma level was 1150  39 ng/ml. As the molar mass of 
riluzole is 234.2, the concentration of riluzole in the plasma at this time would therefore be 
around 5 M (calculated as the weight in ng/ml divided by the molecular weight of riluzole 
and then multiplied by 1000 to convert from ng/ml to ng/L = (1150 / 234) x 1000 = 4.9 M). 
Based upon the previously reported brain:plasma ratio in the rat, one could anticipate brain 
riluzole levels of approximately 5 times that of plasma, i.e. approximately 25 M. No other 
studies have evaluated the effects of riluzole at this concentration in vivo or ex vivo, however 
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in vitro studies indicate an IC50 between 18 – 88 M, which would be consistent with the 
estimated regional level of riluzole reported here (Debono et al., 1993; Jehle et al., 2000; 
Wang et al., 2008; Zona et al., 1998). The brain concentrations reached with a 4 mg/kg oral 
dose may therefore have been sufficient to produce a detectable shift in E-I balance, however 
‘total’ brain region levels do not indicate the location of the drug, or whether it is bound or 
free in the extracellular space. They are not therefore directly comparable, and further, more 
localised studies of riluzole are necessary. Direct measurements of riluzole levels in the 
extracellular space were therefore considered in the next set of experiments.  
 
5.3.3.6 Extra notes on the validity of the Neurexin1-/- model 
The present study focused solely on neurotransmitter levels and did not assess animal 
behaviour- however, some observations were made throughout the experiments which may 
be of relevance. Though not formally assessed, the Nrxn1 -/- rats were notably more ill-
tempered than their wild type littermates, and in two instances, had to be housed individually 
to avoid fighting. Increased aggression is a common phenotype in animal models of ASD 
(Brodkin, 2007; Burrows et al., 2015; Schmeisser et al., 2012; Velez et al., 2010) including 
the Nrxn1 -/- (Grayton et al., 2013). Aggression was not assessed in the human arm of the 
study, though a considerable number of patients with ASD in the wider population report 
aggressive behaviour as a co-morbidity. For example in one study of 1,380 children with 
ASD, 68% of parents reported their child had engaged in some form of aggressive behaviour 
towards them (Kanne & Mazurek, 2011). Likewise in adults, 15-18% of people with ASD 
have been reported to engage in aggression towards others (Matson & Rivet, 2008) and 
‘irritability’ and ‘challenging behaviours’ are common and disabling co-morbidities 
(Accordino et al., 2016). 
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Additionally, the Neurexin1 knock-outs were more prone to biting and were more difficult 
to handle- though not formally measured in the present study, this may be an indication of 
increased anxiety. Other behavioural studies of Neurexin1  deficient rats have previously 
identified heightened anxiety compared to wild type controls in the elevated plus maze 
(Grayton et al., 2013), and increased anxiety was also noted in the symptom profile of the 
patients included in the human arm of this study (see Participant Demographic Table, 
Chapter 3), and the general ASD population (Simonoff et al., 2008). Both of these traits add 
to the face validity of the model. 
 
5.4 Limitations  
Back-translating a human study into a rodent is not without limitations and despite all efforts 
to link the two studies, there remained discrepancies. 
 
5.4.1 Study design 
Dissected brain regions did not differ in size, though unfortunately, whole brain weights were 
not assessed before dissection, hence it was not possible to control for potential group 
differences in total brain volume. This is of particular relevance to the present thesis, as 
volumetric differences have been observed between ASD and control brains in humans 
(Haznedar et al., 2006). However, dissections were performed ‘by eye’, using regional 
landmarks, so any gross differences in brain volume would have been noticeable.  
 
In two cases, Nrxn1-/- rats were housed individually after displaying aggressive behaviour 
towards handlers. To match the groups and avoid any potential confounds, two wild type rats 
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could have been housed individually, as isolation may have its own effects on brain E-I 
balance (Lukkes et al., 2012; Sestito et al., 2011). However, in both cases, surgery was 
planned for the following day, hence one night of isolation was not deemed to be sufficient to 
cause changes in E-I balance over such a short period of time. Additionally, social isolation 
mostly affects juvenile rats during weaning, hence the adult rats in the present study were 
most likely unaffected. Finally, although the behaviour may be a characteristic phenotype, 
housing wild type rats singly may not have been an equivalent control, as the reaction of wild 
type rats to being housed singly may be different to that of a knock out animal.  
 
Wistar rats were used as the genetic background for the Nrxn1-/- model used in present 
thesis, which are an outbred stock, and are therefore genetically diverse (compared to an 
inbred strain, such as a Brown Norway rat). This diversity may pose disadvantages, as the 
sample used for the control group may have a genetically different background to those in the 
knock-out group, which may influence their genotype and subsequently, their phenotype 
(NC3Rs, 2018). To mitigate this risk, all rats were genotyped and no significant differences 
were noted. On the other hand, it could be argued that the human population is also 
heterogeneous, therefore selecting an inbred strain may not have effectively translated to the 
human study. 
 
5.4.2 Study translation 
Brain regions were closely matched across studies, but due to the low spatial resolution of 
MRS, and the potential for human error during manual brain dissection, the regions examined 
are not directly comparable. In the basal ganglia in particular, the rodent measures were 
selectively from the caudate putamen, and whilst this region was included in the basal ganglia 
MRS voxel, so too were others (the lateral thalamus for example). It is possible therefore that 
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results from the human are due to brain regions other than the caudate, which are not 
accounted for in the animal study. 
 
Additionally, the analysis techniques used to capture these regions are different. Both capture 
bulk measures of intracellular metabolites, though MRS does so in a living, active brain, and 
HPLC is performed on ex vivo tissue post-mortem. Future work may consider using 
1[H]MRS in living rodents to obtain a more direct comparison. Though GABA and 
glutamate measures have been successfully obtained using this method in studies of 
neurodevelopmental animal models (Gonçalves et al., 2017; Vernon et al., 2015), it was 
deemed inappropriate in the present study due to the need for E-I acting sedatives (e.g. 
isoflurane), which could potentially interfere with interpretation of riluzole action (Petrinovic 
et al., 2016).  
 
5.5 Conclusions 
The Nrxn1 -/- rat modelled the baseline regional E-I imbalance observed in the patient 
cohort examined in previous chapters. The in vivo disruptions to E-I flux seen in the patients 
using MRS however, were not replicated in the animal ex vivo. The time difference in data 
acquisition between studies may account for this discrepancy, hence a real-time measure of 
neurotransmitter flux over time in vivo in animals may better capture any dynamic effects of 
riluzole.  
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5.6 Next steps 
In order to examine changes in E-I efflux, experiments were subsequently undertaken using 
in vivo microdialysis, which allows sampling of neurotransmitters and metabolites in the 







E-I responsivity of Neurexin1 knock out rats: in vivo 
microdialysis 
6.1 Introduction 
In the thesis thus far, E-I dynamics have been examined in both humans and animals 
primarily at the intracellular level, using MRS and equivalent ex vivo analyses, respectively. 
However, both of these techniques capture bulk E-I tissue measures and as a result, are not 
likely to be sensitive to differences in extracellular metabolite flux. In humans, fMRI was 
utilised as an additional approach to assess the effect of modulating E-I on brain function, 
which is assumed to reflect neurotransmission. However, whilst fMRI is useful, it still does 
not directly access extracellular levels of neurotransmitters in the living brain. Examination 
of neurotransmitter efflux into the extracellular space is however possible in animals using in 
vivo microdialysis.  
 
The present study therefore aimed to use microdialysis to address extracellular E-I dynamics 
and test the hypothesis that there would be group differences in neurotransmitter efflux in 
response to riluzole. I elected to continue to use the Neurexin1 knock out rat (Nrxn1 -/-) as 
it replicated at least baseline ASD E-I. Glutamate and GABA effluxes were sampled in the 
extra-synaptic space of the medial prefrontal cortex (mPFC) and caudate putamen (CPu) in 
rats, after an oral dose of 4 mg/kg riluzole, a dose which was previously demonstrated to be 




15 adult male Wistar Nrxn1 -/- and 16 littermate control rats were sourced from SAGE labs 
and housed in standard conditions. Rats did not differ in weight nor age (see Figure 5.2). 
 
The microdialysis protocol is detailed in full in General Methods section 2.2.4. Briefly, all 
rats underwent probe implantation surgery, followed by in vivo microdialysis experiments the 
next day. MAB 4.7.4 (4 mm) and MAB 4.7.3 (3 mm) microdialysis probes were implanted in 
the mPFC and CPu respectively, at the following co-ordinates (from bregma) with nose bar 
set to -3.3 mm: 
 
mPFC; +3.0 mm anterior, ±1.5 mm lateral, -5.0 mm vertical (from dura); at a 12 degree 
angle 
 
CPu; +0.3 mm anterior, - 3.0 mm lateral, -6.0 mm vertical (from dura) 
 
To match the location of the human MRS voxels (bilateral medial prefrontal cortex and left 
basal ganglia), placement of the mPFC probe altered between left and right mPFC co-
ordinates; whereas placement of the CPu probe was only in the left CPu.  
 
From the day after probe implantation, 4 animals per experimental day were connected to the 
microdialysis rig. Probes were attached to the rig via an infusion pump filled with aCSF, 
which was continuously perfused into the rat brain at a flow rate of 1.5 µl/min. Rats were left 
for an initial settling period of 90 minutes, then samples were acquired at 20 minute intervals 
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for a total of 15 samples. After 6 ‘baseline’ samples were collected, rats were dosed with 
either 4 mg/kg riluzole (in 1% HEC), or vehicle only (1% HEC) via oral gavage (p.o.); WT 
vehicle n=8, Nrxn1-/- vehicle n=7, WT riluzole n=8, Nrxn1-/- riluzole n=8.  
 
All samples were immediately frozen on dry-ice and stored at -80C pending analysis by LC-
MS/MS (see General Methods section 2.2.6 for further details on sample analysis). 
 
6.2.2 Data analysis 
Data were represented as a ‘percentage change from baseline’, where the baseline was the 
average of the final 3 samples prior to drug/vehicle administration (i.e. the average of 
samples at 80-120 minutes) for each rodent. In this way, each animal was normalised to their 
own pre-dose control.  
 
Repeated measures two-way ANOVA with factors of strain and treatment were used to 
compare any main effects of group, riluzole and time. Data from 140 to 300 minutes were 
included in these analyses to exclude the pre-dose settling period. In order to equalise the 
variance across the response range over time, it was necessary to first Log the data. To 
compare the difference in the effect of riluzole between groups (i.e. how responsivity to 
riluzole differed between the two strains), drug by strain interactions were analysed at each 
time point. Briefly; log estimates were calculated, and then transformed (antilogged) to ‘raw 
values’, so raw estimates = LSMean (Ril) / LSMean (Veh). This measure represents a ratio, 
rather than absolute difference, but may be taken as the relative effect of drug compared to 
vehicle. Differences in ‘raw’ treatment effects were again calculated as the antilog of Log 
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estimates, so that raw ratio estimates = LSMean (Ril_Nxn) / LSMean (Veh_Nxn) all divided 
by LSMean (Ril_WT) / LSMean (Veh_WT). 
 
SAS software was used to analyse the data presented in this thesis, which was undertaken by 
Lilly in-house statisticians (RM). SAS was selected as it has the advantage of handling 
missing data without removing subjects.  
 
Riluzole concentration in each sample was measured using LC/MS-MS, in the same manner 
as GABA and glutamate. Riluzole levels per dialysate sample in ng/ml were divided by the 
molecular weight of riluzole (234.199) and multiplied by 1000 to convert to a concentration 
in nM. Linear regressions were performed and then compared to determine whether the slope 
of riluzole in each group were equal.   
 
6.3 Results 
6.3.1 Glutamate efflux from the medial prefrontal cortex 
There were no significant overall effects of rat strain or treatment type on glutamate efflux in 
the mPFC (strain, F (1,24) =0.52, p=0.47; treatment, F (1,24) =0.56, p=0.46, see Figure 6.1). Nor 
was there a main effect of time (F (8,11) =1.58, p=0.23). Further analyses of drug by group 
interactions indicated no significant effects of riluzole at any time point within strains (See 
Figure 6.3 B and D), and hence the response to riluzole in the wild type rats did not differ to 





Figure 6.1: Glutamate efflux in the mPFC following riluzole administration 
There were no effects of treatment, nor strain on glutamate efflux from the medial prefrontal 
cortex; RM Two-Way ANOVA; treatment, F (1,24) =0.56, p=0.46; strain, F (1,24) =0.52, 
p=0.47. Further analyses of drug by group interactions showed no significant differences in 
treatment effects between groups at any time point. Arrow indicates time of riluzole/vehicle 
dose (120 minutes). 
 
6.3.2 GABA efflux from the medial prefrontal cortex  
Likewise, there were no significant overall effects of drug (F (1,27) =0.07, p=0.79) or strain (F 
(1,27) =0.18, p=0.67) on GABA efflux from the mPFC (see Figure 6.2). A main effect of time 
almost approached significance (F (8,19) =2.12, p=0.08), which may represent a trend towards 
a slight increase in GABA efflux across all groups over time. However, this may have been 
skewed by larger SEM values towards the end of the study timeline. There was no main 
effect of drug in either strain (see Figure 6.3 A and C), nor did responsivity to riluzole differ 







































Figure 6.2: GABA efflux in the mPFC following riluzole administration 
There were no effects of treatment, nor strain on GABA efflux from the medial prefrontal 
cortex; RM Two-Way ANOVA; treatment, F (1,27) =0.07, p=0.79; strain, F (1,27) =0.18, 
p=0.67. Further analyses of drug by group interactions showed no significant differences in 
treatment effects between groups at any time point. Arrow indicates time of riluzole/vehicle 








































Figure 6.3: No effect of riluzole on glutamate and GABA efflux in the mPFC of wild 
type and Neurexin1 knock out rats 
A) No effect of 4 mg/kg riluzole p.o. on GABA efflux in wild type rat mPFC 
B) No effect of 4 mg/kg riluzole p.o. on glutamate efflux in wild type rat mPFC 
C) No effect of 4 mg/kg riluzole p.o. on GABA efflux in Nrxn1 -/- rat mPFC 
D) No effect of 4 mg/kg riluzole p.o. on glutamate efflux in Nrxn1 -/- rat mPFC 
Riluzole/vehicle dose was administered at 120 minutes. 
 
  



































































































































6.3.3 Riluzole levels in the medial prefrontal cortex 
After oral dosing of riluzole at 120 minutes, riluzole rapidly entered the brain and was 
detected at a peak concentration of around 8 nM in the mPFC (see Figure 6.4). However, this 
value does not take into account that each probe samples from its immediate vicinity, and is 
therefore not an accurate representation of the concentration of riluzole in the wider brain 
region in which the probe is placed. Therefore, in a separate in vitro experiment (see 
Appendix 5), the percentage recovery of riluzole by the mPFC microdialysis probe was 
assessed, and found to be on average, 7.5%. The concentration observed in the present 
experiment was therefore extrapolated by a scale factor of 13 (100 / 7.5 = 13), and the total 
riluzole concentration in the wider mPFC region estimated at 100 nM (peak riluzole 
concentration measured multiplied by the scale factor). Riluzole concentration did not 
significantly differ between wild type and knock out rats (wild type slope best fit = 0.03  










Figure 6.4: Concentration of riluzole in rat mPFC dialysate following 4 mg/kg p.o. dose 
Concentration of riluzole did not significantly differ between groups; F (1,26) =1.98, p=0.17. 
Arrow indicates time of riluzole/vehicle dose (120 minutes). 
































6.3.4 Glutamate efflux from the caudate putamen 
No main effect of treatment, group, nor time was found for glutamate efflux in the caudate 
putamen (see Figure 6.5; main effect of treatment; F (1,22) =1.7, p=0.2; strain; F (1,22) =2.63, 
p=0.12; time; F (8,14) =1.2, p=0.36). There was no main effect of drug in either strain (see 
Figure 6.7 B and D), nor did responsivity to riluzole differ between groups at any time point 




Figure 6.5: Glutamate efflux in the CPu following riluzole administration 
There were no effects of treatment, nor strain on glutamate efflux from the caudate putamen; 
RM Two-Way ANOVA; treatment, F (1,22) =1.7, p=0.2; strain, F (1,22) =2.63, p=0.12. Further 
analyses of drug by group interactions showed no significant differences in treatment effects 








































6.3.5 GABA efflux from the caudate putamen 
Likewise, there were no main effects of treatment, nor time on GABA efflux of the caudate 
putamen; treatment, F (1,27) =0.99, p=0.33; time, F (8,17) =1.5, p=0.23. There was a trend 
towards a group difference; main effect of strain, F (1,27) =3.4, p=0.075, however this may 
merely represent group differences in variability, as the response profile of the Nrxn1 -/- rats 
was much more varied than that of the wild types (see Figures 6.6 and 6.7). There was no 
main effect of drug in either wild types or knock outs (see Figure 6.7 A and C, respectively), 
and responsivity to riluzole did not differ between groups at any time point (no significant 
drug by group interaction at any time).  
 
 
Figure 6.6: GABA efflux in the CPu following riluzole administration 
There were no significant effects of treatment, nor strain on GABA efflux from the caudate 
putamen; RM Two-Way ANOVA; treatment, F (1,27) =0.99, p=0.33; strain, F (1,27) =3.43, 
p=0.075. Further analyses of drug by group interactions showed no significant differences in 
treatment effects between groups at any time point. Arrow indicates time of riluzole/vehicle 






































Figure 6.7: Effect of riluzole on glutamate and GABA efflux in the CPu of wild type and 
Neurexin1 knock out rats 
A) No effect of 4 mg/kg riluzole p.o. on GABA efflux in wild type rat CPu 
B) No effect of 4 mg/kg riluzole p.o. on glutamate efflux in wild type rat CPu  
C) No effect of 4 mg/kg riluzole p.o. on GABA efflux in Nrxn1 -/- rat CPu 
D) No effect of 4 mg/kg riluzole p.o. on glutamate efflux in Nrxn1 -/- rat CPu 
Riluzole/vehicle dose was administered at 120 minutes. 
 
  



































































































































6.3.6 Riluzole levels in the caudate putamen 
After oral dosing of riluzole at 120 minutes, riluzole rapidly entered the brain and was 
detected at a peak concentration of around 5 nM in the caudate putamen (see Figure 6.8). As 
for the mPFC probe, the percentage recovery of the CPu microdialysis probe for riluzole was 
calculated in a separate in vitro experiment (see Appendix 5) and was estimated at 4.7%. By 
scaling up the concentration observed in the present experiment by a factor of 21 (100 / 4.7 = 
21), the total riluzole concentration in the wider CPu region was estimated at around 100 nM 
(peak riluzole concentration measured multiplied by scale factor). Riluzole concentration did 
not significantly differ between wild type and knock out rats (wild type slope = 0.024  











Figure 6.8: Concentration of riluzole in rat CPu dialysate following 4 mg/kg p.o. dose 
Concentration of riluzole did not significantly differ between groups; F (1,26) =0.45, p=0.51. 
Arrow indicates time of riluzole/vehicle dose (120 minutes). 
 
  

































The present study was conducted to investigate extracellular E-I dynamics, using 
microdialysis as a direct measure of neurotransmitter efflux into the extracellular space. 
There were no group differences in responsivity to riluzole in terms of GABA or glutamate 
efflux from either brain region tested, in both wild type and Nrxn1 -/- rats. 
 
6.4.1 Neurotransmitter efflux in the medial prefrontal cortex 
There were no significant effects of riluzole compared to vehicle in wild type, or Nrxn1 -/- 
rats on glutamate (Figures 6.1 and 6.3), or GABA (Figures 6.2 and 6.3) efflux from the 
medial prefrontal cortex (mPFC). Additionally, there were no overall effects of strain, 
treatment or time on the efflux of either metabolite when all groups were compared together.  
 
6.4.2 Neurotransmitter efflux in the caudate putamen 
Likewise, there were no significant effects of riluzole compared to vehicle in either strain on 
glutamate (Figure 6.5 and 6.7) or GABA (Figures 6.6 and 6.7) efflux from the caudate 
putamen (CPu). As in the mPFC, there were no overall effects of strain, treatment or time 
across all groups. 
 
6.4.3 Riluzole levels 
It is possible that these results are false negative findings because riluzole was not present in 
sufficient quantities to engage relevant molecular targets and evoke an E-I response. Previous 
in vitro and in vivo studies report the concentration of riluzole required to inhibit glutamate 
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release to be in the micromolar range (10 M), whereas a 10 times higher dose (100 M) is 
required for inhibition of GABA release (Cheramy et al., 1992; David Martin et al., 1993). 
Analyses of riluzole levels within mPFC and CPu dialysate samples in this study confirmed 
that riluzole was present in the brain of both strains at nano-molar concentrations, from the 
time of dosing (Figures 6.4 and 6.8). Specifically, riluzole presence in the brain remained 
continuous throughout the data collection period, with a peak concentration of extracellular 
(presumably free, unbound) riluzole at 8 nM and 5 nM in the PFC and Cpu, respectively. 
However, in order to consider the efficacy of the microdialysis probe at sampling riluzole, an 
estimated concentration was calculated by extrapolation (see Appendix 5), resulting in an 
approximate concentration of 100 nM riluzole in the extracellular space of each brain region 
(see section 6.3.3 and 6.3.6). Hence, whereas in Chapter 5 the ‘total’ ex vivo brain measures 
of riluzole suggested it was present at 25 M, the free extracellular levels were likely to have 
been much lower (100 nM).  
 
Such discrepancies between tissue and extracellular riluzole concentrations may indicate that 
a large proportion of riluzole is either bound in membranes, or located within compartments 
of the cells. It is impossible to know from the present data whether riluzole is evenly 
distributed across whole brain and where (intracellular or extracellular) it is acting. As 
riluzole acts via a multitude of mechanisms, at glutamate and GABA receptors and ion 
channels, it is likely that the majority of riluzole is either bound to these receptors, or 
partitioned in membranes. 
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6.4.4 Receptor availability and location 
Preclinical studies suggest riluzole acts by reducing excitatory, and potentiating inhibitory 
neurotransmission. Amongst many actions (see Bellingham 2011 and Doble 1996 for a full 
review), riluzole causes inhibition of NMDA receptors (Debono et al., 1993; Prakriya & 
Mennerick, 2000) and sodium and potassium channels (Hebert et al., 1994; Zona et al., 
1998), and potentiation of GABAA receptors (He et al., 2002; Jahn et al., 2008). However, the 
majority of these mechanisms were determined using in vitro cell cultures or brain slices, 
which may represent a more direct evaluation than the complex in vivo environment 
examined in the present microdialysis experiments. It is certainly possible that the abundance 
of other neurotransmitters in living tissue may alter, or mask riluzole’s effects on E-I.  
 
Furthermore, the majority of the literature investigating riluzole’s actions on specific 
glutamate and GABA receptors and pathways cite the hippocampus as the primary location 
for these effects (He et al., 2002; Martin et al., 1993). The thalamus has also been a region of 
interest in previous research; a microdialysis study by Abarca et al. (2000) previously 
reported a significant reduction of thalamic glutamate levels after only a 2 mg/kg dose of 
riluzole (half that of the present study). However, this experiment was conducted in wild type 
rats only and riluzole administered subcutaneously, hence it cannot be directly compared with 
the present protocol. Nonetheless, the lack of results in the mPFC and CPu may be due to 
riluzole having regional efficacy, which was not captured by the present study. 
 
The mPFC and CPu were however, specifically selected to match the human study, where 
effects of riluzole in both the PFC and basal ganglia were apparent (see Chapter 3 and 4). 
Translation between species may therefore be an issue for replication.  
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6.5 Limitations 
A key concern when sampling neurotransmitters using microdialysis soon after probe 
implantation surgery is the potential tissue damage as a result of the surgery. An example of 
the brain tissue after probe implantation can be found in section 2.2.8 of the General 
Methods, where histology was performed to verify the correct placement of each probe 
(Figures 2.10 and 2.11). Minor damage to the surrounding tissue can be seen in both brain 
regions, however it must be noted that these images were captured after probes had been 
inserted, and removed, whereas microdialysis samples were collected only after probe 
insertion. Previous literature has estimated up to 1 mm of tissue damage may occur 
surrounding the probe (Borland et al., 2005). Tissue damage to this extent would likely 
invoke activation of an inflammatory response (Stenken et al., 2010), including activation of 
glial mechanisms, which may in turn affect E-I balance (Auld & Robitaille, 2003; Graeber, 
2010). All groups underwent the same surgery; hence any effects should be consistent across 
all animals- however this may be a factor in why no overall group differences were found if 
glial mechanisms across all groups masked any effects of riluzole. 
 
Further, it is unknown whether the way in which riluzole exerts its effects is compatible with 
detection by microdialysis. Previous analyses of microdialysis studies have shown that 
manipulations which increase neurotransmitter uptake, and simultaneously decrease 
neurotransmitter release, may result in no apparent change in dialysate neurotransmitter 
levels, even though extracellular levels may be reduced (Chefer et al., 2009). This may apply 
to riluzole, as it is known to both increase glutamate reuptake (Dall’Igna et al., 2013; Frizzo 
et al., 2004) and prevent glutamate release (Cheramy et al., 1992; David Martin et al., 1993). 
However other microdialysis studies have found significant effects of riluzole on glutamate 
efflux (Coderre et al., 2007), though admittedly using a higher dose (6 and 12 mg/kg).  
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Finally, whether microdialysis captures glutamate and GABA efflux in response to neural 
signalling has been questioned. As explored in section 2.2.4.3 of the General Methods, 
previous studies have implied that unlike other neurotransmitters such as serotonin and 
noradrenaline, GABA and glutamate are only involved in short distance signalling which 
may not reach the microdialysis probe (Del Arco et al., 2003). Hence, the extracellular 
concentrations of glutamate and GABA may therefore not provide a reliable indication of 
their synaptic exocytotic release (see page 107 for further details). 
 
6.6 Conclusions 
The aforementioned limitations may have contributed to the lack of findings in this 
microdialysis study, however the animal research conducted as a whole has provided 
valuable insight into the Neurexin1 knock out rat model of ASD. This study in particular 
has highlighted the need for other direct evaluations of synaptic activity in the ASD brain, 








7.1 Summary of findings 
Evidence to date implicates E-I imbalance in ASD, though thus far E-I has only been 
investigated at rest in mostly cross-sectional studies. To date, no one has examined the 
responsivity of the E-I system, which may well be important, especially when looking 
towards treatment discovery. No single technique can fully capture E-I dynamics in the living 
brain, therefore I looked at E-I responsivity at different levels, using several modalities, 
across both humans and an animal model of ASD. For an outline of the levels of investigation 






Figure 7.1: Investigating E-I pharmacology at the intracellular, functional and 
extracellular level 
Responsivity to E-I challenge with riluzole was investigated at three levels using different 
techniques; 1) bulk intracellular measures of E-I metabolites, i.e. the total ‘neurotransmitter 
pool’, was measured in humans using [1H]MRS and in animals using ex vivo tissue analysis; 
2) whole brain functional connectivity was captured in humans using fMRI as a proxy for 
neuronal activity; and finally, 3) extracellular neurotransmitter efflux was examined in 
animals via in vivo microdialysis. 




To first capture E-I dynamics at the intracellular level, I investigated riluzole-evoked changes 
in bulk tissue levels of GABA, Glx and the inhibitory index (the relative proportion of 
GABA within the total ‘GABA + Glx’ pool) using in vivo [1H]MRS in the human prefrontal 
cortex and basal ganglia (Chapters 3 and 4), and ex vivo HPLC-MS/MS in a rodent model of 
ASD (the Nrxn1-/- rat) in equivalent brain regions (Chapter 5). In humans with and without 
ASD, despite comparable baseline measures of Glx and GABA between groups in the 
prefrontal cortex, the response to riluzole challenge was diametrically opposite; riluzole 
increased the inhibitory index in ASD, but decreased it in controls. In the basal ganglia, a 
group difference in baseline E-I balance was observed, whereby ASD subjects had 
significantly lower Glx compared to controls. Despite this difference at rest, both groups 
responded in the same manner to riluzole challenge, with an increase in the inhibitory index. 
These intracellular findings in the human cohort partially translated to the animal studies. In 
the Nrxn1-/- rat I recorded lower baseline glutamate in the basal ganglia region (as in 
humans with ASD), but there was no effect of riluzole on E-I dynamics in either wild type or 
knock-out animals in any brain region.  
 
Given that tissue E-I balance is thought to determine network activity, I also explored group 
differences in E-I dynamics at the whole brain connectivity level. Where a group difference 
in tissue responsivity was observed (prefrontal cortex), the responsivity of functional 
connectivity of that region with the rest of the brain was examined using resting-state fMRI 
(Chapter 3). In the ASD group, functional connectivity of the prefrontal cortex was shown to 
be abnormal at baseline, and was restored to control levels after riluzole administration. 
Conversely, riluzole had no effect on functional connectivity in the control group; hence 
again, irrespective of baseline activity, control and ASD subjects significantly differed in 
their prefrontal response to E-I challenge.  
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Finally, to examine E-I dynamics at the extracellular level, I explored neurotransmitter efflux 
into the extracellular space in the living rat brain, using in vivo microdialysis (Chapter 6). I 
hypothesized that differences in E-I dynamics in a rat model of ASD would be present at the 
extracellular level. I hoped that the findings would inform me what extracellular E-I changes 
were driving the observed differences in functional connectivity response. However, riluzole 
had no measurable effect on glutamate or GABA efflux in either brain region in either wild 






Figure 7.2: Summary of results at each level of investigation 
Intracellular measures of E-I (MRS in humans and animal ex vivo studies) showed baseline 
differences in E-I balance in the basal ganglia in men with and without ASD and mice with 
and without the Nrxn1 gene. In the prefrontal cortex, despite no group difference at 
baseline, the human study reported a group difference in E-I responsivity. E-I baseline and 
responsivity differences were also found in functional connectivity measures of the human 
prefrontal cortex. No effect of riluzole on E-I dynamics was found in microdialysis studies in 
either brain region. 
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7.2 E-I dynamics at the intracellular level 
Investigations into bulk tissue E-I dynamics in humans 
highlighted group differences in regional responsivity to an E-I 
challenge with riluzole. The findings presented in Chapters 3 and 4 confirm previously 
reported E-I imbalances at the intracellular level in ASD (Bernardi et al., 2011; Harada et al., 
2011; Hassan et al., 2013; Horder et al., 2013; Joshi et al., 2013; Tebartz van Elst et al., 2014) 
and for the first time, show that E-I balance is open to modulation in adults with ASD. The 
potential causes for such group differences in regional responsivity profiles are numerous and 
are discussed in full in Chapter 4.  
  
One potential explanation, is that the cellular composition of the two regions are very 
different in terms of their relative proportions of neurons to glial cells. Abnormalities in both 
neuronal, and in particular glial activity have been reported in the prefrontal cortex, but not 
basal ganglia regions in ASD, which may go some way to explain why the ASD response in 
the prefrontal cortex is different to that of controls, but the basal ganglia effect is the same. 
This is speculative however, as MRS does not distinguish between neuronal and glial effects; 
and though [1H]MRS was able to detect alterations to E-I at rest and when challenged, it is 
unknown where in the total neurotransmitter ‘pool’ this signal arises. 
 
In addition to a lack of cellular specificity, the analysis techniques used in humans in this 
study were also unable to differentiate between some key metabolites, most notably between 
glutamate (glu) and its metabolite, glutamine (gln). In the present study, excitatory 
neurotransmitter measures were reported as the combined ‘Glx’, as is commonly accepted in 
the literature. Capturing Glx in this way, despite being an indicator of E-I flux, does not 
account for potential differences in glu-gln ratios, which may be altered in ASD (Cochran et 
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al., 2015; Shimmura et al., 2013). The importance of eventually investigating glutamine and 
glutamate levels separately in human studies was suggested by the animal ex vivo analyses 
(Chapter 5). Specifically, there were no group differences in the combined Glx measure in 
the animal model and WT at baseline in either brain region tested; yet when analysed as 
individual metabolites, significant differences in baseline glutamine and glutamate were 
found in the PFC and CPu, respectively. In light of these findings, future MRS studies in 
people should endeavour to use new techniques which are capable of quantifying both 
glutamate and glutamine as separate measures (Ramadan et al., 2013), as any group 
differences in human glutamine levels may have been overlooked here, and thus the 
combined Glx findings may present a false negative result. A simple way of tackling this 
problem may be to scan at a higher magnetic field strength, such as 7T, which has proven to 
be capable of separating the Glx signal, whilst also capturing GABA (Cai et al., 2012; Lally 
et al., 2016; Wijtenburg, Rowland, Edden, & Barker, 2013).  
 
Likewise, the GABA measure in the present thesis was also potentially contaminated, as it 
contained macromolecule (MM) signal and was therefore reported as GABA+. New GABA 
editing techniques allow for the detection of GABA alone (Harris et al., 2015; Henry et al., 
2001) and should be considered in addition to separation of the Glx signal to obtain a ‘clean’ 
measure of GABA and glutamate in future MRS studies of E-I.  
 
Finally, pre-selecting the MRS voxels restricted data capture to two specific locations, but it 
is clear from the present thesis (Chapters 3 and 4) and the previous literature (Table 1.3) that 
E-I imbalances in ASD may be found in multiple regions across the brain. These regions 
work together in complex networks, therefore, to further investigate E-I dynamics at the 
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7.3 E-I dynamics at the functional level 
Regional E-I dynamics are thought to regulate the functional 
connectivity of resting state networks in the brain, yet responsivity 
of these networks to E-I challenge has not previously been investigated. In Chapter 3, having 
found group differences in intracellular responsivity of the prefrontal cortex, I next examined 
responsivity of the anterior cingulate cortex (the core region captured by the MRS voxel) in 
terms of its connectivity with the rest of the brain.   
 
Riluzole restored absent functional connectivity of prefrontal-posterior networks in the ASD 
group, and did not alter functional connectivity in the control brain. Thus, for the first time, I 
showed that functional connectivity of the adult ASD brain is open to pharmacological 
modulation, and that functional networks in the ASD brain respond differently to controls. 
Previous studies have indicated that resting tissue measures of glutamate and GABA are 
predictive of network activity in control subjects (Duncan et al., 2013; Enzi et al., 2012; Horn 
et al., 2010; Kapogiannis et al., 2013; Kwon et al., 2014), however the present study showed 
no correlation between MRS and fMRI measures in either controls or those with ASD. This 
disconnect between bulk measures of neurotransmitter pools and neural activity may be 
unsurprising. Functional connectivity is a measure of the oxygen demand of brain tissue, 
which is assumed to be required for neuronal activity. However, this activity could be 
glutamatergic or GABAergic/excitatory or inhibitory. fMRI is unable to distinguish between 
the two and is therefore a measure of ‘bulk’ brain activity, in the same way as MRS is a 
measure of the bulk (metabolic and active) neurotransmitter pool- hence the two may not 
necessarily correlate. Particularly in the ASD cohort, the relationship between brain function 
and tissue metabolite concentration may not be straightforward. Consistent with this, 
intracellular findings have previously been shown to correlate with functional outputs in 
 217 
control subjects, but not in those with ASD. For example, in the absence of a group 
difference in GABA levels in the occipital cortex in adults with and without ASD, Robertson 
et al. (2016) reported a relationship between GABA levels and performance in binocular 
rivalry tasks in controls and not ASD. Likewise, Schallmo et al. (2017) recently presented 
early data indicating modulation of the GABA receptor by lorazepam affected individual 
perception across control individuals in opposite ways. 
 
Therefore, in an attempt to understand the driving factors behind the fMRI result, I sought to 
investigate E-I dynamics at the extracellular level using in vivo microdialysis in a rodent 





7.4 E-I dynamics at the extracellular level 
Having established that the Neurexin1-/- rat had comparable 
baseline E-I balance to ASD (Chapter 5), this model was used to 
investigate extracellular E-I responsivity. I postulated that there would be group differences 
in riluzole-evoked E-I efflux between wild type and Nrxn1-/- rats, which would help to 
further understand what was driving the connectivity findings in the human brain. However, 
no effect of riluzole was observed on either GABA or glutamate efflux in either the medial 
prefrontal cortex or caudate putamen. 
 
Whilst extracellular measures provided a step closer to understanding synaptic activity, they 
are not necessarily indicative of the levels of active neurotransmitters involved in signaling. 
The efflux of neurotransmitter into the extracellular space may therefore not give sufficient 
information to understand the complex mechanisms underlying altered E-I 
neurotransmission, and hence connectivity. 
 
The negative findings from the microdialysis studies could be due to a number of reasons. 
First, as previously discussed - the concentration of riluzole may have been too low to engage 
with relevant molecular targets. In previous in vitro studies, riluzole altered neurotransmitter 
efflux when in the micromolar range (Cheramy et al., 1992; Hubert, Delumeau, Glowinski, 
Prémont, & Doble, 1994; Martin, Thompson, & Nadler, 1993), whereas in my in vivo 
experiment (Chapter 6), riluzole was calculated to be present in nanomolar concentrations. 
Future studies should therefore aim to investigate the effect of a range of doses. This would 
be of particular interest as riluzole has been shown to have different effects on E-I balance at 
different concentrations. For example at low micromolar levels, riluzole reportedly inhibits 
release of excitatory neurotransmitters and potentiates GABAA receptor activity, whereas 
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GABA release is inhibited at 10 fold higher concentrations (Jahn et al., 2008; Martin et al., 
1993). In my human experiments, the poly-pharmacology of riluzole at glutamate and GABA 
systems (in addition to reports of wide-ranging mechanisms of action at ion channels by 
Bellingham, 2011, and Doble, 1996) was advantageous when attempting to evoke a ‘Proof of 
Concept’ response in a heterogeneous cohort of individuals. Yet this same broad range of 
actions may hinder attempts to understand the effect of the drug on specific targets. For this, 
further, more directed probes of E-I may be required. I suggest that future experiments could 
use E-I acting drugs which are more selective for specific targets (for example mGluR5 
antagonists such as 2-methyl-6-phenylethyl-pyrididine (MPEP), or GABAA receptor 
modulators such as benzodiazepines, both of which have shown promise in preclinical and 
clinical studies of ASD models and patients (Han et al., 2014; Mehta et al., 2011; Silverman 
et al., 2010). 
 
7.5 Implications for future research of E-I pharmacology (back-
translation) 
The present thesis attempted to ‘back-translate’ from humans to animal models in order to 
explore the effects of an E-I challenge on neurotransmitter efflux. Going forward, more direct 
measures of E-I in ASD models are needed. 
 
Possible approaches include electrophysiological techniques such as patch clamp recordings, 
which have previously identified differences in the neuronal activity of cultured neurons and 
brain slices from animal models of ASD. For example in cortical neurons, decreased 
glutamatergic transmission was recorded in ubiquitin protein ligase E3A (UBE3A) mice 
alongside social and interaction impairments (Smith et al., 2011), and increased GABA 
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transmission was shown in mice carrying the autism-associated neuroligin 3 point mutation 
(Tabuchi et al., 2007). In vitro electrophysiology may therefore be useful for measuring 
changes in glutamatergic and GABAergic neuronal activity after riluzole administration. 
However, these measurements must be carried out ex vivo, and are therefore not ideal for 
capturing the complex environment of the living brain. Equivalent in vivo alternatives may be 
available however, as shown by a recent study in awake macaque monkeys, which 
demonstrated pharmacological manipulation of E-I balance in the auditory cortex by NMDA 
channel blockers, ketamine and MK-801, in terms of auditory-evoked-potentials as an 
electrophysiological biomarker (Holliday et al., 2017). 
 
There is currently no methodology available to directly measure neural activity in the living 
brain, yet there is hope, as new techniques such as oxygen amperometry can highlight in vivo 
changes in extracellular oxygen, in a similar manner to the BOLD fMRI signal (Bolger et al., 
2011; Lowry et al., 2010). Unlike the BOLD signal however, there is a good degree of 
certainty that recorded changes in oxygen level are functionally related to discrete neural 
activation events (Li et al., 2011). Future experiments could utilize this technique in awake, 
freely moving rats, to investigate the effect of riluzole on the activation of specific regions 
within brain networks. 
 
However, alongside probing E-I regulation of neuronal activity relevant to ASD, it has been 
noted that glia help maintain E-I balance (Auld & Robitaille, 2003; Domercq et al., 2013; 
Liang et al., 2006) and may be involved in the pathology of ASD (Bernstein et al., 2009; 
Durieux et al., 2015; Onore et al., 2012; Shigemori et al., 2015). Furthermore, in addition to 
an effect on neural activity and neuronal glutamate and GABA release, riluzole has been 
shown to affect glial mechanisms. For example, riluzole is reported to enhance glutamate 
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uptake into glia via glutamate transporter GLT-1 (Carbone et al., 2012; Dall’Igna et al., 2013; 
Yoshizumi et al., 2012), whilst paradoxically also facilitating release of glutamate from glia 
(Hayashida et al., 2010).  
 
It may be beneficial therefore for future studies to also investigate riluzole’s glial-specific 
mechanisms of action in the atypical brain. The benefits of investigating drug action in 
different cell types has previously been shown in the field of depression, whereby the 
discovery of riluzole’s effects on glutamate metabolism in astrocytes prompted the 
exploration of its therapeutic potential as an antidepressant. Indeed, the results supported 
riluzole-evoked reversal of a depressive like phenotype in rats, via restoration of glutamate 
homeostasis in glia (Yu et al., 2011). In future, examinations of glial mechanisms may come 
in the form of investigating drug effects on glial specific targets, such as the GLT-1 and 
GLAST glutamate transporters (Chaudhry et al., 1995). Together, findings from more in-
depth back-translation studies, which dissect the mechanism of action of riluzole will, I hope, 
inform future clinical studies. It may eventually be possible to identify which groups along 
the spectrum may respond best to a specific E-I intervention (see Figure 7.3). 
 
Nevertheless, I do not rule out the possibility that the ability of riluzole to affect both 
neuronal and glial targets may itself be beneficial for a spectrum disorder such as ASD, as it 
may be able to modulate E-I in a variety of ways in people with varied clinical presentations.  
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7.6 Implications for future research into E-I acting therapeutics 
(forward-translation) 
In line with this, open label studies in children and adults have provided supportive evidence 
for the effectiveness of riluzole in patients with psychiatric disorders, including OCD (Coric 
et al., 2005; Grant et al., 2007), schizophrenia (Farokhnia et al., 2014), depression (Zarate et 
al., 2004) and generalized anxiety (Mathew et al., 2005). Yet in trials in patients with ASD, 
the primary outcome of improving core symptoms has not yet been reached. For example, in 
a study by Ghaleiha et al., riluzole was used as an adjunct to risperidone for the treatment of 
irritability in 49 children (age 5-12 years) with ASD. Participants in the riluzole treatment 
group demonstrated improved irritability scores, reduced social withdrawal and lethargy, 
reduced stereotypical behaviours and reduced hyperactivity. Within the study, more patients 
within the riluzole group were deemed ‘responders’ than those in the risperidone-only group, 
however despite improvements across symptoms, none reached statistical significance, and 
there were no significant differences in the primary outcome of an improved Clinical Global 
Impressions (CGI) score (Ghaleiha et al., 2013). Likewise, an open-label study of riluzole in 
6 adult men with Fragile X syndrome showed limited improvements in the primary outcome 
of reduced repetitive behaviours, and again showed no significant change in CGI scores 
(Erickson et al., 2011). Wink et al., demonstrated moderate improvements in repetitive 
behaviours and irritability in three adult men with ASD, though the small sample size and 
lack of a placebo control did not allow for a full review of its efficacy (Wink et al., 2011). 
Finally, a single case study of one 13 year old girl with ASD reported an observed reduction 
in screaming and compulsivity after taking riluzole for 6 weeks, but no change in the core 
symptoms of ASD (Veenstra-Vanderweele, 2010). In this case, and in other studies of 
children (Mechler et al., 2017), riluzole treatment was terminated due to adverse side effects 
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(such as mild elevation of liver enzymes), however this is less common in studies of adults, 
who appear to tolerate riluzole well. 
 
Though the results are positive overall, clinical trials of riluzole are hindered by a lack of 
significant outcomes, which may potentially be due to the heterogeneity of the participants in 
the study. Initial stratification of the patient sample, by examining E-I responsivity to a single 
dose of riluzole, potentially using a protocol as outlined in Chapters 3 and 4 of this thesis, 
may highlight those patients who are capable of E-I modulation, and therefore more likely to 
be ‘responders’. For example, in Chapter 3, I observed that the extent of riluzole-evoked shift 
in prefrontal E-I balance was linked to clinical symptom presentation- patients with the most 
symptoms in the social and communication symptom domains responded the least to riluzole 
challenge.  
 
Therefore, based on the results outlined in this thesis, an 8 week clinical study, ‘Predicting 
treatment response in ASD’, is currently under ethical review for implementation in 2018. 
This study will aim to invite patients with ASD to undergo an initial MRS scan after a single 
dose of riluzole, followed by an 8 week period of daily riluzole administration and will 
examine whether response to a test dose is correlated with outcome. The primary end points 
for this study will be acute (initial scan) and persistent (8 week scan) riluzole-induced 
changes in imaging indices (MRS and fMRI) and improvements in clinical scores (from 






Figure 7.3: Future plans for back and forwards translation of results 
7.7 Conclusions 
From the outset of this thesis, it was clear that improved treatment targets are required for 
ASD. In addition, evidence that these targets can be shifted in advance of starting lengthy and 
expensive clinical trials is much needed. This thesis has begun to address this by identifying 
the glutamate-GABA system as a dynamic biomarker for ASD, against which drugs can be 
targeted and individual response to a test dose i.e. ‘target-engagement’ measured. Over the 
course of this PhD, I have shown the E-I system in ASD can be modulated, even in the 
mature adult brain. Additionally, the results presented here indicate the brain in ASD is 
pharmacologically different to the control brain.  
 
These findings have implications for both back-translation, to better understand the biological 
mechanisms of E-I in ASD, and forward-translation, towards identifying subgroups of 
patients likely to respond to a particular drug prior to treatment, thereby working towards a 
personalized approach to medicine in ASD. 
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Information Sheet: Version 4, 29 August 2013 
 
Brain chemistry in Autism Spectrum 
 
Principal Investigator: Dr Grainne McAlonan 
 
Invitation:  
You are being invited to take part in a research study. Before you decide if you want to take part, it is 
important for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with others if you wish. Ask us if there 
is anything that is not clear. Take your time to decide whether or not you wish to take part in the 
study. You will be given a copy of this form. Thank you for reading this. 
 
What is the purpose of the study? 
Autism spectrum disorder (ASD) is a group of related conditions including autism and Asperger’s 
syndrome. There is evidence that ASD may be caused by differences in the levels of two signalling 
chemicals in the brain, GABA and glutamate. However, direct evidence is missing. 
 
This study aims to measure GABA and glutamate in the brain of people with and without ASD using 
an MRI brain scanning technique called magnetic resonance spectroscopy (MRS). We hope that 
longer-term the results of our study will improve diagnosis of ASD and confirm a potential novel 
treatment target (the glutamate-GABA system). 
 
We wish to measure glutamate and GABA at ‘rest’ (when taking an inactive “dummy” pill or 
placebo) and when ‘activated’ by a single dose of the drug probe Riluzole.  Riluzole temporarily 
alters GABA and glutamate activity in the brain.  
 
What if I don’t want to take part? 
Whether you agree to participate or not in this study does not in any way affect your clinical care (if 
any). If you do decide to take part, you can still decide to leave the study, at any time in the future, for 
any or no reason. 
 
What will happen to me if I take part?   
If you decide to take part in the study, you will attend our research centre at the Institute of 
Psychiatry, London, on two separate visits. The two visits will be about one week apart (e.g. Friday 
Prof. Declan Murphy 
Head of Department 
Forensic and 
Neurodevelopmental Sciences 
PO Box 50 








one week, and then the next Friday) and last about 3 hours. We will ask you to fill out some short 
questionnaires and also carry out some assessments with one of the research team. If you have an 
ASD, we will confirm diagnosis, either (with your permission) by checking a recent clinic record if 
available, or by an assessment with you and/or an informant, depending on what is practical. 
 
On each visit, you will have an MRS scan which lasts about 60 minutes. Before the scan, you will be 
given a tablet to take. The tablet will contain either a 50 milligram dose of riluzole, or a placebo 
(‘dummy pill’). You will not know which tablet you are getting on each occasion. After the scan, we 
will ask you to complete a short interview and checklist with the doctor and we will ask you to wait 
for one hour to make sure you are ok before going home. 
 
Will I be compensated for my time and travel expenses? 
We will reimburse your travel expenses, and also pay you in compensation for your time, £60 per 
session, (i.e. £120 if you complete the study.) For more details please contact one of the researchers. 
 
What is riluzole? 
Riluzole is licenced for the treatment of Amyotrophic Lateral Sclerosis (ALS, “Lou Gehrig’s 
Disease”). More recently it has been shown to improve mood symptoms in adults and symptoms of 
OCD in children with and without ASD. It works by altering glutamate and GABA transmission in 
the nervous system and is thought to protect against neuronal damage. People with ALS take at least 
50 mg riluzole every day. In this study Riluzole is used as a drug probe not a treatment, therefore you 
will only take a one-off standard single dose of 50 mg. 
 
Riluzole has a good safety profile even when used in children. Examples of adverse effects following 
regular treatment are headache, nausea, chest symptoms and liver problems, but these are very rare 
and disappear when the drug is stopped. You will only have a single dose of Riluzole, therefore it is 
extremely unlikely that you will experience any problems as a result of taking the drug. However, a 
doctor will be present throughout the study. 
 
What is MRS scanning? 
The type of scan we use is called a Magnetic Resonance Spectroscopy (MRS) scan. The scanner is a 
magnet and does not involve the use of harmful radiation such as X-rays. 
 
You cannot have a scan if there is any chance that you have magnetic metal inside your body. For 
example, you must not be scanned if you have a pacemaker, if you have ever had surgery on your 
eyes, heart, or head; of if you have suffered an injury that might have left metal fragments in your 
body. Dental fillings and braces, however, are generally safe for MRS scanning, because they are not 
made of magnetic metal. A radiographer will go over a list of possible risks with you before scanning 
begins. 
 
There is a microphone inside the MRI scanner so that you can talk to us at any time during the 
procedure. Some people can feel claustrophobic inside the scanner. If you feel uncomfortable we can 
stop the scanning immediately. The scanner is noisy, so you will be provided with ear plugs for your 
comfort. However, if you feel any distress we will stop the scan and assess any discomfort you may 
experience. You may choose whether you wish to continue and stop the study at any point. 
This is a research scan and is not designed to provide clinical information. Therefore, we will not 
routinely feedback any of the results to you. If, however anything obviously abnormal shows up on 
the scan, we will inform you and (with your permission) your G.P.  
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Will my data be kept confidential? 
The information obtained from your study is covered by the Data Protection Act.  The computerised 
information is protected by a software and hardware barrier and the records are handled in the same 
way as hospital records.  Only members of the research team or responsible persons from the NHS 
Trust, where it is relevant to your taking part in this research, will have access to your data and only 
with permission from the Principal Investigator. We will ensure this data is kept strictly confidential 
and use a subject number to code your data separately from your personal information.  
Are there any reasons why I can’t take part in the study? 
This is a small study therefore you can’t take part in the study if you are: 
. Female  
. Aged under 18 years, or over 60 years 
. Taking certain regular medications (discuss with researcher) 
. Diagnosed with a major psychiatric illness 
. Diagnosed with a medical or genetic illness which is linked to autistic spectrum disorders e.g. 
epilepsy or Fragile X. 
. Suffering from any kind of liver disease; or have ever suffered a serious head injury. 
. Drinking more than 28 units of alcohol per week, or a very heavy smoker or using illegal drugs, 
or have been a heavy user of these substances in the past (discuss with researcher). 
. Not safe to have an MRI e.g. you have a cardiac pacemaker or any other metal implants in your 
body. 
. Learning disabled 
. Claustrophobic, or feel that you would be unable to lie still on your back for a period of 1 hour. 
 
Who has reviewed the study? 
This study has been review by the NHS Research Ethics Committee London – Camden & Islington. 
 
If you have further queries, or would like more information, please feel free to contact us: Dr. 
Andreina Mendez on 0207 848 0934 or email maria.mendez@kcl.ac.uk 





In case of any complaint please contact a member of the team in the first instance. The NHS 
complaints procedure for our Trust is provided at http://www.slam.nhs.uk/patients/frequently-asked-
questions/complaints  
 
If the team have been unable to resolve your concerns and you want to make a formal complaint you 
can contact the Trust's Chief Executive or Complaints Department: 
Complaints Department, Maudsley Hospital, 111 Denmark Hill, London. SE5 8AZ 
Telephone: 020 3228 2444/2499 
Email: Complaints@slam.nhs.uk 
 
If you have something you want to say about our services, you can also visit the Patient Opinion 
website. This is an independent site which has been set up to give people the opportunity to tell their 
story about their experience of using NHS services. See www.patientopinion.org.uk 
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APPENDIX 3 
Patient Consent Form 
 
  
NREC ref: 13-LO-0091 Version 2 






CONSENT FORM FOR STUDY OF BRAIN CHEMISTRY IN AUTISM SPECTRUM 
Version 2, submission date 08 March 2013 
 
IN CONFIDENCE 
Have you read the information sheet about this study?   Yes / No 
 
Do you understand that you are free to withdraw from the study at any time, without having 
to give a reason for withdrawing, and without influencing current or future treatment? 
Yes / No 
Do you understand that relevant sections of your medical notes and data collected during the 
study, may be looked at by responsible individuals from the study team, or from the NHS 
Trust, where it is relevant to your taking part in this research. Do you give permission for 
these individuals to have access to your records?      
         Yes / No 
Do you understand that all the information will be kept strictly confidential within the 
research team?         Yes / No    
                                                                                                               
Do you understand that your GP will be aware that you are participating in the study, but will 
only be informed if there are any clinically significant results?   Yes/No                           
 






Your Name (capitals)  …………………………………………   
 
 





Researcher Name …………………………………………. 
 
 




Date of Consent …………………………………………. 
 
Prof. Declan Murphy 
Head of Department 
Forensic and Neurodevelopmental Sciences 
PO Box 50 









Inclusion and Exclusion criteria for human MRI study 
 
Criteria Reasoning Exceptions 
Males Unknown effect of MRI on 
pregnancy  
- 
Right handed Data was collected from the 
left Basal Ganglia; therefore, 
only right-handed participants 
were recruited to avoid 
possible lateralisation effects 
 
Aged 18-60 Adults only - 
IQ > 70 
As assessed by Wechsler 




Symptom scores of those with 
IQ < 70 may be confounded 
by potential learning 
difficulties 
- 
No major comorbid medical 
illness e.g. epilepsy 
Modulating the GABA 
system may trigger seizures 
in those with pre-existing 
disposition 
- 
No major comorbid 
psychiatric diagnosis 
To ensure any observed 
pathophysiology and 
ADHD, Anxiety and 
Depression (if not 
medicated) may be 
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symptoms are due to autism 
alone 
considered on an 
individual basis due to the 
high association of these 
conditions with ASD 
No regular medication use Potential drug-drug 
interaction with riluzole 
Non-psychotropic 
medication may be 
considered if taken 
consistently over the 
study duration 
No recent (at least 1yr) use of 
illicit substances  
Potential drug-drug 
interaction with riluzole 
- 
No drug allergy In particular those acting on 
the GABA/Glutamate system 
Common allergies e.g. 
penicillin 
No contraindication for MRI MRI safety  - 
Alcohol intake < 28 
units/week 
Excessive alcohol 




Tobacco intake < 4/day Nicotine increases brain 
GABA levels  
Due to paired design, 
heavy smokers may be 
considered if necessary 
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APPENDIX 5 
An in vitro experiment to assess recovery of the microdialysis 
probes 
A5.1 Background 
Microdialysis probes sample from their immediate vicinity, and are therefore not 
representative of the wider brain region we intend to capture (see Figure A1). To an extent, 
this is due to several factors which impact upon the dialysing property of the probe, also 
known as the probes ‘recovery’. For example, recovery may depend upon the flow rate, 
temperature, length of the microdialysis probe and molecular weight of the substance. 
Therefore, the sample concentration in the microdialysis effluent may be an underestimation 
of the true extracellular or regional brain concentration. To calculate the sample 
concentration in the entire region, it is necessary to ‘scale up’ the concentrations we obtain 







Figure A1: Schematic representation of microdialysis probe recovery efficacy 
The microdialysis probe samples from the immediate vicinity (navy dots), and is therefore 
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not representative of the concentration of sample in the wider brain region (yellow). Diagram 
not to scale. 
Previous studies have estimated the percentage recovery of glutamate and GABA in different 
probe lengths (CMA Microdialysis, 1991), however the recovery of riluzole is as yet 
unknown. It is particularly important to assess the level of riluzole in the brain regions 
sampled, in order to know whether any changes in brain neurochemistry are a result of an 
efficacious riluzole concentration.  
By measuring the concentration of riluzole in the microdialysis probe effluent after dialysing 
artificial cerebrospinal fluid (aCSF) containing a known concentration of riluzole, it is 
possible to calculate the percentage recovery of riluzole by the probe, and ultimately gain a 
more accurate estimate the amount of riluzole in the brain region sampled. 
 
A5.2 Methods 
An initial concentration curve of riluzole from 0.1-10ng/ml (Sigma, UK) in aCSF (NaCl 
(141mM), KCl (5mM), MgCl2 (0.8mM) and CaCl2 (1.5mM)) was analysed to calibrate the 
LC-MS/MS apparatus.  
 
Six stock samples of riluzole were diluted in aCSF in Eppendorf tubes at a concentration of 
1ng/ml (37oC). Three 3mm and three 4mm probes were perfused with aCSF at 1.5μl/min and 
placed into each stock Eppendorf tube. Three consecutive 20 min samples were collected 
from each probe. Samples were then immediately frozen on dry ice and stored -80°C pending 
analysis by LC-MS/MS (see General Methods section 2.2.6 for full details). The calculated 
amounts of riluzole from each of the three 20 min samples were averaged, then divided by 
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the concentration of the stock sample, and multiplied by 100 to give an estimation of 
percentage recovery for each probe. 
 
A5.3 Results and discussion 
The average accuracy for LC-MS/MS detection of riluzole from the known standards was 
96.2  1.4%. The average percentage recovery for riluzole using the 3mm probe was 4.7  
0.3 %, compared to 7.5  0.4 % with the 4mm probe (see Table A1). The higher recovery of 
the 4mm probe is to be expected, as the larger surface area would allow for more riluzole to 
pass into the probe.  
 
Probe Length Percentage Recovery Mean 
(SEM) 
Scale factor 
3mm 4.7 (0.3) 21 
4mm 7.5 (0.4) 13 
 
Table A1. In vitro recovery of 3mm and 4mm microdialysis probes for riluzole  
 
The percentage recovery was converted to a scale factor (100 / average recovery), this factor 
can be multiplied by the reported concentration of riluzole in in vivo microdialysis samples, 
to determine an estimate of riluzole levels- see Chapter 6 for further details. 
 
Whilst attempts were made to replicate the in vivo scenario, for example by conducting the 
experiment at physiological temperatures, it is impossible to fully translate the results from in 
vitro to the living brain, where more complex interactions may also play a role in altering 
probe recovery. However, the scale factors determined in this short study allow for a more 
accurate assessment of the in vivo microdialysis data presented in Chapter 6.
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APPENDIX 6 
Index and metabolite changes in response to riluzole in the basal ganglia and prefrontal cortex of 
adults with ASD 








Region Measure Control ASD F p F p F p 
  n Placebo Riluzole n Placebo Riluzole     
Basal Ganglia Index 13 .765 (.01) .783 (.01) 13 .795 (.01) .810 (.01) 2.8 .108 4.4 .048 .31 .505 
 GABA 13 4.06 (.2) 4.40  (.2) 15 3.84 (.3) 4.16  (.2) 1.2 .291 3.6 .069 .37 .550 
 GLX 16 1.19 (.08) 1.22 (.02) 15 1.06 (.06) 1.02 (.06) 4.9 .034 .07 .936 .35 .562 
Prefrontal 
Cortex 
Index 14 .725 (.2) .714  (.2) 13 .709 (.2) .731   (.2) .4 .847 2.3 .146 4.3 .049 
 GABA 15 3.29 (.1) 3.25  (.2) 14 3.01 (.2) 3.50  (.2) .25 .875 1.2 .275 3.1 .091 




Metabolite and E-I changes in the basal ganglia and prefrontal cortex of controls and 
ASD subjects in the presence and absence of riluzole. 
Index and GABA RM-ANOVA analyses are corrected for state anxiety measures. GABA and 
GLX mean and SEM are expressed as (x10-4). Significant p values are highlighted in bold. 
Degrees of freedom=1 for each analysis. Repeated measures ANOVA displays between 
group (effect of diagnosis), within group (effect of drug treatment) and drug by group 
interactions.   
 
